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Abstract
Background: Rosacea  is  a  common  skin  disorder  that  predominantly  affects  fair 
skinned  people,  particularly  of  Celtic  origin.  It  usually  presents  with  erythema, 
telangiectasia, and papulo-pustular lesions on the face and chest and usually triggered 
by  sun  exposure.  The  finding  of  a  positive  anti-nuclear  antibody  (ANA)  has  been 
reported in rosacea, as a consequence, those rosacea patients may be mislabeled as 
lupus erythematosus,  often with important  consequences in  terms of  treatment,  and 
presumed prognosis. There is a limited literature examining rosacea and its associations 
with the positivity of ANA and connective tissue diseases (CTD).
Objectives:  This study investigated the relationship of different sub-types of rosacea 
with  positivity  of  ANA test,  musculo-skeletal  systemic  symptoms  including  myalgia, 
arthralgia and Raynaud’s phenomenon and CTD particularly lupus.  
Method: This  was principally an observational study, I  investigated a large group of 
patients  (169  patients)  with  different  subtypes  of  rosacea,  identified  from  the 
dermatology and rheumatology departments in Doncaster Hospitals (93 patients) and 
Leeds  Hospitals  (76  patients).   All  patients  had  ANA blood  screening  test  and  all 
required data about their rosacea, associated systemic symptoms and previous history 
of CTD were recorded in special proformas after  patients read information leaflet sheet 
and signed participation consent form.
Results: The results showed no significant increase in the ANA positivity test (overall 
13%), however, in patients without a history of CTD, the level of ANA positivity of both 
centres combined was (5.3%) which is similar to that reported in the general population; 
(One-sample  Binomial  test  compared  to  null  hypothesis  proportion  [5%]  p=0.500). 
Around  15  -  20% of  patients  had  one  or  more  systemic  symptoms.  Arthralgia  and 
myalgia  had  the  same percentage  as  reported  by  the  control  group  and  in  normal 
populations; however, Raynaud's phenomenon was slightly greater than reported in the 
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control  group  and  the  general  populations.  There  could  be  an  inverse  relationship 
between Raynaud's treatment with vasodilators and rosacea flushing symptom.
Conclusion: This study confirmed that there is no evidence that any particular clinical 
sub-type  of  rosacea  is  associated  with  increased  positivity  of  ANA or  has  specific 
relationship with CTD. The study also did not  find any specific  relationship between 
rosacea and systemic symptoms. 
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Table (1) - Abbreviations
No Abbreviated ward          Explanation 
1 ANA Anti-nuclear antibody
2 CTD Connective tissue disease
3 NRS National Rosacea Society 
4 UV Ultraviolet light
5 UVA Ultraviolet A
6 UVB Ultraviolet B
7 DIF Direct Immunofluorescence 
8 IIF Indirect Immunofluorescence 
9 TLR Toll-like receptor
10 ER Endoplasmic reticulum
11 VEGF Vascular endothelial growth factor
12 DF Demodex folliculorum
13 HP Helicobacter pylori
14 IL Interleukin 
15 TNF-α Tumour necrosis factor alpha
16 ETR Erythematotelangiectatic rosacea
17 PPR Papulopustular rosacea
18 PR Phymatous rosacea
19 OR Ocular rosacea
20 GR Granulomatous rosacea
21 MMP Matrix metalloproteinase
22 ROS Reactive oxygen species
23 NO Nitric oxides 
24 AMP Anti-microbial peptide
25 EGFR Epidermal growth factor receptor
26 LE Lupus erythematosus
27 CLE Cutaneous lupus erythematosus
28 ACLE Acute cutaneous lupus erythematosus 
29 SCLE Subacute cutaneous lupus erythematosus
30 CCLE Chronic cutaneous lupus erythematosus
31 SLE Systemic lupus erythematosus
32 DLE Discoid lupus erythematosus
33 ENA Extractable nuclear antigen
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1. Background
This thesis has its origins in a clinic scenario well recognised by those Dermatologists 
working in the field of connective tissue disease. 
A female patient of 38 was seen with a prior diagnosis of lupus erythematosus. Her 
current complaint was that her facial skin rash, on which the diagnosis of lupus was 
based, had failed to respond to a number of treatments commonly used for cutaneous 
lupus including antimalarials, dapsone, and oral gold. Her skin rash was papular, but 
never pustular and intermittently itchy. It was aggravated by exposure to ultraviolet light 
(UV)  and  she  had  mild  arthralgia  affecting  a  number  of  small  joints.  She  had  an 
intermittently  present  ANA at  low  titre  1:80.  A skin  biopsy  was  reported  as  being 
compatible  with  cutaneous lupus.  At  the time the patient  was examined,  she had a 
background  erythema of  her  face,  with  a  widespread  papular  eruption  affecting  the 
central face. There were no pustules, and the eruption was relatively monomorphic. She 
had aching finger joints but no joint swelling. Her nail fold capillaries were normal, and 
no other abnormal physical signs were found. Her ANA was positive at a titre of 1:80. A 
repeat  skin  biopsy  showed  a  follicular  eruption,  with  a  predominantly  lymphocytic 
histology, no basal layer degeneration nor basement membrane thickening. A specialist 
dermato-pathologist  reported  the  histology  as  being  unequivocally  rosacea,  and 
certainly not lupus. This raised the question of whether the patient had both lupus and 
roscaea. A review of the original pathology showed changes very similar to the recent 
biopsy,  suggesting that  the diagnosis  of  the facial  rash had been rosacea all  along. 
Treatment with oral tetracycline produced complete resolution of the skin eruption. The 
arthralgia  responded  to  anti-inflammatory  agents,  and  the  ANA  continued  to  be 
intermittently present. The patient did not have lupus, but the question of the interaction 
between these two conditions was raised, and merited further investigation.
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The diagnosis  of  rosacea is  often an easily  made clinical  one,  but  other  differential 
diagnosis  conditions  may  need  biopsy  (see  later),  and  some  clinico-pathological 
correlation to ensure that the right choices of diagnosis and therapy are made. It is not 
surprising that the combination of symptoms and signs seen in the patient described 
above may lead to a diagnosis of lupus of the predominantly cutaneous type, and may 
often  be  correct.  However,  as  this  case  indicates,  even  a  skin  biopsy  may  be 
misinterpreted  if  the  reporting  histo-pathologist  is  inappropriately  ‘guided’  by  the 
clinician. The microscopic changes in both rosacea and lupus are predominantly dermal 
and lymphocytic, so confusion is easily explained.
There is a small literature concerning the frequency of the presence of a positive ANA in 
patients with rosacea, and in some studies (see later), the frequency is higher than in a 
‘normal’  population,  and  may  occur  in  association  with  other  immunological 
abnormalities. Rosacea is also frequently aggravated or precipitated by physical stimuli, 
including UV exposure. There is sufficient commonality therefore for the separation of 
these  two  conditions;  rosacea  and  cutaneous  lupus  to  be  difficult,  even  for  those 
experienced in the dermatological aspects of CTD. Since many such patients are often 
under the care of non-dermatologists, it would be surprising if there was not occasional 
mis-diagnosis,  or  at  least  over-interpretation  of  the  meaning  of  combinations  of 
symptoms  and  signs.  In  any  specialist  practice,  it  is  difficult  to  be  certain,  until 
appropriate  research  is  carried  out,  whether  an  observation  made  is  real  and 
generalisable, or is specific to the area of work of the observer, or indeed is not ‘real’ at  
all, but a function of the heightened suspicions of the observer. The observation that the 
diagnosis of rosacea and lupus was complicated by the apparent increase in frequency 
of ANA positivity, as well as the occurrence of relatively non-specific joint and muscle 
symptoms in those with rosacea,  led to the generation of this piece of work. Although 
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the increase in ANA positivity in rosacea has been described, the studies are few and 
the numbers of patients small, and so was this a real and generalisable finding? If so, 
was it associated with extra-cutaneous symptoms, and what was the relevance of these 
findings if they were genuine? Did these features indicate a sub-clinical CTD, or did they 
indicate that rosacea and CTD were related in some way, possibly through the impact of 
treatment? It is well known that topical or oral steroid use can produce a rosacea like 
cutaneous eruption,  and that  certain tetracycline antibiotics can produce a lupus-like 
illness. 
With all of this in mind, the research described in this thesis was designed and carried 
out  as an extended piece of  data collection and clinico-pathological correlation,  with 
patient numbers sufficient to answer the key questions. The involvement of two quite 
different out-patient clinics, one a general clinic in Doncaster District General Hospital, 
the other in a specialist unit in a large Leeds Teaching Hospital, allowed comparisons 
between  two  cohorts  with  similar  demographics,  but  different  disease  backgrounds, 
whilst also producing valuable combined data. A control group of non-rosacea patients 
allowed  standardisation  against  published  norms,  and  provided  useful  control  data 
where none existed previously.  Data collection was prolonged, since finding patients 
who fitted the inclusion criteria was less easy than anticipated, but the planned numbers 
were achieved, and the questions addressed. 
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2. History of Rosacea (1)
“ … I never think of your face but I think upon hell fire … ''  Shakespeare  (Henry IV)
“ … Rosacea, a nice name for an unpleasant complaint ... '' John Banville  (The Sea)
                 
                      
                   Figure 1 - Illustrated figure of rosacea in nineteenth century (1)
Robert Willan (1757 – 1812) an English Dermatologist, originally described rosacea in 
exacting detail. He practiced at the Carey Street dispensary in London. He introduced 
the term acne rosacea as a type of acne that initially affects those in middle age and 
which presents with facial papules and pustules on a background of red skin. He was 
the first  to mention the inflammation of  the eyes in  patients  with acne rosacea.  His 
description of rosacea was published by his student Bateman one year after Willan’s 
death, in his book on the classification of diseases of the skin in 1813.  In 1800, other 
dermatologists described rosacea as a skin condition with a marked redness of the face. 
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It was thought to result from continual heat exposure and at that time was called lichen 
agrius.  Jean-Louis  Alibert  (1768 -  1837) and Alphonse Devergie (1798 -  1879) both 
French dermatologists, working in the Hospital Saint-Louis in Paris, classified rosacea in 
the  group  of  dermatoses  with  sebaceous  gland  pathologies  within  which  was  also 
included  acne  vulgaris.  Erasmus  Wilson  (1809  -  1879)  an  English  dermatologist 
suggested that there was a common pathogenesis of acne rosacea and acne vulgaris. 
Paul Gerson Unna (1850 - 1929) a German physician in Hamburg, one of the famous 
dermatologists of the early decades of  the 20th century,  supported the hypothesis of 
sebaceous  gland  dysfunction  in  rosacea.  Radcliff-Croker  (1845  -  1909)  an  English 
dermatologist, considered the term acne rosacea was inappropriate. He suggested that 
the erythema of acne rosacea was not a result of inflammation of the pilosebaceous 
glands,  but  rather that  it  was the result  of  abnormal dilation of  facial  blood vessels, 
leading to leakage of fluid into perivascular dermal tissue and resulting in a reactive 
inflammatory  papulopustular  skin  eruption.  He  and  other  English  dermatologists 
recommended dropping the ward acne and simply naming the condition  rosacea,  a 
disorder completely different from acne vulgaris. They also postulated that chronic facial 
blood vessel congestion could lead to hypertrophic tissue changes and in this way to the 
end  stage  of  rosacea.  This  theory  proposed  that  rosacea  started  with  a  red  stage 
(erythematotelangiectatic) and was followed by an inflammatory stage (papulopustular) 
and  ended  in  hypertrophic  tissue  changes,  the  phymatous  stage.  This  hypothesis 
remains  broadly  accepted  today,  although  it  is  clear  that  not  all  patients  with 
papulopustular disease have necessarily started with erythematotelangiectatic disease. 
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3. Definition
Rosacea is a common chronic skin disorder in which follicular inflammation and vascular 
instability occur, together or alone, and that may be followed by phymatous change. It is 
poorly  understood  despite  its  frequency,  often  misunderstood  and  lacks  satisfactory 
definition in a number of circumstances. It usually affects facial skin and less commonly 
may affect the neck and chest; it may also occur at non-facial sites. It is characterized in 
its early phases by erythema (flushing and redness) on the central face and across the 
cheeks, nose, or forehead. 
As  rosacea  progresses,  other  symptoms  can  develop  such  as  semi-permanent  or 
permanent erythema, telangiectasia, red domed papules and pustules, red gritty eyes, 
and  burning  and  stinging  sensations.  In  some  advanced  cases,  rosacea  can  be 
complicated by chronic skin lymphoedema, thickening of the affected skin and a red 
lobulated nose (rhinophyma). Not all patients have all elements of the condition: some 
have only the vascular elements, whilst others have a predominantly papular or pustular 
version without much vascular hyper-reactivity. Occasionally, the condition may occur at 
sites away from the face, when the diagnosis may be less obvious, but the morphology 
of the skin lesions remains consistent. The disorder can be confused and co-exist with 
acne vulgaris or seborrheoic eczema.
Rosacea is predominantly a clinical diagnosis and whilst histology is helpful to assist in 
diagnosis,  and to exclude other conditions,  there is no benchmark laboratory test  to 
confirm diagnosis. In 2002 an expert committee assembled by the National Rosacea 
Society (NRS) in the USA set up diagnostic clinical criteria for rosacea. The expert panel 
also recognised 4 subtypes of rosacea (see later) (2).      
13
4. Epidemiology
Rosacea  is  a  common  skin  disease,  however  the  epidemiological  data  remain 
fragmentary  and  the  methodological  quality  of  many  studies  is  debatable.  The 
prevalence statistics published in Europe and the United States are highly variable from 
one  study  to  another,  depending  on  the  method  used  and  populations  studied. 
Published results range from 1% to 20% of the adult population (3).  Rosacea affects 
both sexes, but is almost three times  more common in women aged 30 to 50 years, 
although the development of the complication of rhinophyma is more common in men. It 
has a peak age of onset between 30 and 60 years, but it can occur rarely in children (4).  
Rosacea predominantly affects white-skinned people of mostly north-western European 
descent, particularly those of Celtic origin; however it can occur in any race (5). 
In  one  hospital-based  study,  rosacea  made  up  2%  of  all  patients  who  consulted 
dermatologists  (6).  A Swedish  epidemiology  study,  in  1989, investigating  809  office 
workers  (454  women and  355  men),  showed that  81 persons were diagnosed  with 
rosacea,  giving  the  prevalence  of  10% (women 14% and  men 5%)  (7).  In  another 
epidemiological  study  from  Ireland,  the  country  which  is  thought  to  have  a  high 
incidence of rosacea, the prevalence of rosacea was 13.9% (8). The prevalence rate in 
these two studies was high and this is probably reflects the patients skin type (Celtic 
skin origin). A further study from Estonia, in 2010 reviewed the prevalence of rosacea in 
348 participants selected randomly from a working population of  30 years of age or 
more. They used the NRS diagnostic criteria. The results showed that 78 candidates 
(22%) had one or more primary features of rosacea (9). The prevalence  was high, this 
is could be result from patients selections, where age of patients involved were above 
30 years,  as well  as the flushing was not considered a prerequisite for  diagnosis of 
rosacea subtype 1. Furthermore, the numbers of participants were small. 
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A retrospective study from Tunisia, in 2010 included 244 patients. The prevalence of 
rosacea was 0.2%, with a sex ratio of male (69 patients) to female (175 patients) of 0.4. 
The mean age of patients was 49 years (10).  There is clearly a very large difference 
between these prevalence figures and those of the other studies. The explanation is 
unclear, but may be related to racial factors.  In a recent study of the epidemiology of 
rosacea  in  UK  in  2012, where  the  data  was  collected  from  UK  General  Practice 
Research Database identified patients with an incidental diagnosis of rosacea between 
1995 and 2009  and matched them (1:1)  to  rosacea  free control  patients.  The total 
identified  number  of  rosacea  patients  was  60,042  with  60,042  controls.  The  overall 
incidence rate was 1.65 per 1000 person - years and 61.5% were women (11). These 
figures are much closer to those seen in the earlier study from Tunisia, and feel more 
realistic than higher figures reported from other studies. 
There are  many  discrepancies  in the results of the  epidemiological studies performed 
over  the  last  few  decades.  These  may  have  resulted  from  the  differences  in 
methodology  including  patients  selections  and  diagnostic  criteria  used  as  well  as 
populations, skin type, geographical areas with the effects of  environmental factors, 
cultural and social perceptions of the disease. Also the epidemiology may be affected by 
the different access to the different health services among the different countries, where 
some  countries  only  have  private  health  sector  while  other  countries  have  free 
governmental  health  services  and  others  have  both.  This  may  affect  patient 
participations  and  recruitment,  research  data  collection,  as  well  as  funding  and 
performing epidemiology research studies.
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5. Aetiopathogenesis
The precise aetiology of rosacea is still unknown, and a multi-factorial aetiology is likely. 
Over the years, many suspected but unconfirmed factors have been reported. These 
include genetic predisposition, innate immunity, vascular abnormalities, micro-organism 
infestation such as demodex folliculorum, helicobacter pylori,  reactive  oxygen species, 
environmental factors and hormonal changes. None explain the disease entirely.
Figure 2 - Hypothetical Sequences of Rosacea Development: (2)
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1. Inherited Susceptibility 
2. Innate Immunity
3. Small Vessel Abnormalities
4. Micro-organisms
5.  Reactive Oxygen Species 
6. Environmental and other 
Factors
Erythema and 
Telangiectasia
Inflammation
Increased 
Dermal 
Damage
 Rhinophyma   Erythema, Papules 
and Pustules 
5.1 - Genetic:
     Although there are many triggering factors which may be implicated as a cause of  
rosacea, these triggers are also experienced by healthy persons who never go on to 
develop the symptoms or signs of rosacea. Therefore, rosaceous individuals may 
have an inherent sensitivity to these triggering factors, and this predisposition may 
be genetic. The evidence for a genetic predisposition in rosacea is not proved and no 
specific gene defect has been discovered. 
In a survey from the NRS of 2052 rosacea patients, about 40% of respondents gave 
a strong family history of rosacea, 27% confirmed that one or both of their parents 
suffered from rosacea, 18% had a brother or sister having a history of rosacea, 13% 
had their grandparent suffering from rosacea, 16% had their aunt or uncle affected 
with rosacea, 11% had rosacea already diagnosed in their sons or daughters. Sixty 
percent of the respondents had fair skin with 33% having at least one parent of Irish 
ancestry, 27% had one of their parents of Scandinavian origin and 26% had a parent 
of English descent (12). Another survey from the NRS of 600 rosacea participants 
showed that 52% had a positive family history of rosacea mainly affecting fathers 
(35%) followed by mothers (30%) and sisters (24%) (some patients had more than 
one member of the family affected). There were 42% originally from Irish, German or 
English nationality (13).  
These surveys show that rosacea is a skin disease that runs in families and that is 
also more common in people of certain nationalities. It is likely that there is a genetic 
element in these areas of enhanced risk.
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5.2 - Innate Immunity:
The role of innate immunity in the pathogenesis of rosacea has been studied widely 
over the last few years. The recognition system of the Innate Immunity includes TLR 
(Toll-like  receptors)  responds  to  environmental  stimuli  such  as  UV,  microbes, 
physical and chemical trauma and leads to a controlled increase in cytokines and 
anti-microbial  molecules  in  the skin.  One of  these anti-microbial  molecules  (anti-
microbial peptide AMP) is a peptide called cathelicidin, which is known to have both 
vasoactive  and  pro-inflammatory  actions  (14).  Cathelicidin  is  expressed  in 
keratinocytes,  leukocytes  such  as  neutrophils,  monocytes  and  natural  killer  (NK) 
cells and in epithelial cells of the skin. In the skin, cathelicidin is processed by serine 
proteases of  the kallikrein family particularly kallikrein 5  (stratum corneum tryptic 
enzyme) and kallikrein 7 (stratum corneum chymotryptic enzyme) (15).  The main 
resulting  peptide  is  LL-37;  however,  LL-37  can  be  processed  further  to  smaller 
peptide  fragments.  These smaller  peptide  fragments  exert  immune functions  but 
differ in their antimicrobial and immune activating capacities (16). 
A number of studies have investigated the role of the innate immune system, and 
cathelicidin in particular in rosacea.  In one study, it was shown that cathelicidin is 
significantly increased in the lesional skin in rosacea compared to the skin of non-
affected individuals. Also injection of these peptide fragments, found in the skin of 
rosacea patients,  into the skin of mice leads to a rosacea-like disease. In contrast, 
the isolated increase of  protease activity in  cathelicidin  knock-out  mice does not 
cause dermal inflammation (17). 
These  cathelicidin  peptides  promote  and  regulate  leukocyte  chemotaxis  (18), 
angiogenesis (19), and expression of extracellular matrix components (20), so would 
be ideally placed to have a role in rosacea.
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The mechanisms underlying the increased cathelicidin production and the enhanced 
protease activity in skin of the rosacea patients are not well known. Both seem to be 
regulated  by  different  signalling  pathways  with  retinoid,  vitamin  D-  and  cytokine 
activated cascades playing important  roles (21). Cathelicidin  LL-37 expression in 
human keratinocytes is regulated by the vitamin D pathway and this could explain 
why  rosacea  occurs  mainly  in  the  sun  exposed  areas  as  exposure  to  UV  light 
triggers  activation  of  vitamin  D  in  keratinocytes  and  subsequent  cathelicidin 
expression (22). Recently, a second vitamin D independent pathway triggering the 
induction of cathelicidin synthesis in keratinocytes was identified. In keratinocytes, 
cathelicidin  expression increases upon several  external  stimuli  such as  infection, 
injuries,  UV  irradiation,  and  permeability  barrier  disruption  which  also  trigger 
endoplasmic reticulum (ER) stress. The ER stress increases cathelicidin expression 
via nuclear factor KB-carbohydrate responsive element binding protein α activation 
independent of vitamin D receptor (VDR) activation demonstrating a novel role for 
ER stress in stimulating innate immunity (23). This again could explain why rosacea 
patients often report on nonspecific triggers (e.g. heat) which would mediate their 
pro-inflammatory activities through ER stress and cathelicidin induction. 
The keratinocytes express elevated level of TLR2 resulted from chitin released from 
demodex mites’ colonization in rosacea skin. This leads to further higher expression 
of  kallikrein proteases and higher  protease activity.  Thus,  decreasing the load of 
demodex mites  on the skin  or  blocking the TLR2 by  retinoids  could  reduce  the 
protease  activity  and  consequently  reduce  the  rosacea  inflammation.  Also  oral 
tetracycline  and topical  azelaic  acid  inhibit  protease activity  and  exert  their  anti-
inflammatory effect through this mechanism (24). 
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Figure 3 - Role of cathelicidin in the pathogenesis of rosacea: (24)
Figure 3 shows the role  of  cathelicidin  in  the pathogenesis  of  rosacea.  UV light 
increases  the  synthesis  of  vitamin  D  which  induces  cathelicidin  expression  in 
keratinocytes.  ER  stress  is  an  alternative  inducer  of  cathelicidin  production. 
Demodex mite colonization increases the protease activity through the activation of 
TLR2 receptor which leads to increased cleavage of cathelicidin LL-37 and further 
fragments.  The increased  level  of  the  vasoactive  and inflammatory host-defense 
peptide  LL37  and  its  fragments  result  in  rosacea  changes  including  erythema, 
telangiectasia  and  inflammation.  Oral  doxycycline,  topical  azelaic  acid  and  oral 
retinoids have their inhibitory effect on the expression and production of cathelicidin 
through different mechanisms. 
  20
Cathelicidin
LL-37
Protease 
Activity
LL-37
Fragments
Vitamin 
D
RetinoidsDoxycycline
Azelaic Acid
Inflammation
Chemotaxis
Erythema
DemodexER 
Stress
UV 
Light
TLR2
5.3 - Vascular Abnormalities:
Many believe that rosacea may be a predominantly vascular disorder because of its 
association  with  flushing,  redness  and  visible  blood  vessels,  and  certainly,  the 
majority  of  patients  appear  to  have  a  vascular  element  to  their  disease.  The 
association of rosacea with migraine seems to support this hypothesis (25) as well 
as the fact that factors that trigger flushing such as emotional stress, spicy food, 
alcohol  and  hot  beverages may all  worsen  rosacea.  The  flushing  response  or 
transient  erythema  is  mediated  by  release  of  vasoactive  substances  including 
Serotonin,  Bradykinin,  Prostaglandins,  Substance P,  Opioid  peptides  and  Gastrin 
(26); however, there is still a lack of convincing supporting experimental evidence of 
the role of these soluble substances. 
There is an increase in the expression of vascular endothelial growth factor (VEGF) 
which  is  induced  by  ultraviolet  irradiation  and  produced  in  the  keratinocytes in 
rosacea. This may explain the photo distribution and the reported photo aggravation 
of  rosacea.  VEGF  stimulates  the  proliferation  of  vascular  endothelial  cells  and 
increases angiogenic  processes.  This may  be  implicated  in  the  production  of 
erythema in rosacea. It also increases permeability of the blood vessels as well as 
the expression of the lymphatic endothelial marker D2-40 (27).
In addition, as previously discussed, the cathelicidin-derived peptide LL-37 has been 
shown to be increased in papulopustular rosacea. It  exhibits angiogenetic activity 
and can induce alteration in endothelial cells via multiple signalling pathways. These 
include promotion of angiogenesis with neovascularization mediated by interaction 
with endothelial cell receptors, receptor transactivation with downstream signalling in 
epithelium and receptor mediated induction of VEGF in keratinocytes (28)  
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There have been studies confirming the vascular changes in rosacea.  In one such 
study, it was demonstrated that the blood flow in rosacea lesions was 3-4 times that 
of  controls  measured  by  Laser  Doppler  Flowometry  (29).  A  further  study, 
investigating the association of neurovascular and neuroimmune changes in different 
clinical  presentations  of  rosacea  using  quantitative  real-time  polymerase  chain 
reaction  (PCR)  and  immunohistochemistry,  supports  the  major  presence  of 
vasodilation of blood vessels and lymphatics. It also demonstrates the up-regulation 
of genes involved in vasodilatation, and supports the observation that blood vessels 
in  rosacea retain their  ability to respond to vasoactive stimuli  (30).  Rosina et  al, 
investigated the changes in the cutaneous vasculature on the facial cheek skin of 30 
patients  with  erythematotelangiectatic  rosacea  by  videocapillaryscopy  and  these 
changes were correlated with  clinical  observation by both clinicians and affected 
patients.  The  larger  vessel  diameter,  more  prominent  telangiectasias, 
neoangiogenesis, and larger capillary nets were noted to be more frequent in those 
patients compared to healthy controls (31).     
So, all the above studies showed that either there is an increase in the blood flow, 
dilatation  of  blood  vessels  or  formation  of  new blood  vessels  (telangiectasia)  in 
rosacea skin which, all result in the erythema and the redness features of rosacea. 
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Table 2 - Pathophysiologic Vascular Changes in Rosacea: (32)
Intermittent Flare 
Episodes with Diffuse 
Erythema
Intermittent Flare 
Episodes + Early 
Persistent Diffuse 
Erythema
Intermittent Flare Episodes
 + Advanced Persistent 
Erythema
- Altered blood flow.
- Neurovascular / 
neuroimmune deregulation.
- Augment innate immune 
response (cathelicidin) 
leads to inflammation.
- Increased blood flow in 
the affected skin more than 
none affected skin.
- Increase in VEGF 
stimulation of vasculature.
- Repeated endothelial 
nitric oxide (NO) 
stimulation leads to 
vasodilatation.
- Activated cathelicidin 
cascade leads to more 
inflammation and 
angiogenesis.   
- Vascular / dermal matrix 
degeneration leads to 
more angiogenesis
- Permanent dilatation of the 
superficial vessels.
- More fully developed fixed 
structure changes.
- Facial cheek skin with sub-
papillary plexus dilatation, 
with thickened walls, enlarge 
telangiectasias and increase 
neoangiogenesis.
Table 2 demonstrates the progression of vascular changes and physical alterations 
of cutaneous vasculature that develop over time in rosacea and their correlation with 
visible manifestations.
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5.4 - Micro-organisms:
• Demodex Folliculorum (DF):
Demodex  are  considered  to  be  commensal  organisms  in  human  skin  and  their 
numbers increase with the host age. The tendency of rosacea to develop after age of 
30 years is paralleled by an increase in demodex mites in facial skin. Many authors 
believe that demodex folliculorum (DF) has some role in the rosacea development 
and many studies support this argument.
 Figure 4 - Demodex mites in skin biopsy
A comparative study, compared standardized skin surface biopsy (1cm²) performed 
in 49 rosacea patients. The density of DF was significantly higher in patients with 
rosacea (mean = 10.8/cm²) than controls (mean = 0.7/cm², p < 0.001). This density 
was most statistically significantly higher than in controls in the PPR patients (mean 
= 12.8/cm², p < 0.001). This study demonstrated a high density of DF in rosacea 
particularly in PPR (33). In a case control study, the prevalence of DF mites was 
investigated in facial biopsies of 75 patients with rosacea as the case group, and 
compared with 75 patients with discoid lupus erythematosus and 75 patients with 
actinic lichen planus as control groups.  The prevalence of DF mites in patients with 
rosacea  (38.6%)  was  significantly  higher  than  the  patients  with  discoid  lupus 
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erythematosus (21.3%) and actinic lichen planus patients (10.6%) (p < 0.001). This 
study suggests that DF mites were increased in rosacea skin compared to other skin 
dermatoses which indicate that it might play a role in pathogenesis of rosacea (34). 
In  another  study investigated 38 rosacea patients  and 38 age and sex matched 
healthy control using skin surface biopsy technique from three facial sites. The mean 
DF mite count  in  the rosacea group (6,684)  was significantly higher  than that  in 
controls (2,868, p < 0.05). The cheek was the most heavily infested facial region. In 
conclusion  large  numbers  of  DF  may  be  found  in  rosacea  and  may  have  an 
important  role  in  the  pathogenesis  of  the  disease  (35).  In  a  multicentre,  cross 
sectional prospective study, 50 rosacea patients were compared with 48 age and sex 
matched  healthy  volunteers.  The  quantity  of  DF  was  measured  by  PCR. 
Inflammatory and immune markers were also assessed.  The results showed that 
Demodex was detected more frequently in rosacea patients (5.7 times) than controls 
(96% vs. 74%, p < 0.01). Skin sample analysis showed a higher expression of genes 
encoding  pro-inflammatory  cytokines  (IL-8,  IL-1b,  TNF-α)  in  rosacea,  especially 
PPR.  Also over  expression of  LL-37 and VEGF were observed,  indicating  broad 
immune system activation in patients with rosacea (36).  
All of the above studies confirmed that the density number of DF in rosacea skin 
increased  compared  to  healthy  controls  or  other  skin  dermatosis,  however  the 
number of patients studied were small but it is an interesting finding. 
On the other hand many other authors argue that although the DF frequently isolated 
in  the  rosacea  skin  and  an  immunological  response  against  demodex may  be 
detected in those patients, the prevalence of this microorganism in healthy adults 
reaches up to 100%, and because of this fact, its association with rosacea does not 
imply an etiopathogenic relationship (37).  Also clearing of  rosacea physical signs 
after  oral  tetracycline did not  affect the resident  DF population as well  as topical 
application of sulfur  ointment improves rosacea without  affecting the mite density 
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number (38). Furthermore, it is impossible to establish the pathogenesis of DF  by 
producing experimental infestation according to the following Koch postulates (39): 
1. Demodex is a parasite of healthy skin.
2. Pathogenicity depends on the immunological background of the patients.
3. It is an obligate parasite, and cannot be grown in vitro.
So, in conclusion although it has been found that DF is substantially more numerous 
in rosacea patients, it is still unclear whether this is a cause or a result of rosacea.  It  
is not clear whether rosacea provides a suitable environment for multiplication and 
overgrowth  of  these  mites,  or  whether  the  mites  play  a  role  in  the  pathological 
changes of rosacea through activation of innate immune system particularly through 
the cascade of activation and expression of the cathelicidin LL-37.
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• Helicobacter Pylori (HP):
Several studies have suggested a potential relationship between helicobacter pylori 
(HP) and rosacea, as it has been shown in some studies that the prevalence of HP 
infection  is  higher  in  patients  affected  by  this  condition  when  compared  to  the 
general population. 
Rebora et al in 1994  was the first  published report  of an association of HP with 
rosacea in a study of 31 rosacea patients that documented positive HP gastritis in 
84%, and all  the rosacea patients were cleared or improved after  treatment with 
metronidazole (40). 
Since that time, there have been many studies that showed the prevalence of HP 
infection was reported more in rosacea patients compared to healthy controls, and 
eradicating  HP  infection  in  those  infected  rosacea  patients  helped  to  clear  the 
rosacea  symptoms  particularly  in  papulopustular  rosacea  subtype  (41  -  45). 
However, all these studies used different eradication regimens to treat HP, which all 
contained  antibiotics  known  to  be  effective  in  clearing  rosacea. In  these 
circumstances, it is difficult to prove whether the rosacea improved because of the 
eradicating of HP or because of the antibiotic effect. This is an almost universal fault 
of these studies, together with their small scale. 
Others suggest that because HP is so common in the normal population, it is most 
unlikely that this organism can be related to cutaneous disease.  It is certainly the 
case that no study so far performed is large enough to answer the question fully. 
A comparative study, compared the prevalence of HP between rosacea patients and 
controls,  and evaluated  the effect  of  HP eradication.  HP was  detected by  using 
gastroscopic  biopsy in 84% of  50 rosacea patients and 78% of  50 controls.  The 
results showed no significant difference in the prevalence of HP between rosacea 
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patients and controls. There was no significant improvement of the erythema, and 
there  was  only  temporary improvement  in  papulopustules  during the 2  weeks of 
treatment. This was probably a result of the antibiotic regime. So, this study rightly 
concluded  that  no  significant  lessening  of  rosacea  lesions  was  achieved  by 
eradicating HP infection,  and that  HP is not  related to rosacea (46). In a further 
double  blind  controlled  study on  the effect  of  eradicating  HP in  those  with  both 
rosacea and HP, showed no benefit was found on an overall rosacea assessment 
score (47).  
Summarising these data, HP is commonly found in patients with rosacea and in the 
general population. There is no clear evidence of an association, even if a short term 
improvement  of  rosacea symptoms is  reported after  eradication  therapy in  some 
patients. 
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5.5 - Reactive Oxygen Species (ROS):
The reactive oxygen species include superoxide and hydroxyl  radicals  and other 
inactivated oxygen forms such as hydrogen peroxide and singlet oxygen. The role of 
ROS in rosacea has been investigated through the actions of the medications used 
for  treating  rosacea.  Rosacea  treatment  including  oral  tetracyclines  (48),  topical 
azelaic  acid  (49),  topical  metronidazole  (50)  and  retinoids  (51)  all  inhibit  the 
generation of ROS in neutrophils. This results in low level of ROS and supports the 
hypothesis that ROS involvement is relevant to rosacea. The level of ROS in the skin 
was compared in rosacea patients and healthy individuals and the levels were higher 
in  rosacea  skin  lesions  than  normal  healthy  people  (52).  The  UV  generates 
production  of  ROS  which  activate  cellular  signalling  in  keratinocytes  mediating 
cytokine  induction  by  TNF-α  and  chemokine  production  by  TLR2  stimuli  in 
monocytes.  Also  ROS  stimulate  fibroblasts,  actuates  matrix  metalloproteinases 
(MMP) and tissue inhibitors of metalloproteinases expression. ROS increases MMP-
1 and MMP-2 mRNA expression and depress proalpha I and proalpha III (53). 
Oztas et al, found decreased activity of the superoxide dismutase (an oxygen radical 
quenching  enzyme)  and  increased  malondialdehyde  levels  (lipid  peroxidation 
product as a result of free radical activity) in patients with severe rosacea compared 
with controls (54).  Another study investigated plasma ROS activity and antioxidant 
status and their relationship with the HP infection in 29 rosacea patients. The result 
showed higher level of malondialdehyde and a lower level of antioxidant in rosacea 
patients compared with controls but no correlations with HP seropositivity (55).
Therefore,  up-regulated  activity  of  the  ROS  in  the  skin  could  result  in  the 
inflammation,  vascular  changes,  and collagen degeneration observed in  rosacea. 
However,  once  again,  these  studies  demonstrate  involvement  in  the  process  of 
inflammation in rosacea, but fall short at implying a pathogenic role.
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5.7 - Environmental Factors:
It has been proposed that damage to dermal connective tissue often caused by solar 
irradiation  may  be  the  initiating  event  in  rosacea.  Sun  damage  may  affect  the 
lymphatic and blood vessel function due to damage to the dermal support network of 
elastic and collagen fibers. This may result  in endothelial  damage and leaking of 
serum containing inflammatory mediators, and metabolic waste, which may cause 
the telangiectasia, persistent erythema, and skin odema. These finding are usually 
present in sun-exposed areas of rosacea patients including the face and chest and 
are usually more common in fair-skinned people.  
Many authors believe that rosacea results from the effects of climatic exposures that 
damage both cutaneous blood vessels and dermal connective tissue. The pivotal 
role of sunlight is supported by the distribution of the erythema and telangiectasia on 
the facial convexities and sparing of the sun-protected areas. Also, the reputed flare 
up of the rosacea in the spring and summer seasons, as well as the presence of 
solar elastotic changes in the histology of rosacea support this view (56). 
The UV exposure may trigger activation of the innate immune and / or neurogenic 
effects.  Ultraviolet  B  (UVB)  has  been  shown  to  induce  the  production  of  many 
immunomodulatory cytokines such as IL-1,  IL-4, IL6,  IL8,  IL10,  and TNF-α, while 
Ultraviolet  A (UVA) can inhibit  synthesis  of  collagen and modulate  the activity of 
some MMPs involved in the degradation and remodelling of the dermal extracellular 
matrix (57). Bielenberg et al, showed that UV-B increased the production of VEGF 
and  basic  fibroblast  growth  factor  2  (bVGF-2)  by  keratinocytes  in  mice.  These 
cytokines are able to stimulate the proliferation of new blood vessels and increase 
telangiectasia (58).  
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Common  Triggers of  Rosacea Flare-up:  
Based on the NRS survey of  400 rosacea patients, the percentages  of the most 
common triggering factors of rosacea are as shown in table  3 (59). While the list of 
these potential trigger factors range from weather changes, to emotions, to different 
types of food, nearly all  are related to flushing. To help rosacea patients to avoid 
triggering factors, patients are advised to keep a rosacea trigger diary on a daily 
basis to observe and record weather conditions, types of food and drinks consumed, 
facial products used, medications, and any other relevant factors.
Table   3  - Triggering Factors: (59)
No Trigger Patient affected %
1 Sun exposure 81%
2 Emotional stress 79%
3 Hot weather 75%
4 Wind 57%
5 Heavy exercise 56%
6 Alcohol 52%
7 Hot baths 51%
8 Cold weather 46%
9 Spicy food 45%
10 Humidity 44%
11 Indoor heat 41%
12 Skin care products 41%
13 Heated beverages 36%
14 Cosmetics 27%
15 Medications 15%
16 Medical conditions 15%
17 Fruits 13%
18 Marinated meats 10%
19 Vegetables 9%
20 Dairy products 8%
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5.8 - Medications:
• Topical Steroids:  
It is well know that oral or topical steroids can induce features resembling rosacea. 
The prolonged use of potent topical steroids on the face often produces symptoms 
and signs resembling papulopustular rosacea. If  application of steroids continues, 
fixed erythema and telangiectasia develop and may give similar features to idiopathic 
rosacea (60).  Whenever corticosteroid application stops,  rosacea flares up badly, 
leading to state of dependency. Patients usually do not recognise the cause and on 
the  contrary  continue  applying  steroids  as  the  application  produces  transient 
improvement in the symptoms. Even mild topical steroid application for a long period 
of time can produce rosacea especially in children (61). Long term use of a nasal 
steroid spray may also provoke steroid rosacea (62). 
• Topical  Calcineurin Inhibitors:  
Topical  application  of  calcineurin  inhibitors  can  cause  a  rosaceiform  dermatitis 
characterized by numerous small papules and pustules with mild erythema on the 
face.  The  distribution  of  this  eruption  is  generally  more  widely  spread  than  the 
centrofacial  pattern  of  papulopustular  rosacea.  Demodex  mites  have  been  have 
found  to  be  abundant  in  the  skin  of  those  patients.  This  is  attributed  to  the 
immunomodulating effects of calcineurin inhibitor agents which may act on a number 
of ways, including through an impact on the numbers of these mites in and on the 
skin (63).  
• Epidermal Growth Factor Receptor (EGFR) inhibitors:  
There  is  an  increasingly  reported  development  of  a  papulopustular  eruption 
resembling papulopustular rosacea that results from the use of Epidermal Growth 
Factor Receptor (EGFR) inhibitors in oncology. This may happen in up to 90% of 
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patients. It is more similar to papulopustular rosacea than acne vulgaris as it lacks 
comedones. These inflammatory lesions can involve the skin on the face, scalp, and 
trunk. The eruption has been attributed to the role of EGFR inhibitors in modifying 
cytokine signalling in the skin (64). It is reported that this eruption is also associated 
with an increased density of DF in the affected skin (65).  
• Other Medications:  
Some other drugs such as amiodarone or vaso-dilating drugs (e.g. nifedipine) may 
affect rosacea through vasodilatation by inducing flushing.
5.9 - Hormonal Changes:
Some authors  have noted  an increase  in  rosacea  during  pregnancy,  menses or 
perimenopausal periods. This has been attributed to the hormonal changes found at 
these times. There are many case reports of the association of rosacea fulminans 
and  pregnancy  (66).  Others  have  reported  rosacea  fulminans  occurring  abruptly 
during pregnancy with no history of preceding disease or any other triggering factors. 
This may resist treatment and persist during pregnancy. However this case improved 
and responded to treatment after delivery (67).
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Figure 5 - Molecular mechanisms of rosacea pathogenesis :(57)
Figure  5  shows  summary  of  molecular  mechanisms  of  rosacea  pathogenesis. 
Environmental changes, hormones and microbes challenges sensed the TLRs and 
other  pattern  recognition  receptors.  TLRs  signaling  induce  effector  molecules 
including cathelicidin, kallikrein, MMP, ROS, NO, cytokines and chemokines. These 
effectors  modify  the  dermal  structure  by  vascular  changes  and  collagen 
degeneration accompanied with inflammatory cells recruitment. Infiltrated neutrophils 
and  lymphocytes  will  be  the further  source of  effector  molecules,  which  activate 
TLRs directly and indirectly.   
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6. Diagnosis
To date,  no diagnostic  test  for  either cutaneous or ocular  rosacea,  including any 
serological  or  histological  markers,  has  been  described.  Diagnosis  of  cutaneous 
rosacea still depends on the clinical symptoms and signs and history review. The 
diagnosis may helped by skin biopsy for histology and direct immunofluorescence 
studies  (DIF)  to  exclude  other  skin  conditions  affecting  the  face  such  as  lupus 
erythematosus, facial dermatitis, facial sarcoidosis, and other alternative diagnosis. 
The diagnosis of  ocular  rosacea also relies on observation of  the eye signs and 
symptoms  including  conjunctivitis,  foreign  body  sensations,  burning  or  stinging, 
dryness, itching, light sensitivity, blurred vision, telangiectases of the conjunctiva and 
lid  margin,  lid  and  periocular  erythema,  anterior  blepharitis  or  meibomian  gland 
dysfunction.
There have been recent and ongoing studies to try to develop a diagnostic marker 
which may enable earlier diagnosis and treatment of both skin and eyes in rosacea. 
These studies are working on the glycomic profile of tears and saliva of rosacea 
patients, particularly those with ocular rosacea, as a biomarker for this disease. It 
was demonstrated that  certain polysaccharides such as sulfated oligosaccharides 
are  increased  in  the  tears  of  patients  with  rosacea.  More  recently  there  was  a 
published report on glycomic analysis of tears and saliva, and this confirmed that O-
glycans were increased in roseatic tear and saliva samples (68).
Until the development of new diagnostic markers, rosacea is still a clinical diagnosis, 
which is sometimes confirmed by histological examination and negative DIF study as 
well as by negative autoantibody screening. 
In  2002,  the  Committee  of  the  National  Rosacea  Society  (NRS) implemented 
standard  clinical  diagnostic  criteria  for  rosacea  (2).  The  committee  based  the 
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standard  classification  system  on  present  scientific  knowledge  and  morphologic 
characteristics.  This  avoids  assumptions  on  pathogenesis  and  progression,  and 
provides a framework that can be readily updated and expanded in future as new 
discoveries are made. 
The presence of one or more of the following signs as shown in table 4 with a central 
facial  distribution  is  indicative  of  rosacea.  These signs  are usually transient,  and 
each sign may occur independently. Many patients may present with a number of 
features at the same time.  Rosacea can vary substantially from one individual to 
another, and in most cases, some rather than all of the signs and symptoms appear. 
Table 4 - Diagnostic Criteria of Rosacea: (2)
Diagnosis can be made clinically by presence of one or more of the below primary 
symptoms and may include one or more of the secondary features:
No Primary Features Secondary Features
1 Flushing (Transient Erythema) Burning or Stinging
2 Non Transient Erythema Plaque
3 Papules and Pustules Dry Appearance
4 Telangiectasia Oedema
5 Ocular Manifestations
6 Peripheral location
7 Phymatous Changes
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Table 5 - Primary Features:
All these features can be graded as absent, mild, moderate, or severe.
No Sign Features
1 Flushing 
(Transient 
Erythema)
This is characterized by frequent attacks of flushing. This 
facial redness is often the earliest sign of the rosacea. 
Perimenopausal flushing should not be considered 
significant unless accompanied by other features of 
rosacea. 
2 Persistent 
Redness 
(Non-transient 
Erythema)
Persistent  facial  redness  is  the  most  common  individual 
sign of rosacea, and may resemble a blush or sunburn that 
does not go away. 
3 Papules and 
Pustules
Papules  are  small  red  raised  lumps,  which  may  be 
associated with pus-filled lesions. Sometimes these papules 
enlarge  and  form  nodululocystic  lesions.  These  papules 
may resemble acne, blackheads are absent and burning or 
stinging  may  occur.  Comedones  are  not  features  of 
rosacea.
4 Telangiectasia These are small blood vessels that become visible on the 
face. They can present without other features of rosacea in 
other normal people.
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Table 6 - Secondary Features:
These features can present with or without any of the primary features.
No Sign Features
1 Burning or 
Stinging
Burning or stinging sensations may often occur on the 
face. Itching or a feeling of tightness may also develop.
2 Dry Appearance The central  facial  skin  may be rough  and  dry  and  may 
resemble  eczema.  This  is  sometimes  associated  with 
features of seborrheic dermatitis.
3 Plaques Raised red patches may develop as a result of confluent 
areas of inflammation without changes in the surrounding 
skin. 
4 Skin  Thickening 
- Rhinophyma
Skin  may  thicken  and  enlarge  due  to  a  variable 
combination  of  fibrosis,  sebaceous  hyperplasia  and 
lymphoedema.  The  areas  most  affected  are  the  nose. 
Other areas that can be affected by similar changes are the 
forehead, chin, eyelids and ears. 
5 Oedema This is facial swelling, and can affect parts of the face such 
as  periorbital  or  glabellar  areas.  It  can  be  recurrent  or 
chronic persistent, may accompany other signs of rosacea 
or occur independently. 
6 Eye Irritation Ocular manifestations of rosacea are common.  These may 
include  itching,  burning,  stinging  sensations  and  light 
sensitivity. The eyelids also may become red and swollen. 
Other features are Chalazia and styes. Severe cases can 
result in corneal damage.
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6.3 - Histological Features:
The histological features are predominantly dermal changes and reflect the clinical 
subtypes. There is usually evidence of vascular and lymphatic channel dilatation with 
some solar elastosis.  There is a mixed inflammatory infiltrate of lymphocytes and 
neutrophils  and  macrophages,  which  can  be  perifollicular,  interfollicular  and 
perivascular as shown in figure 6 and 7. Some lesions show granulomatous features. 
Demodex mites are often found in the follicle as seen in figure 7 (69).
  Figure 6 - Rosacea Histology                          Figure 7 - Rosacea Histology  
           H&E stain, X40                                                     H&E stain, X40
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7. Classification
The first classification and staging of rosacea was developed by the NRS Experts 
Committee  and  was  published  in  April  2002  issue  of  the  Journal  of  American 
Academy of Dermatology (2). 
The  committee  developed  this  standard  classification  system  alongside  the 
diagnostic  criteria  to  use  as  a  diagnostic  instrument  in  investigating  the 
manifestations and relationships of the subtypes and variants of rosacea. 
The standard description of groups of rosacea is important in research studies to 
ensure  that  data  are  comparable.  The  classification  system  also  helps  in 
communication  between  different  clinical  and  scientific  researchers,  including 
dermatologists, primary care physicians, ophthalmologists and other specialists such 
as health and insurance administrators, patients and the general public.
There are four subtypes of rosacea, defined as common patterns or groupings of 
signs and symptoms and one other variant as shown in table 7.
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Table 7 - Rosacea Subtypes: (2)
Main Rosacea Subtypes  
No Subtype (Name) Clinical Features
1 Erythematotelangiectatic
Rosacea - (ETR)
Persistent central facial erythema, frequent 
flushing, may be telangiectasia.
2 Papulopustular
Rosacea - (PPR)
Red dome shaped papules and pustules with 
back ground erythema.
3 Phymatous
Rosacea - (PR)
Tissue hypertrophy involving different areas of the 
face but commonly affect the nose.
4 Ocular Rosacea - (OR) Different ocular inflammation of eye lid, 
conjunctiva, meibomian gland, and cornea.
 Rosacea Variant
1 Granulomatous Rosacea 
- (GR)
Chronic  inflammatory  facial  eruption  of  dome 
shaped  uniform  hard,  brown,  yellow,  or  red 
papules or  nodules with granulomatous features 
histologically. 
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7.1 - Subtype 1   -  Erythematotelangiectatic Rosacea (ETR):  
Characterized by persistent central facial erythema, with a tendency to repeated and 
prolonged episodes of flushing. This may or may not be associated with visible blood 
vessels. Other features may include stinging and burning sensations or mild facial 
oedema.  Patients  typically  have  skin  type  I  or  II  and  usually  present  with 
photodamage in these areas. This is considered to be an important element both in 
production  and  exacerbation  of  ETR.  In  addition,  patients  have  sensitive,  easily 
irritated skin that is abnormally reactive. Stinging and burning sensations develop 
easily to different stimulants such as facial products, air fresheners, and others. The 
skin  of  these patients  can  be  rough,  slightly  eczematous  and  this  is  sometimes 
referred as rosacea dermatitis (2).
    
      Figure 8 - Erythematotelangiectatic Rosacea (ETR)
ETR can be difficult  to distinguish clinically from heliodermatitis (Farmers face or 
Fisherman's face), a skin condition that affects outdoor fair skinned workers (skin 
type 1 or 2), and result from prolonged exposure to sun. Those people present with 
persistent facial and neck erythema with or without telangiectasia (70). 
  42
7.2 - Subtype 2   - Papulopustular Rosacea (PPR):  
This  is  also  known  as  classic  rosacea  and  is  characterized  by  persistent  facial 
redness with transient papules or pustules or both in various stages of evolution. The 
episodes of inflammation may lead to chronic oedema. Some patients present with 
recurrent  facial  flushing  that  can  precede  the  appearance  of  inflammatory 
papulopustular lesions. This subtype may resemble acne vulgaris, and was called 
acne rosacea. However, there are no comedones unless in some situations where 
rosacea can coexist concomitantly with acne. 
Figure 9 - Papulopustular Rosacea (PPR)
Male bald patients may develop papulopustular  inflammatory lesions on the bald 
scalp area in continuity with the facial eruption. Extra facial PPR has been described 
on the trunk and abdomen which can be difficult to distinguish from folliculitis (71). It 
may present in combination with ETR or ocular rosacea. The condition waxes and 
wanes, sometimes appearing to go into partial remission leaving no scars and at 
other times becoming active and inflammatory for no apparent reasons. 
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7.3 - Subtype 3 - Phymatous Rosacea (PR):
This  subtype  reflects  the  hypertrophy  of  sebaceous  glands  in  nasal  skin,  and 
occasionally elsewhere. It is characterized by persistent, firm, non-painful, non-pitting 
skin thickening with irregular surface nodularities which result in an enlargement of 
the  nose from excess tissue (Rhinophyma).  The earliest  clinical  manifestation  of 
rhinophyma is the appearance of dilated pores (Patulous Follicles) with subsequent 
development of telangiectatic vessels on the end and sides of the nose. It can occur 
with other subtypes of rosacea. However, it  may also occur in patients with acne 
vulgaris and occasionally result from chronic actinic damage.
Rhinophyma is sometimes considered as the end stage of rosacea. However, it can 
occur in patients with very mild rosacea changes or even with no evidence of the 
disease  at  all.  There  is  no  relation  between  the development  of  the  phymatous 
changes and the severity, duration or subtypes of rosacea.
Figure 10 - Phymatous Rosacea (PR)
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Other areas may develop the same changes of rhinophyma; this commonly affects 
male patients and examples are in table 8. 
Table 8 - Other forms of Phyma according to site involved: (72)
No Site of Phyma Features
1 Forehead /
(Mentophyma)
Cushion like firm swelling of the central forehead
2 Chin /
(Gnathophyma)
Rare,  affects  mainly  the  central  chin,  give  rise  to 
asymmetrical swelling.
3 Eyelids /
(Blepharophyma)
Swelling of  the eye lids, usually as a component of 
oedematous rosacea, but also can happen in severe 
papulopustular or ocular rosacea.  
4 Ears / 
(Otophyma)
Affects the lower half of the helices and lobes of ears.
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7.4 - Subtype 4   - Ocular Rosacea   (OR):  
This is defined as a range of changes that occur either in the eye lid, eye lashes, or 
eyes of patients with rosacea. The causes for these changes are unknown. It can 
precede  rosacea  of  the  skin,  so  diagnosis  can  be  very  difficult.  Those  with 
erythematotelangiectatic  and  particularly  papulopustular  rosacea  appear  to  be 
particularly vulnerable to develop ocular  inflammation with up to 50% of  patients 
affected (2). 
Symptoms are non-specific and include itching, tearing, dryness, gritty sensations, 
crusting of the eye lids, irritation to the eye lenses, and recurrent styes. Also light 
sensitivity and sometimes blurred vision may occur. Potential visual loss may result 
from  corneal  damage.  Most  patients  do  not  volunteer  these  symptoms  unless 
specifically asked.
Patients with  PPR appear  to be more prone to  developing OR.  The duration  or 
severity of  ocular  rosacea dose not  relate to the duration or  severity of  the skin 
disease, however it has been suggested that ocular rosacea can be correlated to the 
tendency of  patients to flush (73).   Another study found a significant  relationship 
between ocular involvement and the severity of telangiectasia (74).
One presentation  of  OR is  chronic  conjunctivitis  which is  characterized by inter-
palpebral bulbar conjunctival hyperemia, as well as a chronic papillary reaction (75). 
Akpek et al, described cicatricial conjunctivitis involving the lower eye lid  as one of 
the most common ocular  findings in rosacea (76). Other reports described chronic 
cicatrizing conjunctivitis affecting the upper eyelids, similar to the classical findings in 
trachoma (77). Pinguecula and conjunctival fibrosis have also been reported in up to 
20% of patients (78). 
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The summary of the commonest manifestations of OR according to the site of the 
eye involved are shown in table 9.
Table 9 - Commonest manifestations of ocular rosacea: (1)
No Site of eye 
involvement
Complications / Features
1 Eye Lids Blepharitis, lid telangiectasias.
2 Conjunctiva Conjunctivitis, conjunctival injection, or overgrowth.
3 Meibomian Glands Chalazion, hordeolum internum.
4 Lacrimal Glands Reduced tear secretion.
5 Cornea Punctuate erosions, keratitis, and perforations.
6 Sclera Scleritis, episcleritis.
7 Uvea  Uveitis. 
8 Iris  Iritis.  
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7.5 - Relationship of Rosacea Subtypes to each other:
Many patients experience characteristics of more than one subtype of rosacea at the 
same time, others may develop the subtypes in succession. While rosacea may or 
may not evolve from one subtype to another, each individual sign or symptom may 
progress from mild to moderate to severe. Early diagnosis and planning long term 
management including patient education and avoiding of any triggering factors are 
therefore recommended.
In  one  of  the  NRS  surveys  of  1231  rosacea  patients  showed  that  83%  of  the 
respondents had ETR, 62% had PPR, 50% had OR and 15% had PR. The survey 
showed that the general trend of the rosacea is to progress from subtype 1 (ETR) to 
subtype 2 (PPR) and then some cases to subtype 3 (PR). However, subtype 4 (OR) 
may develop at any stage even before skin symptoms (79). 
A further  study  of  135  rosacea patients  showed  that  PR  was  more  frequently 
associated with ETR than PPR (p < 0.001). 66% of patients developed ETR before 
PPR, 92% developed ETR before PR and 83% developed PPR before PR. The 
majority of patients developed cutaneous rosacea associated features before ocular 
rosacea (80). 
In conclusion, significant differences exist between the subtypes of  rosacea. There 
are no accurate data indicating the risk of the rates of progression of one subtype of 
rosacea to another.  
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Table 10 - Summary of Rosacea Subtypes: (2)
Rosacea 
Subtype
Signs  and Symptoms %
Subtype I : 
Vascular
Erythemato-
telangiectatic
(ETR)
- Flushing 
- Redness (erythema)     
- Telangiectasia
55% - 
70%
Subtype II : 
Inflammatory 
Papulopustular
(PPR)
- Redness (erythema)
- Papules, pustules
                                       
25% - 
40%
Subtype III : 
Phymatous 
(PR)
- Thick skin, nodules
- Irregular skin surface  
- Enlargement of nose 
 5%
Subtype IV : 
Ocular Rosacea
(OR)
- Foreign body sensation
- Burning and stinging
- Dryness and itching  
- Ocular photosensitivity
- Blurred vision  
 3% - 
50%
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7.6 - Granulomatous Rosacea (GR):
Granulomatous  rosacea  (GR),  considered  as  a  distinct  variant  of  rosacea 
characterized by non caseating epitheloid cell granulomas histologically. It is a rare 
condition characterized clinically by an eruption of  hard reddish papules or  small 
nodules, occurring on a thickened indurated erythematous base as shown in figure 
11.  It  may  be  severe  and  can  lead  to  scarring.  These  lesions  tend  to  be  less 
inflammatory than papules and pustules and can vary in size among patients but are 
monomorphic  in  each individual  patient.  The eyelids,  lower  part  of  the forehead, 
nasolabial  folds,  cheeks and perioral  area are frequent sites of involvement.  The 
course is chronic and unremitting (81).
        
Figure 11 - Granulomatous Rosacea (GR) 
GR may occur in locations other than those in which the phymas are observed. The 
presence of other physical signs of rosacea is not needed for a diagnosis of the GR. 
Although  the  exact  etiopathogenesis  of  GR  is  unknown,  the  role  of  a  delayed 
hypersensitivity  reaction  against  keratinized  cells,  pilosebaceous  structures  and 
microbial organisms has been suggested (82). Treatment of GR is not different from 
that  of  classical  rosacea and so the use of  oral  antibiotics  such as  tetracycline, 
doxycycline, or minocycline is usually effective (83).  Nevertheless, a tendency to 
relapse or recur may persist for several years. 
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8. Other Rosacea Variants
There are other similar skin conditions considered as variants of rosacea reported in 
the literature. However, many authors believe these variants may not be related to 
rosacea as they may have different histology and may have a different pathogenesis. 
The NRS committee recognizes these conditions as separate entities and concluded 
that  there  is  insufficient  basis  at  present  to  include  the  following  conditions  as 
subtypes or variants of rosacea (2).
8.1 - Rosacea Conglobata / Rosacea Fulminans (Pyoderma Faciale):
This is  a dramatic  development of  large facial  nodulo-cystic  lesions with marked 
erythema predominantly occurring in young women. In the past this was labelled as 
pyoderma  faciale  and  suggested  to  be  related  to  acne  vulgaris.  This  has  been 
renamed  recently  as  rosacea  conglobata  /  rosacea  fulminans  because  of  the 
association with marked redness and erythema. However, this condition can lead to 
devastating cosmetic scarring which is unlike other rosacea subtypes (2).  
The condition is  characterized by sudden generalized facial  pustular  lesions with 
erythema and facial oedema in patients who have suffered from frequent flushing 
and sensitive skin but without any other clinical features of rosacea or acne vulgaris. 
There is usually no preceding history of acne or rosacea. Systemic symptoms may 
occur, along with raised inflammatory markers (84). It  can be present in localised 
forms affecting the cheeks, jaw line or chin. It has been reported to be associated 
with pregnancy, suggesting hormonal factors may play a role as mentioned in the 
aetiology of rosacea in the previous section.
Treatment  is  usually  with  systemic  antibiotics.  However,  because  of  the  risk  of 
scarring, associated systemic symptoms and raised inflammatory markers, It is been 
reported to be most successfully treated with systemic steroids and oral isotretinoin. 
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In  one  series, 10  out  of  20  patients  were  treated  with  oral  prednisolone  at  1 
mg/kg/day combined with oral  isotretinoin 0.2 – 0.5 mg/kg/day.  The prednisolone 
was tapered off over 2-3 weeks and the isotretinoin continued for 3 -4 months (85). 
Figures 12 - Rosacea Fulminans 
Figure 12, is the photo of young lady patient who presented to my clinic in 2011 at  
Doncaster  Royal  Infirmary  Hospital,  with  history  of  sudden  onset  of  diffuse  red 
nodules and pustules with some erythema and skin oedema on the face. There was 
no history of acne, rosacea or flushing in the past and no obvious triggering factors. 
She was diagnosed as rosacea fulminans after skin biopsies for histology and DIF 
showed histological features of rosacea with negative DIF and negative ANA blood 
test with raised inflammatory markers, as well  as negative skin culture.  She was 
treated with a tapering dose of oral prednisolone 20mg daily for 2 weeks with oral 
isotretnoin 0.5mg/kg daily for 4 months with a very good result.
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8.2 - Steroid Induced Rosacea:
The excessive, regular use of topical fluorinated steroids on the face often produces 
an array of skin complications, including an eruption clinically indistinguishable from 
rosacea  called  'steroid-induced  rosacea'  or  ‘latrosacea’  (86).  Steroid-induced 
rosacea  is  characterized  by  centrofacial,  perioral,  and  periocular  monomorphic 
inflammatory papules and pustules distributed in areas that have been chronically 
exposed to topical steroids, especially of fluorinated type. The appearance is of a 
flaming red, scaly, papule covered face (red face syndrome) (87). 
 
         
          Figure 13 - Steroid Induced Rosacea
Continued or overuse of topical steroids can result in thinning of the skin as well as 
skin dependency on the steroid. At first the vasoconstrictive and anti-inflammatory 
effects of the steroids result in what seems to be clearance of the primary dermatitis 
but persistent use leads to epidermal atrophy, degeneration of dermal structure and 
collagen deterioration after several months (88). Also steroids inhibit the release of a 
natural  vasodilator  called  endothelium-derived  relaxing  factor.  Prolonged  used  of 
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topical  steroids  leads  to  vasoconstriction  which  in  turn  leads  to  the  build-up  of 
multiple metabolites such as nitric oxide, a potent vasodilator. Once the steroid is 
discontinued, the vasoconstrictor effect ceases and the diameter of the blood vessels 
is enlarged beyond their original pre-steroid diameter because of the accumulation of 
the nitric oxide, which in turn exacerbates the erythema, burning sensation and the 
pruritus (89). 
Treatment  involves  discontinuation  of  the  steroid  and  administration  of  oral 
tetracycline or  macrolides and non-steroidal topical preparations.  Once therapy is 
begun, clearing of the lesions may take several months.
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9. Differential Diagnoses
There are many other skin diseases which can resemble rosacea and occasionally it 
is  difficult  to  differentiate  between  them.  Investigations  including  skin  biopsy  for 
histology or  DIF,  skin allergy tests  and additional  blood tests  may be needed to 
exclude other differential diagnosis. 
Differential diagnosis of rosacea depends on the subtypes of rosacea as shown in 
tables 11, 12, 13 and these include: (1) 
Table  11  - Differential Diagnosis of ETR:  
No Differential diagnosis How to differentiate it from ETR
1 Disorder of flushing History, clinical examination, blood test.
2 Lupus erythematosus History, clinical examination, blood test, skin 
biopsy.
3 Seborrheic eczema History, clinical examination.
4 Atopic dermatitis History, clinical examination.
5 Contact and photo contact 
dermatitis
History, clinical examination, patch test, photo 
patch test
6 Facial sarcoid History, clinical examination, blood test, skin 
biopsy.
7 Topical steroid misuse History, clinical examination.
8 Facial erysipelas History, clinical examination. 
9 Jessner's lymphocytic 
infiltration
History, clinical examination, skin biopsy.
10 Polymorphic light eruption History, clinical examination.
11 Dermatomyositis History, clinical examination, skin biopsy, blood 
test.
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Table 12 - Differential Diagnosis of PPR:
No Differential diagnosis How to differentiate it from PPR
1 Acne vulgaris History, clinical examination.
2 Acne agminata History, clinical examination, skin biopsy
3 Perioral dermatitis History, clinical examination.
4 Seborrheic eczema History, clinical examination.
5 Facial sarcoid History, clinical examination, skin biopsy, blood test.
6 Tinea faceii / candida History, clinical examination, skin scraping / swabs.
7 Pityriasis folliculorum History, clinical examination, skin scraping.
8 Jessner's lymphocytic 
infiltration
History, clinical examination, skin biopsy.
9 Polymorphic light 
eruption
History, clinical examination.
Table 13 - Differential Diagnosis of PR:
No Differential diagnosis How to differentiate it from PR
1 Lupus pernio (Sarcoid) History, clinical examination, skin biopsy, blood test.
2 Lupus erythematosis History, clinical examination, skin biopsy, blood test.
3 Lupus vulgaris History, clinical examination, skin biopsy, blood test.
4 BCC / SCC/ Lymphoma History, clinical examination, skin biopsy.
5 Angiosarcoma History, clinical examination, skin biopsy.
6 Acrocyanosis History, clinical examination. 
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9.1 - Lupus Erythematosus (LE): 
Lupus erythematosus (LE) is a heterogeneous connective-tissue disease associated 
with polyclonal B-cell activation and is believed to result from the interplay of genetic, 
environmental,  and  hormonal  factors.  LE  is  more  common  in  women  than  men 
especially the systemic variety by at least 6 to 1. It  also varies between different 
ethnicities. For example, the prevalence of SLE in African American women is 4 in 
1000 compared to Caucasian American women at 1 in 1000 (90).
The  spectrum  of  lupus  disease  involvement  can  vary  from  limited  cutaneous 
involvement to devastating systemic disease. Cutaneous lupus erythematosus (CLE) 
is  the  second  most  common  presenting  symptom  of  autoimmune  LE.  Lesions 
precede the onset of systemic symptoms in 25% of patients, many of whom present 
to dermatologists for their initial evaluation (91). 
The  main  subtypes  of  cutaneous  lupus  (CLE)  according  to  the  James  Gilliam 
classification, based on the presence of interface dermatitis,  are acute cutaneous 
(ACLE), subacute cutaneous (SCLE) and chronic cutaneous (CCLE) (92). Further 
subdivisions  of  CCLE  include  discoid  LE  (DLE)  and  other  atypical  LE  specific 
lesions, including chilblain LE, LE tumidus (LET), and LE panniculitis.
ACLE accounts for about 6% of patients with CLE and it  is  characterized by the 
classic “butterfly rash” overlying the malar cheeks and nose as in figure 14. The rash 
is  photo-aggravated and  strongly  associated  with  exacerbations  of  SLE.  Lesions 
typically  resolve  without  atrophic  scarring  although  areas  of  post-inflammatory 
dyspigmentation may persist (93).
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Figure 14 - Butterfly rash of Lupus Erythematosus
DLE is the most common form of CCLE and classically presents as erythematous, 
coin-shaped plaques with central hyperkeratosis as in figure 15, with 70% of cases 
limited to the head and scalp. This pattern is rarely associated with systemic disease 
(94).
Figure 15 - Discoid Lupus Erythematosus
SCLE is characterised by a photosensitive rash in up to 85% of patients and the 
lesions  are  mainly  located  to  sun  exposed  areas;  neck,  chest,  upper  back, 
shoulders, dorsal parts of the arms and hands but surprisingly the face and scalp are 
seldom involved. The lesions start as erythematosus plaques or papules and then 
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become  either  widespread  annular,  polycyclic  lesions  that  clear  centrally  or 
papulosquamous (psoriasiform) lesions or rarely a combination of these two forms 
as in figure 16. The lesions are non-scarring but often heal with pigmentary changes 
that are long lasting. 
Figure 16 - Subacute Cutaneous Lupus Erythematosus
A diagnosis of chronic cutaneous lupus is made based on the clinical  findings of 
photosensitivity,  erythema, follicular plugging, dyspigmentation, telangiectasia, and 
skin atrophy. Scarring and skin atrophy are characteristic of DLE. The diagnosis is 
supported by skin biopsy for histology and DIF studies as well as the detection of 
autoantibodies in the blood in some patients. SCLE is strongly associated with the 
presence of anti-Ro/SSA antibodies, found in about 70% of patients, and positive 
ANA antibodies  in  60  -  80%,  whilst  between  30  -  50% display  the  anti-La/SSB 
antibody which is almost always seen together with the anti-Ro/SSA antibody. In DLE 
the involvement of autoantibodies is less clear but up to 50% may display low titres 
of ANA (95).
The histological features of cutaneous lupus depend on the subtype to a degree; 
however, an overlap in histological findings can occur between the various clinical 
phenotypes, particularly ACLE, SCLE and DLE. The most characteristic features of 
cutaneous  lupus  are  an  interface  dermatitis  with  vacuolar  change  of  the  basal 
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keratinocytes  (vacuolar  degeneration  or  hydropic  changes)  and  lymphohistiocytic 
inflammatory infiltrates in the early stages as shown in figure 17. However, in the late 
chronic  stage  of  those  phenotypes  that  resolve  with  scarring,  thickening  of  the 
basement membrane and dermal fibrosis and scarring are characteristic features as 
shown in figure 18. In DLE, periadnexal inflammation, follicular plugging and scaring 
are  common  features,  whilst  in  SCLE,  epidermal  changes  and  superficial 
lymphocytic infiltrates are more common. In contrast to DLE lesions, SCLE lesions 
tend to have little or no hyperkeratosis, basement membrane thickening, periadnexal 
infiltrate,  follicular  plugging,  deep dermal infiltrate,  or scarring (96).  Despite these 
reported differences, blind assessment of histology from different sub-types of LE by 
experienced skin pathologists is usually unable to accurately diagnose the sub-type. 
      Figure 17 - Lupus Histology                           Figure 18 - Lupus Histology 
                H&E stain, X40                                             H&E stain, X40
The most characteristic DIF finding from a biopsy of lesional skin is linear or granular 
deposition of  the IgG and/or IgM antibodies at  the dermo-epidermal  junction and 
around  the  hair  follicles  as  shown  in  figure  19,  with  or  without  deposits  of 
complement proteins. DIF performed on normal appearing skin can also show the 
presence of antibody deposits at the dermo-epidermal junction in SLE, but not in 
CCLE. When this examination is performed on non-light exposed skin, this is known 
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as the lupus band test as shown in figure 20. In general, a positive DIF test supports 
the diagnosis of cutaneous lupus; however, a negative test does not exclude the 
diagnosis  (97).  Patients  may also  have  circulating  positive  autoantibodies  in  the 
blood including ANA, and anti-DNA as well as anti-Ro and anti-La antibodies directed 
against soluble cytoplasm antigens.
   Figure 19 - Linear Deposition of IgG              Figure 20 - Lupus band in DIF 
All subtypes of cutaneous Lupus may present with facial rashes with varying degrees 
of erythema and papulo-nodular lesions, and so all fall into the differential diagnosis 
of rosacea. The butterfly erythema precipitated by UV and sparing those areas with 
limited UV exposure may be mistaken for ETR, because of the distribution, although 
pustulation would only be seen with the papulo-pustular version of rosacea.  In the 
chronic stage of lupus, especially with the long term use of potent topical steroids, 
telangiectasia and erythema can develop in addition to the lupus rash.  However, 
scarring, follicular plugging and skin atrophy are features of discoid lupus and not 
rosacea. There is, however, a version of discoid lupus that is papular, not pustular in 
nature, and known as rosaceous lupus, and this is easily confused with rosacea (98). 
Nevertheless,  it  is  easy to see therefore that  a patient  with a facial  rash due to 
rosacea, a positive ANA with titre at 1:80 and  joint  symptoms due to degenerative 
disease or fibromyalgia might be misdiagnosed as suffering with lupus. 
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As in rosacea the lupus pathogenesis involved the expression of LL-37. It is been 
proposed  that  LL-37  can  complex  with  self  DNA  activating  dendritic  cells  to 
contribute  to  the  pathogenesis  of  lupus  erythematosus  (99).  In  one  study 
investigating  the  relationship  of  LL-37  in  skin  of  SLE  and  their  role  in  SLE 
pathogenesis, skin biopsies were taken from 9 active SLE patients and compared 
with 6 healthy controls. The expression of LL-37 was significantly higher in the skin 
of the SLE group than healthy controls (detected by immunohistochemical technique 
and in situ hybridization, p<0.001) (100). An other study determined the expression 
of several AMPs including cathelicidin LL-37 in 47 patients of different subtypes of 
CLE compared to 15 healthy controls by analysing the skin lesions for gene and 
protein  expression  using  real  time  reverse  transcriptase  PCR  and 
immunohistochemistry.  The  results  showed  LL-37  was  significantly  more  highly 
expressed in CLE as compared to healthy controls and this is much higher in SCLE 
than in DLE and LE Tumidus (101). 
So, from the above studies, this is may explain partly why rosacea and lupus may 
both be triggered by UV light and why the skin mostly involved is the sun exposed 
areas. This is could be the result of the activation and expression of the cathelicidin 
LL-37 by UV light,  although there is also a role for the Ro antibody in patients with 
SCLE.
Treatment of cutaneous lupus is completely different from that in rosacea, so it is 
important to confirm a diagnosis before starting treatments. Indeed some treatments 
for rosacea such as tetracyclines and particularly minocycline may aggravate lupus, 
and  treatment  of  lupus  such as  topical  or  oral  steroids  may aggravate  rosacea. 
Finally, it is also possible for patients to have both lupus and rosacea at the same 
time. 
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10. Management of Rosacea
Rosacea requires long-term treatment.  There are many treatment  modalities  and 
these treatments depend on stage and severity of  the disease.  These treatment 
modalities include topical, oral, laser, and surgical therapies.
10.1 - Aims of the treatment are:
1. Reduce signs  and  symptoms including skin  irritations,  stinging,  erythema, 
inflamed papules and pustules.
2.  Delay or prevent development progress of the disease from the milder stage 
to the more sever stage.
3. Facilitate remission and control exacerbation.
4. Maintain skin integrity
5. Improve patient quality of life.
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10.2 - Topical Treatments: 
    These include Azelaic Acid (15%, 20%), Erythromycin (2%), Metronidazole (0.75%, 
1%)  or  Sodium  Sulfacetamide  10%  +  Sulfur  5%.  Vehicle  selection  for  topical 
treatment of rosacea is important as most patients have sensitive skin: the choice 
between lotion, gel, cream or foam as the delivery system is important as it will affect 
treatment usage and inevitably influence outcome.
    
      Topical Metronidazole:  
     It is the most widely used topical treatment in rosacea and available in different forms 
and concentrations including 0.75% gel, lotion, and cream for twice a day and 1% 
gel or cream for once daily use. A number of trials have demonstrated it  is more 
effective  when  compared  to  placebo  (102).  there  was  no  statistically  significant 
difference between 0.75% gel or 1% cream with respect to reduction of erythema, 
papules and pustules, (103). 
Topical Azelaic Acid:
    A study  showed  significant  improvement  of  rosacea  inflammatory  papules  and 
pustules with 15% azelaic acid gel (104). An other study has confirmed that there is 
no significant difference between once daily and twice daily use of 15% gel (105).  
Topical Sodium Sulfacetamide 10% and Sulfur 5% in combination:
This combination of sodium sulfacetamide and sulfur has been used for treatment of 
rosacea.  The mechanism of  action  is  not  well  known but  the  sulfacetamide  has 
antibacterial  effect  and  the  sulfur  has  antifungal,  anti-demodectic  and  keratolytic 
effects. In a double blind placebo controlled study, the inflammatory lesions and the 
erythema improved significantly in the treated group compared to the placebo group 
(106).
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Topical Erythromycin and Clindamycin
Both are not  very commonly used in  rosacea however,  topical  erythromycin  has 
been reported to reduce the erythema, papules and pustules in mild rosacea patients 
(107). Topical clindamycin twice daily produced clearance similar to oral tetracycline 
1000 mg daily for 3 weeks followed by 500mg daily for further 9 weeks (108).
Topical Tacrolimus:
Topical  tacrolimus was reported to be effective treatment for  rosacea induced by 
steroids (109).
10.3 - Systemic Treatments:
Systemic  treatment  is  mainly  for  moderate  to  severe  papulo-pustular  or  ocular 
rosacea,  and  this  includes  the  oral  tetracyclines:  Tetracycline,  Oxytetracycline, 
Doxycycline,  Minocycline,  macrolide  derivatives  such  as  Erythromycin, 
Metronidazole, and occasionally drugs such as Dapsone, as well as oral retinoids.
Oral Tetracyclines:
Tetracycline  compounds  were  the  first  systemic  drugs  used  in  the  treatment  of 
rosacea, and have been the mainstay of oral therapeutics in this disease for more 
than 40 years (110). These agents possess anti-angiogenic and anti-inflammatory 
properties that  make them the drugs of  first  choice in  the treatment  of  rosacea. 
Several  studies  have  shown  that  tetracylines,  including  doxycycline,  have 
immunomodulating properties (111). These anti-inflammatory effects have been used 
to target several pathophysiological mechanisms in rosacea.
Oral Low Dose Doxycycline:
Low dose doxycycline 40mg (30mg immediate release and 10mg delayed release) 
once daily is the new trend in rosacea treatment; it provides a sub-antimicrobial dose 
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that reduces inflammatory lesions without risking an increase in bacterial resistance 
(112). Efficacy has been demonstrated in a number of trials, including those in which 
it was compared with placebo (113), conventional dosage of doxycycline 100mg daily 
(114)  and  as  an adjunct  to  topical  therapy (115),  (116),  also  assessment  of  the 
effectiveness and safety (117),  and as an effective promoter of quality of life (118). 
Oral Macrolides:
Oral erythromycin at a dose of 250mg to 1000mg a day is considered an effective 
treatment for papulo-pustular rosacea (119). It is usually used when the tetracyclines 
group is not working or when it is contraindicated such as in the treatment of rosacea 
in pregnancy or lactation and children of less than 12 years. The use of second 
generation of macrolides in rosacea including clarithromycin and azithromycin is less 
common, but they are of proven efficacy (120), (121). 
Oral Metronidazole:
Metronidazole  is  an  effective  alternative  treatment,  as  demonstrated  by  Pye  and 
Burton in 1976 (122) at least for inflammatory rosacea. A second study demonstrated 
equivalence with tetracycline (123).
Oral Isotretinoin:
Multiple reports from the 1980s established the effectiveness of oral isotretinoin for 
rosacea. Importantly, recalcitrant cases of rosacea have been successfully treated 
with  oral  isotretinoin  using  a  dosage  range  of  0.5  to  1mg/kg/day  (124),  (125). 
Isotretinoin also has been reported to reduce nasal size in rhinophyma (126).
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10.4 - Laser and Light Treatments:    
  
Vascular laser therapy for telangiectatic rosacea started in the early 1980, and since 
then it has progressed to include the use of many devices and different types of light 
producing machines. Recently the approaches of treating rosacea with laser have 
extended not  only to include the treatment of  telangiectasia but  also now involve 
remodelling  of  the  dystrophic  dermal  connective  tissue  and  strengthening  the 
epidermal barrier. Some modalities such as intense pulsed light have also been used 
to treat  inflammatory rosacea.  The mode of  action of  non-ablative laser and light 
therapy in rosacea is probably through the impact of thermal induced fibroblast and 
endothelial  proliferation leading to cytokine,  growth factor  and heat  shock protein 
activation.
Vascular Laser:
Laser is used for the treatment of telangiectasia and erythema: the main modalities 
used are the pulse dye laser (585, 595 nm), the long pulsed dye laser (595 nm), the 
potassium titanyl-phosphate lasers (532 nm) and diode laser (532 nm). A number of 
studies have demonstrated effectiveness using the pulsed dye laser (127), and the 
KTP laser (128). The use of pulsed dye laser results in a significant improvement in 
quality of life in ETR patients (129). 
Intense Pulsed Light:
Intense pulsed light penetrates skin deeper than vascular lasers and targets multiple 
chromophores including melanin and hemoglobin.  Angermeier’ study showed that 
174 (92.5%) of a total of 188 patients had at least a 75% clearance of their vascular 
lesions (130). Improvement can be long-term as shown by Weiss and Beasley in a 4 
year follow up study (131).  
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10.5 - Treatment of Phymatous Rosacea:
Isotretinoin been reported to reduce size of  the glandular  rhinophyma in its  early 
stages, especially if it is accompanied with inflammatory pauples and pustules or oily 
greasy seborrhoeic skin (132). Pulsed Dye Laser is another form of treatment for the 
angiomatous type of rhinophyma acting by obliteration of prominent vessels, and the 
CO2 Laser is effective treatment of rhinophyma where the large distorting nodules 
can be successfully destroyed with good cosmetic results (133).
There are many more traditional surgical procedures that may also be effective for 
the nodular lesions in advanced glandular rhinophyma. These include simple shave 
excision  and  razor  modelling  with  subsequent  healing  by  granulation  and 
reepithelization. Excision and skin grafting,  dermabrassion, cryotherapy and radio- 
therapy can also have a role (1). 
10.6 - Treatment of Ocular Rosacea:
The following are the options for treatment of ocular rosacea (134):
1. Artificial tears frequently needed for dry eyes.
2. Lid and lash hygiene using warm soaks or compressor.
3. Topical  antibiotics  for  infected  blepharitis  including  metronidazole, 
erythromycin, and fucidic acid.
4.  Expression of the meibomian glands by manual massage. 
5. Systemic antibiotics including minocycline,  doxycycline,  oxytetracycline, 
and erythromycin.
6. Surgery – incision and drainage of the chalazion. 
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10.7 - New Treatments:
New therapies  are  being  investigated  for  treatment  of  rosacea;  all  are  primarily 
targeted toward control of DF and these include: topical 5% permethrin, topical 1% 
ivermectin or combination of topical permetherin and oral  ivermectin. 
Permethrin: 
Several  case  reports  showed  benefit  of  use  of  topical  permethrin  in  rosacea  in 
combination with or after oral ivermectin therapy (135). Aquilina et al, found topical 
permethrin with single dose of oral invermectin effectively resolve rosacea symptoms 
in  immune  compromised  patients  after  failure  of  topical  ketoconazole  or 
metronidazole treatment (136). 
Ivermectin:
Ivermectin is a strong acaricide; its efficacy against Demodex was reported in many 
case reports (137). The significant impact on DF and possibility of anti-inflammatory 
properties of  ivermectin  has prompted investigation into development  of  a topical 
product  for  treatment  of  rosacea.  Two  randomized,  double  blind-blind,  controlled 
studies  examined  the effect  of  ivermectin  1% cream once  daily  for  12  weeks  in 
treatment  of  moderate to  severe PPR.  The results  showed statistically  significant 
improvement of inflammatory lesions in the treatment groups compared to placebo 
groups (p<0.001) (138). As single oral dose of ivermectin has been reported to be 
effective treatment of a child with ocular and cutaneous rosacea with high density of 
DF mites which did not respond to  doxycyline and isotretinoin treatments (139).
The  above  studies  may  confirm  the  role  of  DF  in  the  pathogenesis  of  rosacea 
particularly PPR and proves that eradication of DF may improve inflammatory lesions 
of rosacea. However, the number of these studies and patients involved were small 
and these new treatments need further large studies to prove their efficacy.
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11. ANA Blood Test
Serum  ANA are  defined  as  all  the  antibodies  that  can  be  detected  by  indirect 
immunofluorescence (IIF) and are reactive against nuclei or sometimes to soluble 
cytoplasmic antigens found in human cells. The current version of the ANA assay 
used  now in  most  laboratories,  including  those  supplying  results  for  this  thesis, 
employs a human tumour cell line such as Hep-2 for the nucleated cell substrate. 
The determination of the ANA is made more relevant by a quantitative assay titre, 
which reflects the serial serum dilutions necessary for fluorescence to disappear. The 
majority of laboratories set a minimum level of dilution to separate relevant positive 
tests from non-specific positives with no clinical relevance. This is usually set at 1:80, 
and this is the level accepted as relevant in this study. It is an effective blood test for 
screening patients for the presence of CTD including lupus erythematosus. However, 
positivity of ANA can also occur in patients without underlying autoimmune diseases. 
Positive insignificant low titre ANA is reported more frequently in females than males 
and their incidence increases with age, with around a fifth of 60 year old women 
being non-specifically positive (140).
In one report, based on 15 international laboratories, the ANA positivity rate in the 
healthy normal populations aged between 20 to 60 years was 13.3% at 1:80, 5% at 
1:160 and 3.3% at 1:320 (141). Shu et al, reported an insignificant positive low titre 
of ANA at 1:10 occurs in 45% of healthy adults between age of 18 and 66 years, a 
titre of 1:40 occurs in 19%, and titre of 1:80 or more present in 5.6% of the same age 
group of  those healthy adults  (142).  Anderson et  al,  found that  the incidence of 
positive ANA of normal adults with age range from 21 years to 40 years was 2%, this 
incidence increased to 9% of adults with age range from 41 years to 60 years and 
further increased to 25% of adults over 65 years of age (143), although this seems 
very high for a UK population, even at low titres. In one Japanese study, investigating 
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the prevalence of ANA positivity in a general population of 2181 residents of small 
town, the results showed that 26 % were ANA positive at 1:40 titre and 9.5% were 
positive at 1:160 dilutions, females having a significantly higher positivity rate than 
males (P<0.0001) (144). Another study from Brazil, of a healthy control population, 
investigating the ANA positivity of 500 normal individuals, showed that ANA positivity 
was almost twice as prevalent in females as in males (145). 
So, although, ANA is still one of the most important screening and diagnostic tests of 
CTD however, false positive result of low insignificant titre can be detected in normal 
populations as in the above studies and this is especially reported more in elderly 
females. The positive results can be variable between different nations and different 
laboratory methods used. 
In  this  study  both  centers  (Leeds  and  Doncaster  Hospitals)  used  the  same  IIF 
method  and  the  same  substrate  (human  tumour  cell  line,  Hep-2  cell)  and  only 
considered ANA positive if the titre is ≥ 1:80.
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Chapter Two – The Study
1. Aims of the Study
2.  Method of the Study
3.  Statistical Analysis
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1. Aims of the study
There is a limited literature examining rosaceous skin disease and its associations 
particularly with the positivity of ANA and systemic symptoms, within dermatology, 
and  also  in  rheumatology.  Given  the frequency of  the  disease,  the  possibility  of 
misdiagnosis of rosacea mostly with skin lupus, and the therapeutic implications of 
this error, the subject is worthy of more significant investigation. 
This was principally an observational study, attempting to identify the relationship, if 
any, between rosacea and immunological and systemic symptomatology suggestive 
of  CTD.  The study investigates  the frequency of  a  positive  ANA with  or  without 
systemic symptoms including myalgia,  arthralgia,  and Raynaud’s  phenomenon.  It 
also investigated if there are any associations between rosacea and CTD particularly 
cutaneous lupus. 
This study investigated a large group of patients with rosacea, identified from the 
Dermatology  and  Rheumatology  Departments  in  Doncaster  and  Leeds.  It 
concentrated on clinical elements of the condition, and their relationship to laboratory 
abnormalities, associated more general symptoms and related CTD.
Patients with more general symptoms were compared with those with only localized 
skin  disease  affecting  the  face  in  a  descriptive  analysis  intended  to  aid  early 
detection of those likely to have more generalized symptoms, and also to help early 
and  more  specific  diagnosis  in  relation  to  those  disorders  often  confused  with 
rosacea. 
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The three principle questions of the study were:
1. In  the  cohorts  of  patients  studied,  what  was  the  frequency  of  ANA 
positivity? 
2. Is  there  a  sub-group  of patients  with rosacea  that  has  systemic 
symptoms with or without immunological abnormalities?
3. Is there any relation between rosacea and its sub-types and connective 
tissue diseases, particularly lupus erythematosus?
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2. Method  s  
Patients with Rosacea were identified from routine outpatient clinics in Leeds (based 
at Leeds General Infirmary and Chapel Allerton Hospitals) and Doncaster (based at 
Doncaster  Royal  Infirmary  and  Bassetlaw  Hospitals).  The  principal  investigator 
identified participants from patients attending routine outpatients appointments at the 
hospital department involved. The study was discussed with potential participants 
verbally and they were supplied with a written information leaflet (see later) about the 
study. Subsequently they gave written consent (see later) if they were willing to be 
involved. Patients who were not able to give the consent for any reason were not 
included in this study. Patients who did not understand or speak English were only 
included if  they had a family member or  interpreter  who was able to convey full 
understanding of the study information sheet.
All information about rosacea was recorded in the rosacea data proforma (see later). 
This included patient age, sex, duration of rosacea, history of acne vulgaris, family 
history of rosacea, triggering factors and previous treatment. The clinical pattern of 
the rosacea was identified (erythemato-telangiectatic, papulo-pustular, phymatous or 
occular) as well  as the skin type. Additional clinical  information was documented, 
concentrating particularly on features suggesting ‘systemic’ upset, such as arthralgia, 
myalgia  and  Raynaud’s  phenomenon.  Previous  blood  test  results  were  used  to 
identify  the  presence of  ANA with or  without  the available skin biopsy results for 
histology and DIF study were all reported. 
It  was intended that 150 patients should be available for investigation, however I 
managed to in investigate 169 patients from both Leeds and Doncaster hospitals (93 
patients from Doncaster and 76 patients from Leeds) of both sex (male = 77 and 
female = 92) of different age group (average = 50 years) and different skin types.  All 
patients  had  ANA blood  test  recorded  but  not  all  patients  investigated  for  the 
histology or DIF study.       
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2.1 - Inclusion criteria:
• Rosacea  patients  who  were  diagnosed  clinically  retrospectively  in  the 
dermatology departments of Leeds and Doncaster hospitals with or without 
confirmation of skin histology or DIF test but with an available ANA blood test 
performed for screening purpose.
• Male and female
• Age 18 and older
• Attending hospital clinics
• Able to give informed consent
2.2 - Exclusion criteria:
• Unable to give informed consent.
• Rosacea patients who had no previous ANA blood test. 
2.3 - Control group:
A control group of patients attending a skin cancer screening clinic with no known 
musculoskeletal  diagnosis were asked to be involved,  and were asked about  the 
presence of the symptoms described in the questionnaire used for the study group. 
This  was  to allow some comparison of  features such as  arthralgia,  myalgia  and 
Raynaud's phenomenon with a local control group, and also to establish consistency 
of the results with the published literature.
2.4 - Data storage:
Data was stored on hospital-based computers in secure offices. All completed paper 
recorded data is kept in a locked filing cabinet in a locked office within a security 
protected NHS hospital dermatology department. Data for analysis did not include 
any identifiable personal data, but was grouped for disease and results status.
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2.5 - Indirect Immunofluorescence (IIF) for the detection of ANA:
This is the method used to detect the ANA in all patients in the study. Both centres 
used multispot slides containing Hep-2 cells as a substrate to detect the antibodies 
in a patient’s serum. The steps of performing the IIF method are:
Step 1 - Addition of controls and samples:
1. 1 drop of positive control and 1 drop of negative control sera are dispensed to 
the appropriate slide wells. 20 - 25 μl of fresh diluted patient serum is added 
to the remaining wells.
2. The slides are placed in a staining container and incubated for 30 minutes. 
During  this  incubation  period,  any  anti-nuclear  antibodies  in  the  patient’s 
serum will bind to antigens expressed by the Hep-2 cells that are fixed onto 
each well.
3. After the incubation period, the serum is washed off with buffer the slide is 
placed into a coplin jar containing wash buffer for approximately 5 minutes.
Step 2 - Addition of fluorescent conjugate:
1. Excess wash buffer is removed and 1 drop of fluorescent conjugate (Anti-
human IgG) added to each well.
2. The slides are incubated for 30 minutes in a humidified container. During this 
incubation period, the conjugate will bind to any anti-nuclear antibodies that 
have  bound  to  Hep-2 cell  antigens.  This  conjugate  binding results  in  the 
presence of fluorescence in the wells.
3. The slides are re-washed and any excess wash buffer removed.
Step 3 - Identification of positive results:
1. The  prepared  slides  are  viewed  with  a  fluorescent  microscope,  first  by 
scanning  20 or  25x  objective  to  assess  cell  distribution  and  uniformity  of 
fluorescence,  then  with  40x  objective  to  make  the  final  interpretation 
regarding positivity and pattern. 
2. Any fluorescence at ≥ 1:80 dilution is accepted as a positive result.
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• Automated Fluorescence Microscopy may be used in modern laboratories. 
Figure 21 - IIF steps for ANA test:
            (Step 1)                                 (Step 2)                                   (Step 3)
Figure  21  shows  the  stages  of  IIF  for  the  detection  of  ANA.  HEp-2  cells  are 
permeablised (step 1) and then incubated with the patient's blood serum (step 2). If 
the  serum  contains  antibodies,  they  will  bind  to  antigens  within  the  HEp-2  cell 
nucleus.  These antibodies can be visualised by subsequent  incubation  with  anti-
human antibodies conjugated to a fluorescent molecule (step 3). 
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2.6 - Rosacea Study Data Proforma:
1. Patient No                         2. Sex                         3. Age - (D.O.B)
4. Skin Type:  According to Fitzpatrick skin types (1 – 6).
5. Duration of Rosacea Symptoms: From the start of the first rosacea symptoms.
6. History of Acne Vulgaris:  Patients considered having history of acne only, if 
they have moderate to severe acne and received any form of systemic treatment 
including different oral antibiotics, retinoids or hormonal treatment either from their 
general practitioners or by dermatologists. 
7. Family History of Rosacea: First degree relatives.
8. History of Steroid Treatment:
• Topical - Any topical steroids from mild to very potent steroids used on the 
face or neck before rosacea symptoms. 
• Systemic  -  Including  oral,  intravenous  or  intramuscular  steroids  taken 
before  the  start  of  rosacea  symptoms.  For  the  intravenous  and 
intramuscular steroids, this means a course of injections and not  a single 
injection.
• Inhalers - Any steroid inhalers either for asthma, allergic rhinitis or others.
9. Triggering Factors:
• Sun
• Cold / Hot weather
• Alcohol
• Spicy Food
• Hot drinks
• Medications
• Others - Include exercise, pregnancy, female period or emotional stress.
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  10. Associated Systemic Symptoms:
• Flushing  -  Recurrent  flushing  not  associated  with  other  systemic 
symptoms that indicate others diseases.
• Eye  Symptoms  -  Any  eye  symptoms  not  related  to  any  other  eye 
diseases. Those patients seen previously by ophthalmologists and other 
eye problems were excluded.
• Myalgia -  Muscle  pain  where the patients  need to take pain killers  to 
relieve  it  and  whether  it’s  related  or  not  related  to  other  systemic 
diseases.
• Arthralgia - Joint pain where the patients need to take regular pain killers 
and whether it’s related to or not related to connective tissue diseases. 
• Reynaud’s  phenomenon -  Typical  history and symptoms of  Raynaud’s 
phenomenon and patients tried some form of treatment either by their 
general practitioners, dermatologists or rheumatologists.
   11. History of Connective Tissue Diseases (CTD):
• Any CTD diagnosed and treated by dermatologists  or  rheumatologists 
and recorded in patient’s hospital notes. 
   12. Type of Rosacea:
• Erythemato-telangiectatic Rosacea (ETR) - Erythema, telangiectasia, with 
or without flushing
• Papulo-pustular  Rosacea  (PPR)  -  Papules,  pustules,  with  or  without 
erythema and flushing.
• Phymatous Rosacea (PR) - Mainly Rhinophyma 
• Ocular Rosacea (OR) - Diagnosed by ophthalmologists where other eye 
diseases were excluded.
• Mixed pattern - Any mixed pattern. 
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 13. Investigations:
• Blood -  (ANA)  -  Titre  ≥ 1:80 detected by IIF  method  and using Hep-2 
substrate is considered positive in both Leeds and Doncaster hospitals 
laboratories. All patients were tested for ANA retrospectively.
• Histology - Typical histology features of rosacea. Not all patients had the 
histology study.
• Direct Immunofluorescence Study (DIF) - Only few patients were tested for 
DIF. 
   14. Treatments:
• Topical  -  Any  topical  treatment  either  by  general  practitioners  or 
dermatologists. 
• Oral  Antibiotics  -  Any  course  of  oral  antibiotics  either  by  general 
practitioners or dermatologists. It was difficult to record specific name of 
antibiotics  as  many  patients  tried  many  courses  by  their  general 
practitioners before referral  to hospital  which are not  recorded in  their 
hospital  notes  and was  not  clearly  and specifically  mentioned  in  their 
general practitioners referral letters.
• Oral Isotretinoin -  Always given by dermatologists and recorded in the 
hospital notes
• Combined Treatments - Any combined treatments of different topical and 
different systemic.
  81
2.7 - Rosacea Study Participant Information Sheet:
Introduction: 
You have been invited to take part in research looking at the features of your skin 
condition, Rosacea. Please take your time to decide whether you would like to take 
part and discuss it  with your friends and family if  you wish. Please ask the study 
doctor to explain anything you do not understand. Your care will not be affected if you 
decide not to take part. 
You have a skin disease called Rosacea, which is a common skin condition that is 
estimated to affect about 1 in 10 people in UK and over 45 million people worldwide. 
Whilst most patients have a rash on their face, with redness, others may get other 
features such as dilated blood vessels, pus filled spots, gritty eyes, and burning and 
stinging sensations. Some other patients develop symptoms such as joint aches that 
may or may not be related to the disease. In these patients, the diagnosis can be 
unclear,  and there may be confusion with other skin diseases. The cause of  the 
disease  is  unknown,  although  there  are  many  unproven  theories,  and  the 
relationship of the various symptoms to the condition may help us to rule out some of 
these, and develop other more promising ones. There are also a number of methods 
of  treatment  for  the  condition,  although  we  are  not  studying  that  aspect  in  this 
research.
What is the purpose of this Study?
This  study will  investigate  a large group of  patients  with  Rosacea,  and is  being 
carried out to be submitted for a higher medical qualification (an MD or Doctorate of 
Medicine). It involves collecting information about the way the condition affects you. 
We will  be able to collect most of the information from your hospital  records,  for 
instance,  the  results  of  laboratory tests,  but  may need  to  talk  to  you  about  the 
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symptoms that the condition causes. This will allow us to compare the condition in a 
large number of patients, and allow us to detect links to other diseases. 
Why have I been chosen?
You are being asked to take part in this research because you are known to have 
Rosacea. 
Do I have to take part? 
No, your participation is voluntary and your care and treatment will not be affected by 
any decision you make about taking part in the study. If you wish to withdraw from 
the study,  you  are  free to  do so at  any time and this  will  not  affect  your  future 
treatment. 
What do I have to do?
In order to participate in the study we will ask you to sign a consent form and the 
study doctor will ask you few questions about your condition. Then, we will collect 
some details, including the results of previous tests such as skin biopsy and blood 
results from your hospital notes. We will not be performing any additional tests that 
have not already been performed by the doctor who normally looks after your skin 
problem. 
What are the possible disadvantages and risks of taking part?
There are no risks at all. You only need to attend an outpatient appointment where 
you been treated before for about 20 minutes only once. 
What are the benefits of taking part?
There  are  no  personal  benefits  for  you;  however,  this  study  will  extend  our 
understanding of Rosacea.
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Will my taking part in the study be kept confidential?
All the information given for the purpose of this study will be treated confidentially. 
What will happen to the results of the research study?
When the study has been completed, we will aim to publish the results in a peer-
reviewed journal. Please let us know if you wish to be informed of the publication of 
the study and we will aim to keep you fully informed. You will not be identified in any 
publication.
Will you inform my GP Doctor?
Yes, we will inform your GP doctor about your participation in this study unless you 
advise us not to inform them, we will also keep your doctors informed about your 
future skin management as before
I am interested in taking part in this study – What do I do now?
Contact the Research Team directly as below and we will give you an appointment to 
come  to  Dermatology  Outpatients  Department  either  in  Leeds  General  Infirmary 
Hospital or Doncaster Royal Infirmary Hospital depends on your convenience.
Whom  can  I  contact  for  participation  in  this  study  or  for  any  further 
information?
Dr. Mark Goodfield - 0113 3922581 (Leeds General Infirmary Hospital) 
Dr. Mustafa Marai - 01302 366666 (Doncaster Royal Infirmary Hospital)
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2.8 - Consent Form:
Title of Project: A clinical and Pathological Investigation of Rosacea.
Name of Researcher: Dr. Mustafa Marai
Title:                         Initial:                                  surname:
1.  I confirm that I have read and understand the information 
sheet dated 22/04/2009 - Version (3) for the above study.
2.  I have had the opportunity to consider the information, ask questions and
have had these answered satisfactory.
3.  I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason and without my medical 
care or legal rights being affected. 
4.  I understand that relevant sections of my medical notes and data 
Collected during the study may be looked at by individuals, from 
regulatory authorities or from the NHS Trust, where it is relevant to 
my taking part in this research. I give permission for these individuals 
to have access to my records. 
5.  I understand that my details will be recorded in the Proforma Sheet 
(Study questionnaire interview sheet), so it will be identifiable and 
will be stored on hospital-based computers. All completed paper 
recorded data will be kept in a locked filing cabinet in locked 
office within security protected NHS Hospital Dermatology Department. 
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Data for analysis for publication in future will not include any of my 
Identifiable personal data,                                                                  
6.  I agree that skin biopsies and blood tests already taken may be used 
for the research.
7.  I agree to my GP being informed of my participation in the study. 
8.  I agree to take part in the above study. 
______________                     ________________                   _________________ 
Name of Patient                         Date             Signature 
_______________                  ________________               ___________________ 
Name of Person                         Date               Signature 
Taking consent 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in 
medical notes. 
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3. Statistical Analysis
3.1 - Sample Size Calculations:
Whilst  the  majority  of  the  analyses  in  this  retrospective  observational  study  are 
descriptive, multivariate binary logistic regression was used to identify the features 
that are most helpful in distinguishing patients with more generalised symptoms. I 
anticipated  that  up  to  6  of  the  features  under  investigation  may  prove  to  be 
independently associated with symptom patterning in a multivariate model, therefore; 
I amid to recruit a minimum of 150 patients.
3.2 - Statistical Analysis:
Descriptive statistics were used to compare the characteristics of the two groups of 
patients with rosacea, and features associated with ANF positivity were identified. 
Descriptive  summary  statistics  provided  are  mean  and  N  (%)  for  categorical 
variables. I used two-sided tests throughout my statistical analysis and the p < 0.05 
as my criterion for statistical significance. The statistical tests I used in the analysis of 
my data include: 
1. Chi-Squared Test /  Test of Association (Dependence):  
A  chi-square  test  is  used  to  check  the  relationship  between  two  categorical 
variables. It gives an estimate on the agreement between a set of observed data and 
a random set of data that I expected the measurements to fit.  The calculated chi 
squared correlated to p-value. I used this test to check the relationships between:
• Subtypes of rosacea, and history of acne vulgaris, (Table 1.7). 
• Subtypes of rosacea and family history of rosacea, (Table 1.9).
• Antinuclear antibody (ANA) and systemic symptoms, (Table 2.7).
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2. A one Sample Binomial Test:
The one sample binomial test used to check whether the proportion of successes on 
two level categorical dependent variable significantly differs from the hypothesized 
value. The binomial test is an exact test of the statistical significance of deviations 
from a theoretically expected distribution of observations into two categories.  I used 
this test to show whether the proportion of patients with or without connective tissue 
disease (CTD) who were ANA positive different from the proportion observed in the 
general population in both Leeds and Doncaster groups, (Table 2.5). 
3. Fisher's Exact Test:
The  Fisher's  exact  test  is  used  when  the  chi-square  test  cannot  be  conducted 
because one or more of the cells have an expected frequency of five or less.  In the 
case of analyzing marginal conditions, the p value can be found by summing the 
Fisher's exact values for the current marginal configuration and each more extreme 
case using the same marginal's. I used this test to check the effect of oral antibiotics 
on the positivity of ANA in presence or absence of connective tissue disease (CTD), 
(Table 2.9).
4. C  o   c h  r   a n   ’s   Test /   Test of Conditional Association (Dependence): 
This test is  used to extend the chi-square test of independence in a 2 X 2 table to 
multiple 2 X 2 tables where each table corresponds to  a  different level of an 
intervening variable. This test has conditional independence-independence of the 
variables forming the rows and columns of the table, conditional on the levels of a 
third variable.  I used this test to check:
• The  relationship  of  positivity  of  ANA  and  different  rosacea  subtypes 
conditioned by presence or absence CTD (Table 2.6).
• The  relationship  of  systemic  symptoms  and  different  rosacea  subtypes 
conditioned by positive or negative ANA result (Table 2.8).
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5. Breslow-Day Test for Homogeneity of the Odds Ratio:
This test statistic sums the squared deviations of observed and fitted values each 
standardized by its variance. The test is used for stratified analysis of 2x2 tables to 
test null hypothesis that the odds ratios for the strata are all equal. When the null 
hypothesis is true, the statistic has an asymptotic chi-square distribution. I used this 
test to check the homogeneity of the odds ratio, (Table 2.6) and (Table 2.8).
6. Binary Logistic regression:
It is a type of probabilistic statistical classification model. It is used to predict a binary 
response from a binary predictor, categorical or continuous predictor variables. It is 
used for predicting the outcome of a categorical dependent variable based on one or 
more predictor variables (features). I used this test to check if any of the rosacea 
subtypes were associated with ANA positivity having controlled centre (Doncaster 
and Leeds), CTD, and oral antibiotic treatment, (Table 2.10).
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Chapter Three – Results
1. Analysis of Dermographic Data
2. Analysis of patients with Positive ANA
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1. Demographic Data of Doncaster and Leeds patients
The results are shown in a series of tables below (Table 1.1 to Table 1.15). 
Table 1.1 - Gender:
Gender Doncaster 
(93 patients)
Leeds 
(76 patients)
Doncaster + Leeds
(169 patients)
Male 42 (45%) 35 (46%) 77 patients (45%)
Female 51 (55%) 41 (54%) 92 patients (55%)
     Table 1.2 - Age:   
Age Doncaster
 (93 patients)
Leeds 
(76 patients)
Male 33 – 81 Years
Average 58 years
29 – 90 Years
Average 53 years
Female 26 – 79 Years
Average 50 years
31 – 70 Years
Average 49 years
Overall 
Range
53 Years 50 Years
Tables 1.1 and 1.2 show the basic  demographics,  indicating  broad comparability 
between the age and sex distributions of the two groups derived from Doncaster and 
Leeds. The Leeds group is marginally younger on average, but this difference is not 
significant.
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Table 1.3 - Skin type:
Skin Type Doncaster 
(93 patients)
Leeds 
(76 patients)
Doncaster + Leeds
(169 patients)
Type 1 86 patients 
(92%)
14 patients 
(18%)
100 patients 
(59%)
Type 2 7 patients 
(8%)
29 patients 
(38)
36 patients 
(21%)
Type 3 0 
(0%)
28 patients 
(37%)
28 patients 
(17%)
Type 4 0
(0%)
0 
(0%)
0
(0%)
Type 5 0 
(0%)
4 patients 
(5%)
4 patients 
(2%)
Type 6 0
(0%)
 1 patient 
(1%)
1 patient 
(1%)
With regard to skin type (Table 1.3), the patients from Doncaster are much more 
typical of the stereotype for patients with rosacea, being of overwhelmingly skin type 
1. In contrast, Leeds patients were of a wider range of skin types, including 5% of 
patients  with  skin  type  5.  This  suggests  that  there  may be  different  aetiological 
factors at  work in  the Leeds group,  and the further  data suggest  some potential 
explanations to be discussed later.
Table 1.4 - Duration of rosacea symptoms:
Doncaster (93 patients) Leeds (76 patients)
12 - 564 months
Average = 87 months
1- 500 months 
Average = 54 months
There was some difference in the duration of the disease between the two groups 
(Table 1.4), with the mean in Doncaster being 87 months whilst that for Leeds was 
54 months,  and this was significant  statistically.  There was little difference in the 
range of disease duration.
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Table 1.5 - Rosacea subtypes:
Rosacea 
Subtype
Doncaster
(93 patients)
Leeds
(76 patients)
Doncaster + Leeds
(169 patients)
Prevalence of different rosacea subtypes 
ETR 63 (68%) 47 (62%) 110 (65% )
PPR 56 (60%) 72 (95%) 128 (76%)
PR 17 (18%) 8 (11%) 25 (15%)
OR 5 (5%) 5 (7%) 10 (6%)
Isolated rosacea subtypes patten
ETR 27 (29%) 4 (5%) 31 (18%)
PPR 20 (22%) 27 (36%) 47 (28%)
PR 4 (4%) 0 (0%) 4 (2%)
Total isolated 51 (55%) 31 (41%) 82 (49%)
Mixed rosacea subtypes pattern
ETR  + PPR 26 (28%) 32 (42%) 58 (34%)
ETR + PR 4 (4%) 0 (0%) 4 (2%)
PPR + PR 5 (5%) 2 (3%) 7 (4%)
PR + OR 1 (1%) 0 (0%) 1 (1%)
ETR + PPR + PR 2 (2%) 6 (8%) 8 (5%)
ETR + PPR + OR 3 (3%) 5 (7%) 8 (5%)
ETR + PR + OR 1 (1%) 0 (0%) 1 (1%)
Total mixed 42 (45%) 45 (59%) 87 (51%)
Table 1.5 shows the prevalence of rosacea subtypes where the PPR (128 patients - 
76%)  and  ETR  (110  patients  -  65%)  were  the  commonest  presenting  rosacea 
subtypes. The most combined rosacea subtypes were ETR and PPR (58 patients - 
34%) more than any other mixed pattern. Half of recruited patients 51% had mixed 
rosacea  sub-types,  while only  2%  had  isolated  PR,  however  the  OR  was  only 
present in those with skin manifestations, and never occurring alone. Whilst 29% of 
Doncaster patients had  ETR alone, the figure for Leeds patients  was only 5%. In 
contrast, 36% of Leeds patients had isolated PPR disease, compared to 22% in the 
Doncaster cohort. This difference may be consistent with the frequency of Type1 skin 
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in Doncaster patients, since ETR is common in those with Celtic skin. The corollary 
is  that  the Leeds patients  with a broader  skin-type mix might  be more prone to 
papulo-pustular disease as a predominant sub-type. 
Table 1.6 - History of acne vulgaris:
Doncaster 
(93 patients)
Leeds 
(76 patients)
Doncaster + Leeds 
(169 patients)
30 patients (32%) 29 patients (38%) 59 patients (35%)
Table 1.6 shows that a history of acne vulgaris was described by 35% of patients 
overall, with no significant difference between the two groups. 
Table 1.7 - Association between history of acne and rosacea subtypes:
Acne
Rosacea Subtypes - No, % present
ETR PPR PR OR
Absent 74/110
67.3%
82/110
74.5%
9/110
8.2%
8/110
7.3%
Present 36/59
61.0%
46/59
78.0%
16/59
27.1%
2/59
3.4%
Pearson’s 
chi-square
Χ2=0.02 
p=0.878
Χ2=0.25
p=0.621
Χ2=10.93
p=0.001
Χ2=1.04
p=0.308
Table 1.7 shows the relationship between a history of acne and rosacea subtypes. 
The  history  of  acne  vulgaris  in  rosacea  was  significant  among  PR  subtypes 
(p=0.001). The numbers are small, but this is an interesting observation that may 
deserve further investigation.
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Table 1.8 - Family history of rosacea:
Doncaster 
(93 patients)
Leeds 
(76 patients)
Doncaster + Leeds 
(169 patients)
16 patients (17%) 8 patients (11%) 24 patients (14%)
Table 1.8 shows 14% of patients had a family history of the rosacea (Doncaster 17% 
and Leeds 11%) the difference is not significant.
Table 1.9 - Association between family history of rosacea and rosacea 
subtypes:
Family 
History
Rosacea Subtypes - No, % present
ETR PPR PR OR
Absent 90/145
62.1%
111/145
76.6%
19/145
13.1%
8/145
5.5%
Present 20/24
83.3%
17/24
70.8%
6/24
25.0%
2/24
8.3%
Pearson’s 
chi-square
Χ2=4.10 
p=0.043
Χ2=0.37
p=0.545
Χ2=2.31
p=0.128
Χ2=0.29
p=0.588
Table 1.9 shows the positive family history of rosacea in the participated patients was 
not highly significantly different between subtypes of rosacea  (24 out of total 169 
patients - 14%), and the most positive family history of rosacea was seen in the ETR 
subtype (20 out of total 24 patients - 83%), and although the numbers are small, this 
would be consistent with the known links with Type 1, Celtic skin types. 
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Table 1.10 - History of previous steroid treatment:
Steroid 
Treatment 
Doncaster 
(93 patients)
Leeds 
(76 patients)
Doncaster + Leeds
(169 patients)
Topical 17 patients 
(18%)
41 patients 
(54%)
58 patients 
(34%)
Systemic 10 patients 
(11%)
21 patients 
(28%)
31 patients 
(18%)
Inhalers 10 patients 
(11%)
5 patients 
(7%)
15 patients 
(9%)
Table 1.10 shows the history of previous steroid treatment in two groups of rosacea. 
The topical treatment was reported by 34% of patients, with a significant difference 
between  Leeds  (54%)  and  Doncaster  (18%).  Also  the  use  of  systemic  steroid 
treatment was more in Leeds compared to Doncaster groups (28% ves. 11%). This 
may have direct relevance both to the sub-types of disease, with papulo-pustular 
disease common in  Leeds where steroid use was commonly reported,  and ETR 
more common in Doncaster, where steroid use was less common and skin type 1 
patients predominated.
Table 1.11 - Associated systemic symptoms:
Associated 
Symptoms
Doncaster 
(93 patients)
Leeds 
(76 patients)
Doncaster + Leeds
(169 patients)
Flushing 53 patients 
(57%)
64 patients 
(84%)
117 patients 
(69%)
Eye 
Symptoms
34 patients 
(37%)
8 patients 
(11%)
42 patients 
(25%)
Arthralgia 21 patients 
(22%)
15 patients 
(20%)
36 patients 
(21%)
Reynaud's 16 patients 
(17%)
12 patients 
(16%)
28 patients 
(17%)
Myalgia 18 patients 
(19%)
5 patients 
(7%)
23 patients 
(14%)
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Many patients reported a number of associated systemic symptoms (Table 1.11). 
Surprisingly, given the nature of the clinics from which the subjects were drawn in the 
two  centers,  joint  symptoms,  Raynaud’s  phenomenon  and  muscle  aches  were 
equally common in both cohorts. Around 15 – 20% of patients had one or other of 
these symptoms. The arthralgia and myalgia had the same percentage as reported 
by the control group (Table 1.12) and normal populations; however the Raynaud's 
phenomenon  was  reported  in  about  16%  in  both  groups  which  is  greater  than 
reported in the control group and the general populations. This is could be an inverse 
relationship where the treatment of Raynaud's phenomenon by the calcium channel 
blocker (vasodilators) triggers the flushing symptom of rosacea. Facial flushing and 
eye symptoms were common in both groups. Flushing occurred in 84% of patients in 
Leeds, even though PPR was more common here. A quarter of patients had eye 
symptoms,  although  it  is  not  clear  that  all  of  these  were  due  to  rosaceous  eye 
disease.
Table 1.12 - Systemic symptoms frequency in control group:
 
Symptoms Number (%)
Flushing 5 patients
(8.3 %)
Eye Symptoms 7 patients
(12%)
Arthralgia 11 patients 
(18.5%)
Raynaud’s 2 patients
(3.5%)
Myalgia 8 patients 
(13.3%)
Table 1.12 shows the frequency of comparable symptoms in the control group of 
non-rosacea patients  of 60 controls (35 female and 25 male) with mean age of 43 
years (age range 17 – 92 years).
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Table 1.13 - Triggering factors:
Triggering 
Factor
Doncaster 
(93 patients)
Leeds 
(76 patients)
Doncaster + Leeds
(169 patients)
Sun 46 patients 
(49%)
46 patients 
(61%)
92 patients 
(54%)
Alcohol 33 patients
(35%)
54 patients 
(71%)
87 patients
 (51%)
Cold / Hot 
Weather
71 patients 
(76%)
9 patients 
(12%)
80 patients 
(47%)
Spicy Food 24 patients 
(26%)
51 patients 
(67%)
75 patients 
(44%)
Hot Drinks 9 patients
(10%)
16 patients 
(21%)
25 patients 
(15%)
Stress 9 patients
(10%)
4 patients 
(5%)
13 patients 
(8%)
Medications 2 patients 
(2%)
8 patients 
(10%)
10 patients
 (6%)
Exercise 3 patients 
(3%)
0 
(0%)
3 patients 
(2%)
Female 
Periods
2 patients 
(2%)
0 
(0%)
2 patients 
(1%)
Pregnancy 1 patient 
(1%)
1 patient
 (1%)
2 patients 
(1%)
Table 1.13 shows the variations seen in triggering factors reported of rosacea. Sun 
was a factor in both cohorts, but temperature change as a triggering factor was much 
more frequently reported in Doncaster (76% of patients), whilst only 12% of patients 
reported in Leeds. This suggests that temperature change may be more relevant to 
ETR than to PPR. However, spicy food was more commonly a problem in Leeds, 
reported in 67% of subjects, but only in 26% of patients in Doncaster. The same was 
true for alcohol (71% of patients in Leeds, but only 35% of patients in Doncaster). 
The remainder of the reported precipitating factors occurred in only small numbers of 
patients and were not statistically different between the two groups. Overall, only 6% 
of  patients  documented that  medication had affected their  disease,  although this 
figure was 10% in Leeds. The results do not tell us whether this related to steroid 
treatments or other medications.
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Table 1.14 - Investigations:
Investigation Doncaster 
(93 patients)
Leeds 
(76 patients)
Doncaster + Leeds 
(169 patients)
Blood - Positive 
ANA
6 Patients 
(6%) 
16 patients 
(21%) 
22 patients (13%)
Histology – 
Rosacea 
Features 
10 patients 
(11%)  
23 patients 
(30%) 
33 patients (20%)
DIF – Negative
DIF – Positive 
8 patients (9%)
0 (0%)
6 patients (8%) 
1 patient (1%) 
14 patients (8%)
1 patient (0.5%)
Not all patients had a diagnosis confirmed by histology, since in many the diagnosis 
was clinically apparent in Table 1.14. Only 20% of patients were biopsied overall, 
with  more  in  Leeds  (30%),  compared  to  Doncaster  (11%).  This  represents  the 
differing clinical settings in which these patients were seen. The biopsy for histology 
and DIF is much more likely when there is a specific need to exclude lupus as the 
cause of the facial rash, particularly in those with papular disease occurring without 
pustules,  and occasionally in patients who were already known to have lupus. In 
those who did  have a biopsy showing histological  features  of  rosacea,  and had 
immuno-fluorescent studies performed, a positive test was seen in only one.  On the 
other hand, ANA positivity occurred in 21% of patients from Leeds, but in only 6 
patients (6%) of those in Doncaster. 
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Table 1.15 - Treatments:
Treatment Doncaster 
(93 patients)
Leeds 
(76 patients)
Doncaster + Leeds
(169 patients)
Topical 86 patients 
(93%)
67 patients 
(88%)
163 patients 
(96%)
Oral Antibiotics 78 patients 
(84%)
61 patients 
(80%)
139 patients 
(82%)
Topical + Oral 
Antibiotics  
73 patients 
(78%)
56 patients 
(73%)
129 patients 
(76%)
Oral Isotretinoin 19 patients 
(20%)
14 patients 
(18 %)
33 patients 
(19%)
Oral Antibiotics 
and Isotrtinoin 
18 patients 
(18%)
11 patients 
(14.5%)
29 patients 
(17%)
Treatment  of  rosacea  was  remarkably  consistent  (Table  1.15)  between  the  two 
cohorts, and was consistent with modern practice and NICE guidance. Most  patients 
received different topical acne treatment (96%) and one or more of oral antibiotic 
courses (82%).  Approximately 20% of patients received oral isotretinoin.
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2. Doncaster and Leeds Patients with Positive ANA Blood Test
Tables 2.1 to 2.10 present the demographic data on these patients, and the analysis 
compares the characteristics of those with and without a positive ANA. 
There  are  significant  differences  in  both  age  and  gender  distribution,  with  ANA 
positive patients being predominantly female (indeed entirely female in Doncaster), 
and  markedly  younger  than  the  overall  group.  This  is  consistent  with  the  well 
documented relationships between positive ANA status and young females (Table 
2.1 and 2.2). 
Table 2.1 - Number of patients with positive ANA:
Centre, 
Total  patients
No, % of ANA 
positive patients
Doncaster  
(93 Patients)
6 patients (6%)
Leeds  
(76 Patients)
16 patients (21%)
Doncaster + Leeds 
(169 patients) 
22 patients (13%)
Table 2.2 - Age and gender of patients with positive ANA:
Patients with 
Positive ANA
Gender Age
Doncaster 
(6 patients)
6 Female (100%) 36 – 79 years (Average 49 Years)
Leeds  
(16 patients)
13 Female (81%)
3 Male (19%) 
31 – 68 Years (Average 45 years) 
31 – 45 Years (Average 38 Years)
Doncaster + Leeds 
(22 Patients)
19 Female (86%)
3 Male (14%)
31 – 79 Years (Average 47 Years)
31 – 45 Years (Average 38 Years)
Overall Average 46 Years
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Table 2.3 - Type of rosacea in patients with positive ANA: 
Type of 
Rosacea
Doncaster
 (6 patients)
Leeds 
(16 patients)
Doncaster + Leeds
(22 patients)
ETR 3 patients 
(50%) 
1 patient 
(6%) 
4 patients 
(18%)
PPR 1 patients 
(17%)
7 patients 
(44%)
8 patients 
(36%)
ETR + PPR 6 patients 
(38%)
2 patients 
(33%)
8 patients 
(36%)
ETR + PPR 
+ OR
2 patients
 (33%) 
0 
(0%)
2 patients
 (9%)
Table  2.3  shows  the  types  of  rosacea  associated  with  a  positive  ANA,  these 
subtypes were distributed in the same way as the subtypes in the overall groups 
where the PPR is more in the Leeds group and the ETR is more in the Doncaster 
group.
Table 2.4 - History of CTD in patients with positive ANA:
 Connective 
Tissue Disease 
Doncaster 
(6 patients)
Leeds
(16 patients)
Doncaster + Leeds
(22 patients)
Lupus 
Erythematosus
1 patient 
(17%)
11 patients 
(69%)
12 patients 
(55%)
Rheumatoid 
Arthritis
0 
(0%)
5 patients 
(31%)
5 patients 
(23%)
Dermatomyositis 0 
(0%)
1 patient 
(6%)
1 patient 
(5%)
Scleroderma 0 
(0%)
1 patient 
(6%)
1 patient 
(5%)
Table 2.4 shows total number of patients with history of CTD and the relationship of 
positive ANA rosacea patients with history of CTD. Not  surprisingly,  in the Leeds 
cohort, the ANA positive patients had a history of CTD in all cases (16 patients) and 
some patients had more than one CTD. In Doncaster group, only 1 patient (17%) out 
of 6 patients positive ANA had history of lupus. 
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Table 2.5 - Prevalence of ANA positivity in patients with or without history of 
CTD:
CTD Centre         ANA
  Negative      Positive 
No
 Leeds 57
95%
3
5%
 Doncaster 87
94.6%
5
5.4%
 Total 144
94.7%
8
5.3%
Yes
 Leeds 3
18.8%
13
81.3%
 Doncaster 0
0.00%
1
100%
 Total 3
17.6%
14
82.4%
Total
 Leeds 60
78.9%
16
21.1%
 Doncaster 87
93.5%
6
6.5%
 Total 147
87%
22
13%
Although,  on first  appearances a greater  proportion of  Leeds patients  were ANA 
positive (21.1%, 16/76) versus Doncaster patients (6.5%, 6/93), this was due to the 
fact  that  more Leeds patients  had a history of  CTD than Doncaster  patients.  In 
patients  without  a  history  of  CTD,  the  level  of  ANA positivity  of  both  centres 
combined (5.3%, 8/152) was similar to that reported in the general population; (One-
sample Binomial test compared to null hypothesis proportion [5%] p=0.500). Patients 
with  a  history of  CTD,  were  much more  likely  to  be  ANA positive  (both  centres 
combined 82.4% (14/17);  (One-sample Binomial test compared to null  hypothesis 
proportion [5%] z=14.08, p<0.001). 
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Table  2.6  -  Prevalence  of  ANA positivity  in  different  rosacea  subtypes  in 
presence or absence of CTD:
CTD Rosacea
Subtypes
Rosacea Subtype -  No, % ANA positive
ETR PPR PR  OR
No
Absent 3/53
5.7%
3/40
7.5%
8/127
6.3%
8/144
5.6%
Present 5/99
5.1%
5/112
4.5%
0/25
00.0%
0/8
00.0%
Total 8/152
5.3%
8/152
5.3%
8/152
5.3%
8/152
5.3%
Yes
Absent 5/6
83.3%
1/1
100.0%
14/17
82.4%
12/15
80.0%
Present 9/11
81.8%
13/16
81.3%
n/a* 2/2
100.0%
Total 14/17
82.4%
14/17
82.4%
14/17
82.4%
14/17
82.4%
Total
Absent 8/59
13.6%
4/41
9.8%
22/144
15.3%
20/159
12.6%
Present 14/110
12.7%
18/128
14.1%
0/25
00.0%
2/10
20.0%
Total 22/169
13.0%
22/169
13.0%
22/169
13.0%
22/169
13.0%
Breslow-Day Χ2  = 0.00
p = 0.992
Χ2  = 0.13
p = 0.715
n/a** Χ2  = 0.97
p = 0.325
Cochran’s Χ2 = 0.03
p = 0.859
Χ2 = 0.71
p = 0.398
Χ2 = 1.66
p = 0.197
Χ2 = 0.01
p = 0.932
*None of the patients with a history of CTD had PR.
 **Tests of homogeneity of odds ratio could not be performed.
Table 2.6 shows the relationship of positivity of ANA in different rosacea subtypes 
conditioned by effect of history of CTD. Splitting the analysis by CTD did not indicate 
that the associations between specific types of rosacea and ANA positivity differed 
depending  on  CTD status  (Breslow-Day  tests  of  homogeneity  of  the  odds  ratio 
supported  this).  For  example,  in  absence  of  CTD,  the  positivity  of  ANA in  ETR 
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patients  is  5.1% which is  nearly the same percentage among non ETR patients 
(5.7%) and in presence of history of CTD, the percentage of positivity of ANA in ETR 
is 81.8% which is not hugely different from other non ETR patients (83.3%). The total 
percentage of ETR patients with positive ANA and with or without history of CTD is 
12.7% which is very close when compared to non ETR patients (13.6%). This trend 
is nearly the same with other rosacea subtypes. So,  the descriptive data did not 
highlight any conspicuous trends i.e. having a particular subtype of rosacea (whether 
or not a patient also had CTD) did not seem to greatly influence the odds of being 
ANA  positive,  and  this  was  supported  by  Cochran’s  tests  of  conditional 
independence.
Table 2.7 - Association between ANA and systemic symptoms:
ANA
Systemic Symptoms - No, 
% Present
Myalgia Arthralgia Raynaud’s Mixed 
Symptoms
Negative 16/147
10.9%
21/147
14.3%
16/147
10.9%
34/147
23.1%
Positive 07/22
31.8%
15/22
68.2%
12/22
54.5%
17/22
77.3%
Total 23/169
13.60%
36/169
21.3%
28/169
16.6%
51/169
30.2%
Pearson's
Chi-Square
Χ2 = 7.13
p= 0.008
Χ2 = 33.10
p<0.001
Χ2 = 26.39
p<0.001
Χ2 = 26.62
p<0.001
Around  a  third  of  patients  (30.2%)  had mixed systemic  symptoms;  patients  who 
tested positive for ANA were more likely to have systemic symptoms (77.3%) than 
patients  who  tested  negative  for  ANA (23.1%,  p<0.001).  The  largest  effect  was 
observed for arthralgia (68.2% ves. 14.3%, p<0.001). This appeared to be simply 
due to the increased frequency of real CTD in those who were ANA positive.
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Table 2.8 - Prevalence of systemic symptoms in different  rosacea subtypes in 
positive and negative ANA patients:
Rosacea 
Subtypes
ANA
Rosacea subtype  -  No, % with Systemic 
Symptoms
ETR PPR PR OR
Absent
Negative 13/51
25.5%
12/37
32.4%
28/122
23.0%
30/139
21.60%
Positive 7/8
87.5%
2/4
50.0%
17/22
77.3%
15/20
75.00%
Total 20/59
33.9%
14/41
34.1%
45/144
31.3%
45/159
28.30%
Present
Negative 21/96
21.9%
22/110
20.0%
6/25
24.0%
4/8
50.00%
Positive 10/14
71.4%
15/18
83.3%
n/a* 2/2
100.00%
Total 31/110
28.2%
37/128
28.9%
6/25
24.0%
6/10
60.00%
Breslow- Day Χ2=0.43 
p=0.512
Χ2=3.67
p=0.057
n/a** Χ2=0.19 
p=0.665
Cochran’s Χ2 =26.6 
p <0.001
Χ2=27.3
p<0.001
Χ2=25.6 
p<0.001
Χ2=26.1
p<0.001
*None of the patients with PR were ANA positive. 
**Tests of homogeneity of the odds ratio could not be performed.
Table 2.8 shows the prevalence of systemic symptoms in different rosacea subtypes 
conditioned by effect of ANA result. The results showed that the PPR subtype had 
systemic symptoms and positive ANA when compared to other non PPR subtypes 
(83.3%  ves.  50.0%).  This  has  some  indication  that  in  patients  with  PPR  the 
association  between  ANA and  systemic  symptoms  was  stronger  than  it  was  in 
patients  without  PPR (Breslow-Day  test  of  homogeneity  of  odds  ratio  p=0.057). 
However, only a small  number of  patients without PPR were ANA positive (n=4). 
Therefore, we cannot conclude that this was a genuine effect. This would need to be 
confirmed in a larger study.
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Table 2.9 - The influence of oral antibiotics on patients with positive ANA:
CTD Antibiotics
ANA - No, %
Negative  Positive
No
No 23 
(92%)
2 
(8%)
Yes 121
(95.3%)
6 
(4.7%)
Total 144
(94.7%)
8 
(5.3%)
Yes
No 0
(0.00%)
5 
(100%)
Yes 3
(25%)
9
(75%)
Total 3
(17.6%)
14
(82.4%)
Total
No 23
(76.7%)
7
(23.3%)
Yes 124
(89.2%)
15
(10.8%)
Total 147
(87%)
22
(13%)
Patients taking antibiotics were if anything less likely to be ANA positive, whether or 
not they had a history of CTD; there was no statistically significant effect; combined 
across CTD status 23.3% of patients not taking antibiotics (7/30) tested positive for 
ANA compared to 10.8% of  those taking antibiotics (15/139);  (Fisher’s  exact  test 
p=0.076). The previous antibiotics therapy did not appear to influence ANA positivity. 
This  is  important  because  tetracycline  antibiotics  in  general  and  minocycline  in 
particular, are well known to increase antibody positivity. 
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Table 2.10 - Binary Logistic Regression:
A multiple exact binary logistic regression model was used to assess whether any of 
the specific types of rosacea were associated with ANA positivity having controlled 
for centre, CTD and oral antibiotics.
Variable Odds Ratio
(95% CI)
p-value
Centre 1.0 (0.2 - 7.4) 1.000
History of CTD 53.3 (9.9 - 471.6) <0.001
Antibiotic 
Treatment
0.5 (0.1 - 2.8) 0.525
ETR 0.6 (0.1 - 3.4) 0.721
PPR 0.4 (0.0 - 3.5) 0.607
PR 0.4 (0.0 - 2.9) 0.414
OR 1.7 (0.1 - 41.2) 1.000
Whilst history of CTD increased the odds of a patient being ANA positive, neither 
rosacea subtypes nor antibiotic treatment were associated with ANA status.
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1. Demographic Data
Rosacea is a common disease that predominantly, but not only, affects middle aged 
women with fair skin. It most often affects the face, occasionally the neck and chest 
and rarely other sites. There are 4 major subtypes and these can present at different 
stages in  the  same patient  at  different  times or  can be  consistent  throughout  a 
patient’s history. There are many differential diagnoses for rosacea, and with regard 
to this study, the confusion with lupus erythematosus, especially when it resembles 
the facial erythema of LE, or the papular form of rosacea which is easily confused 
with rosaceous LE, is very important. 
In this thesis, I have investigated the hypothesis that patients with rosacea may have 
a  positive  ANA blood  test  and  also  that  this  may  be  associated  with  systemic 
symptoms  in  a  patient  who  does  not  have  CTD.  I  have  also  investigated  the 
possibility that certain CTDs, particularly lupus, may occur concurrently with rosacea. 
There  are  very  limited  data  on  this  subject  and  very  few  publications.  To  my 
knowledge, this is the largest study in terms of the number of patients in which the 
prevalence of a positive ANA blood test has been investigated and related to the 
various subtypes of rosacea. I have also produced data on the presence of CTD in 
the different subtypes of rosacea.
Most of  the 169 patients were diagnosed clinically after  a full  history and clinical 
examination.  All  the associated symptoms,  triggering factors or  any other  history 
related to rosacea were documented from the clinical interview. All patients had a 
blood test to detect the presence of ANA and this is considered positive if the titre ≥ 
1:80.  The test  was  a  pre-requisite  to  inclusion  in  the  study.  And  this  may have 
influenced the results,  since it  is  possible that  some patients had the blood test 
performed because of the suspicion of an alternative diagnosis, but the overall data 
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are consistent with other published studies (140 -145) so this is less likely to be a 
confounding factor. The overall frequency of ANA positivity was 13%, but when those 
patients with a known CTD were excluded, the figure was close to that reported in 
normal  populations  (i.e.  around 5%).  The age and sex distribution of  the patient 
group is consistent with that reported in the earlier literature. The skin type of the 
patients was one of the interesting variables, being significantly different between the 
two  centres.  Type  1  skin  was  much  more  prevalent  in  the  cohort  derived  from 
Doncaster, whilst the Leeds cohort included a significant proportion of patients with 
types 3, 4 and even 5. This difference may be relevant to other differences between 
the cohorts and may be a result of the much larger numbers of patients with co-
existent  CTD  seen  in  Leeds.  Other  results  suggest  that  treatment  exposure, 
particularly to steroid preparations, may be implicated in the aetiology of the rosacea 
in some of these patients, and in this circumstance, the role of skin type may be less 
important.  Most  of  the  investigated  patients  presented  with  combined  rosacea 
subtypes of ETR and PPR more often than a single subtype 34%. More than half of 
recruited patients (51%) had mixed rosacea subtypes, with only 2% with isolated PR. 
However, because of the recruitment methodology, the OR wasn't present alone, but 
could only be seen in patients who presented with skin manifestations. This may 
explain the low overall frequency of ocular disease when compared to the published 
literature.
The data showed that 35% had a history of acne vulgaris (that required systemic 
treatment either by at least one course of oral antibiotic, oral retinoids or hormonal 
treatment), which was more significant among PR subtypes (p=0.001). The numbers 
were  small,  but  this  is  an  interesting  observation  that  may  deserve  further 
investigation. There are a very limited number of studies that have examined the 
rosacea relationship with acne. However, to my knowledge, there were no studies 
checked the relationship between rosacea subtypes and history of acne. In a survey 
reported by the NRS, of more than 100 women with rosacea, 40% of these patients 
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provided a history of acne in adolescence. Furthermore, about 40% of those women 
who had a history of acne exhibited moderate flushing triggered by the same triggers 
common to rosacea (146). In a further investigation of rosacea patients compared to 
controls, researchers found that rosacea patients had nearly twice the rate of facial 
sebum  production,  numbers  of  microcomedones  and  propionibacterium  acnes 
bacteria compared to controls (146). 
The family history was not a significant finding, since only 14% recorded a positive 
family history of rosacea in first degree relatives. In many surveys performed by the 
NRS, a strong positive family history in one close family member was often seen 
(12), (13). There were 34% of patients who recorded the use of topical steroids as 
treatment for their skin problem at one stage. However, none of these patients were 
using topical steroids during the time of study and all of them confirmed that they had 
stopped using these agents some time before participating in the study. Also 18% 
gave a  history of  taking systemic  steroids  in  the  past  before  the appearance of 
rosacea. The role of steroid usage in association with rosacea and steroid induced 
rosacea has been discussed on multiple occasions in the literature (86 - 89), as well 
as previously in this thesis. It is particularly interesting that steroid usage was much 
higher  in  the  Leeds  cohort,  and  that  the  pattern  of  rosacea  in  this  group  was 
significantly more PPR than ETR. It seems a reasonable conclusion that this may 
well  be relevant,  particularly in those patients thought to have a co-existent CTD 
since they are likely to have used both local and oral steroid. Steroid usage may well 
be one of the more important reasons for differences between the cohorts and for the 
occurrence  of  rosacea  in  patients  with  co-existent  CTD derived  from the  Leeds 
clinics. With regard to the presence of associated systemic symptoms in patients 
with  rosacea,  a  number  were  specifically  recorded:  a  history  of  flushing,  eye 
symptoms, arthralgia, Raynaud's phenomenon and myalgia symptom were enquired 
for. Out of these potentially systemic symptoms, not surprisingly,  flushing was the 
most common associated symptom and affected more than two thirds of patients in 
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both Doncaster and Leeds. This was not associated with any other symptomatology 
and was almost certainly simply a feature of the rosacea itself. In terms of frequency, 
this was followed by eye symptoms including itching, burning and soreness, as well 
as redness which were recorded in up to 25% of Doncaster and Leeds patients. The 
frequency of eye disease in the reported literature is up to 50%, a figure which is  
very high compared to the current data, and feels high compared to that found in 
routine practice. It is interesting, however, that eye disease is reported to occur more 
frequently in patients with marked flushing, and that does seem to be the case here. 
Symptoms  potentially  more  related  to  CTD,  including  myalgia,  Raynaud's 
phenomenon and arthralgia were present in less than a quarter of patients, between 
14%  and  21%  depending  on  the  symptom.  The  frequency  of  occurrence  of 
Raynaud's phenomenon in the general population is between 3 and 5% (147), and 
that of non-specific arthralgia around 20% (148), so in this data set, Raynaud's is 
more common than would be expected, and this could be an inverse relationship 
where  the  treatment  of  Raynaud's  with  vaso-dilators  such  as  calcium  channel 
blockers  might  trigger  flushing  symptom  in  rosacea  patients.  The  arthralgia  and 
myalgia occurred in the anticipated frequency. To my knowledge there have been no 
previous studies  that  have investigated the association  of  rosacea with  systemic 
symptoms that might be suggestive of CTD. Regarding the triggering factors, the sun 
was the most  recognised triggering factor  affecting more than half  of  the total  of 
patients (54%). This was followed by eating spicy food, exposure to cold and hot 
weather  and  alcohol  consumption,  occurring  in  between  44%  to  51%  of  total 
patients. These results were consistent with the previous surveys performed by the 
NRS (59).
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2. Positive ANA Patients
There  are  limited  data,  but  a  number  of  studies  indicate  a  higher  incidence  of 
immune  abnormalities  in  patients  with  rosacea.  These  include  the  detection  of 
different types of ANA in the blood and the deposition of immunoglobulins at the 
basement membrane zone of the skin as detected by DIF.
Salo's  series  in  1970  (149), studied  27  rosacea  patients  who  were  diagnosed 
between 1964 and 1968.  This was a review of  those patients with investigations 
including ANA and skin biopsies for DIF from involved facial skin and uninvolved, but 
light exposed skin of the forearms. The results showed that 15 patients out of 27 had 
deposition of a thick band of immunoglobulin of homogeneous or granular pattern at 
the  dermo-epidermal  junction  in  samples  taken  from affected  facial  skin,  with  4 
patients having deposition of these immunoglobulins in the uninvolved skin of the 
forearms. Only 4 patients had a positive ANA of low titre ranging from 1:5 to 1:20. 
Out of the 15 patients with positive DIF, 9 patients had no specific joint symptoms. 
However, none of the patients had sufficient criteria to make the diagnosis of lupus 
erythematosus.  The  conclusion  drawn  from  this  study  was  that  deposition  of 
immunoglobulins seen on DIF as well as a weak positive ANA titre could be a feature 
of  both  rosacea  and  a  form  of  lupus  erythematosus.  However,  the  numbers  of 
patients studied were small, and there was no control group. The number of patients 
who had positive ANA is low and the titre of positive ANA was also too low. The 
positive DIF from normal facial skin is common, it is well known that sun-exposed 
skin has a higher frequency of  positive immunofluoresence on biopsy,  even in  a 
normal population (150), so the relevance of this finding is unclear in the absence of 
a control group and the findings from this study are somewhat speculative.
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Nunzi et al in 1980 (151), investigated 7 untreated patients (4 males and 3 females) 
with papulopustular rosacea on the face for a period that ranged from 1 to 4 years. 
The patients were investigated with both direct  and indirect  immunofluorescence. 
The results showed that 5 patients out of 7 had positive immunoglobulin deposition 
at the basement membrane zone when the samples were taken from the involved 
area (area A), 2 patients had positive immunofluorescence from the uninvolved light 
exposed  area  (area  B),  and  1  patient  was  positive  from  uninvolved,  non-light 
exposed skin (area C). In addition anticollagen antibodies were found in 6 out of 7 
patients in area A, 4 in area B and 1 in area C. Also, circulating ANA (IgD, IgM, and 
IgE) with a homogeneous pattern at  a titre of  1:40 was found in 2 patients.  The 
suggestion from this study was that the positive DIF at the basement membrane 
zone in  rosacea patients could be a result  of  antibodies directed against  altered 
collagen  type  4  due  to  photo-damage.  The  actinic  elastosis,  which  is  usually 
excessive  in  rosacea  patients,  may  be  the  cause  of  this  anti-collagen  antibody 
induction.  Also, the anti-collagen activity may account for the telangiectasia as a 
result of immunological injury to the endothelial cells of the vessel wall. Once again, 
the study is too small and has no control group. The positive ANA detected in 29% (2 
out of 7 patients) and the titre was low but the hypothesis with regard of DIF and 
anticollagen antibodies is an interesting one.  It is also possible that some of these 
patients  had both rosacea and lupus,  since a positive  immunofluorescent  biopsy 
from non-light exposed, uninvolved skin is usually believed to be diagnostic of lupus.
Manna and Marks in 1982 (152), studied 25 patients with rosacea (14 females and 
11 males with a mean age of 48 years) and compared them with 25 matched control 
subjects  for  past  medical  history  and  family  history  of  autoimmune  disorders. 
Patients were also tested for DIF and ANA. They found that rosacea patients and 
their first degree relatives had a higher incidence of auto-immune disorders including 
thyroid diseases, rheumatoid arthritis, and diabetes compared to the control group, 
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although the difference was not statistically significant because of the small size of 
the study. In addition 23 patients had biopsies for DIF and 18 patients had deposition 
of IgM and / or IgG and / or complement at the dermo-epidermal junction and / or in 
the dermal collagen. They also found that 6 patients had a positive circulating ANA of 
IgM type. The conclusion from this study was that  rosacea patients probably are 
more predisposed to autoimmune disorders and associated with increased positivity 
of DIF, which could be related to the altered immunogenicity of their facial dermal 
collagen and their dermal dystrophy. This study is larger in number than the previous 
studies and is controlled. Although the positive DIF was found in 72%, the positivity 
of ANA is only detected in 24%, so again the ANA was not significantly positive in this 
study and its relationship with rosacea was not confirmed. The combination of these 
findings with those of  Nunzi  et  al  does raise  the possibility  of  an immunological 
reaction at the basement membrane being a part of rosacea pathology that would 
merit further study.
Alison Black in  1992 (153),  studied the prevalence of  rosacea in  rheumatic  skin 
disease in a dermatology department – based rheumatic skin disease sub-specialty 
clinic. She studied 21 patients retrospectively. These patients ranged in age from 22 
years to 67 years with a male to female ratio of 1:9.5. There was a history of a facial 
erythematous rash, diagnosed as CLE, occurring in the 5 years before the study was 
performed. The review of these patients records showed that 9  patients of the 21 
(43%) had a positive ANA test, with insignificant or marginal titres, and on repeating 
ANA test, all of these patients had insignificant ANA titres. Reviewing the diagnosis 
of these 21 patients after a full history, physical examination, skin biopsy and new 
laboratory tests revealed that 16 (76%) patients had symptoms and signs of rosacea, 
and the remaining 5 (24%) patients  had other  dermatological  disorders including 
perioral dermatitis, allergic contact dermatitis, seborrheic dermatitis and chloasma. 
The 16 patients with rosacea were treated with topical and oral antibiotics and 15 
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patients exhibited 75 – 100% clearing of  their  facial  rash.  This study shows how 
physicians can be misled in their diagnosis of rosacea by a low titre ANA. These 
findings emphasized the need for knowledge of the standard reference values for 
ANA testing as well as the need to make a full evaluation of ANA positive patients. 
Even  in  patients  with  a  confirmed  diagnosis  of  lupus,  not  all  skin  disease  is 
necessarily a manifestation of the lupus. 
Anna Woźniacka in  2013 (154),  in  a prospective study investigated 101 rosacea 
patients with regard of their ANA test and 26 controls matched in sex and age. Over 
a half of rosacea patients (53.5%) had ANA positive with titer of ≥ 1:160. Within this 
group 13.86% had a titer of 1:320, 8.91% had a titer of 1:640, and 6.93% had a titer 
of 1:1,280 or higher.  The elevated ANA titers were present more often in women 
(55.8%) than in men (44.15%). Only 2 of 26 healthy controls had elevated ANA titers, 
one had a titer of 1: 160 and the other of 1:320. During a two year observation study 
period, after the initial ANA testing, none of the patients with ANA titers above 1:640 
developed an apparent autoimmune disorder. The conclusion from this study was 
that the elevated ANA titers were commonly found in rosacea patients, and this is 
with  simultaneously  existing  facial  erythema  and  photosensitivity  might  lead  to 
misdiagnosis of lupus erythematosus. Clinicians should be aware of these findings to 
avoid  misdiagnosing lupus erythematosus in  rosacea patients  with  elevated ANA 
titers. This is a large study in terms of number of patients, and was controlled. The 
positivity of ANA among those rosacea patients was significant (53.5%) and the titre 
was high of ≥ 1:160 which indicate that there might be true relationship between ANA 
and rosacea. These figures are very high in comparison with the previous studies, 
certainly suggestive of a relationship. These findings would ideally be confirmed in a 
similar national group, since it may be a feature that is unique to this population. It 
certainly requires confirmation.
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So, the above studies showed variable data, indicating a range of views between 
there being no relationship (Black et al), and a very significant relationship, with over 
half the patients with the disease having an ANA titre of over 1:160 (Wozniacka et 
al). Whilst the latter study is extreme and is certainly an outlier compared to most 
studies, the literature does provide an appropriate basis for this study, particularly 
given the two very different recruitment centres.
In the study performed for this thesis, all the patients both in Doncaster and Leeds 
had the ANA blood test performed, however the titre was not recorded. Nevertheless, 
the rules of the testing laboratories ensured that only titres of ≥ 1:80 were reported 
as positive. Whilst there is some basis for the value of higher ANA titres being more 
likely to represent CTD than lower titres, there is also general agreement that an 
ANA titre  of  ≥ 1:80 represents a  positive  test.  The purpose of  the  study was to 
identify patients with rosacea with a positive ANA at a level that would prompt further 
investigation, and would be accepted as a positive test in someone with a real CTD. 
The level of ≥ 1:80 is the level accepted by both of the localities involved in the study. 
Whilst an investigation of titres would have been interesting, it would not have had a 
great  impact  on interpretation  in  this  study,  mainly  because the overall  levels  of 
positivity were low, and the majority of  patients  with a positive test  were already 
known to have CTD. 
Only 22 patients  (13%) out  of  total  169 rosacea patients  had a positive  ANA (6 
patients from Doncaster and 16 from Leeds). All the 6 patients from Doncaster and 
13 patients from Leeds were females and only 3 patients from Leeds were males. 
The numbers of patients with a positive ANA was greater among the Leeds patients 
probably because patients were recruited predominantly from a specialised clinic for 
skin and CTD. There is only 1 patient from Doncaster out  of  the 6 positive ANA 
patients had a history of lupus and 11 patients from Leeds out of 16 ANA positive 
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patients had a diagnosis of lupus already made. Another 5 patients from Leeds had 
rheumatoid  arthritis,  one  had  dermatomyositis  and  one  had  systemic  sclerosis. 
Some Leeds patients had history of more than one CTD.  In the patients without a 
history of CTD, the percentage of the patients positive for ANA was only 5% and was 
equivalent  in  both  hospitals.  None  of  these  patients  were  found  to  have  an 
underlying CTD. This level of positivity was representative of the range of positive 
ANA tests recorded in the normal healthy general population both from the local 
laboratories (unpublished data) and in the published literature (140 - 145). 
It  is  the  case  therefore,  that  this  study  did  not  support  the  hypothesis  that 
uncomplicated  rosacea  is  related  to  higher  rates  of  ANA positivity.  In  a  general 
dermatology clinic, there is also no relationship to an excess of CTD. In addition, the 
analysis of the subtypes of rosacea with a positive ANA and a history of CTD did not 
show any specific relationship when the group is taken as a whole. These overall 
results indicate that a positive ANA alone is found in the same proportion of subjects 
with rosacea as is seen in the general population. As in other circumstances, the 
finding of a positive ANA should not of itself lead to the diagnosis of a CTD without a 
full evaluation, probably including a skin biopsy. However, rosacea and CTD may co-
exist. From the data presented here, patients will have additional symptomatology, 
will usually have used topical, oral or inhaled steroids, and will probably have a PPR 
pattern to their rosacea. Great care is needed in these patients to make an accurate 
diagnosis, to ensure appropriate treatment. In particular, if a facial rash is to be used 
as a diagnostic criterion for lupus, histology will be an essential part of the work up of 
the patient. 
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3. Effect of Oral Antibiotics on ANA
Tetracyclines are used orally in the treatment of moderate to severe inflammatory 
acne  vulgaris  and  rosacea,  because  of  their  effectiveness,  favorable  dosing 
characteristics  and  the relatively  low rate  of  resistance.  All  tetracyclines  may be 
associated with the risk of inducing or precipitating ANA positivity, but this is most 
marked for  Minocycline,  where it  can occur  in  up to 15% of  patients  (155).  The 
association between minocycline and drug induced systemic and cutaneous LE has 
been  extensively  documented.  Minocycline  exposure  results  in  a  three-fold 
increased risk of developing either the systemic or cutaneous form, with a longer 
duration  of  exposure  correlated  with  increased  incidence.  The  degree  of  risk 
associated with other tetracyclines is less clear, but is certainly very much less (156). 
Consequently,  minocycline  has fallen  out  of  favour  in  this  context,  but  the  other 
tetracyclines are still widely used. 
Drug  induced  SCLE  and  idiopathic  SCLE  display  almost  identical  morphologic 
features, although idiopathic SCLE tends to spare the lower extremities in contrast to 
drug induced SCLE. SCLE occurs most frequently in women in the third and fourth 
decades of life, although the drug induced form occurs in both genders and typically 
at an older age. SCLE typically presents with either scaly,  erythematous, annular 
plaques or with papulosquamous lesions. However, more uncommon morphologies, 
such as exanthematous, pityriasiform, erythrodermic, bullous and poikilodermatous 
have been described. Lesions usually are restricted to a photosensitive distribution 
on the anterior  chest,  upper back,  shoulders,  and extensor aspects of  the arms. 
Lesions are longer lasting than those observed in ACLE and are non-scarring in 
contrast  to  those in  DLE.  Up to 70% of  patients  with idiopathic  SCLE and drug 
induced SCLE have anti-Ro/SS-A antibodies, whereas up to 40% have anti-La/SS-B 
antibodies  (157).  The anti-histone  IgG autoantibodies  are  traditionally  associated 
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with drug induced LE in up to 75% of  patients although this test  is uncommonly 
positive in SCLE. In contrast, up to 70% of patients with idiopathic SLE are positive 
for anti-double stranded DNA antibodies, whereas less than 5% of patients with drug 
induced SLE and SCLE are positive (158).
There is no clear consensus on the diagnostic criteria for drug-induced lupus, but it 
should be expected in patients who do not have a history of idiopathic lupus, who 
develop antinuclear antibodies, and who have at least 1 clinical feature of lupus after 
an  appropriate  duration  of  drug  treatment.  The  condition  should  improve  with 
elimination of the offending drug. Most patients experience improvement within eight 
weeks of discontinuing the offending medication, with anti-Ro titers becoming normal 
within eight months (159).
Several mechanisms have been suggested for drug induced lupus and include the 
possibility  that  a reactive metabolite  binds to the class II  major  histocompatibility 
antigen and induces an autoimmune reaction analogous to a graft-vs-host reaction. A 
drug or its potentially reactive metabolites may bind directly to histones and act as 
haptens,  producing  an  antigenic  complex  capable  of  stimulating  autoantibody 
formation. Factors that have been implicated in causing drug induced lupus include 
use of  the drug for  long-term therapy,  dose dependency,  and the presence of  a 
functional group that is easily oxidized to a reactive metabolite. It was hypothesized 
that the presence of an amino acid side chain in minocycline, which may yield a 
reactive  metabolite,  and  the  absence  of  such  a  functional  group  in  the  other 
tetracyclines  might  explain  why  drug-induced  lupus  is  observed  mainly  in 
minocycline users (160). 
  121
The first case report of minocycline and lupus appeared in 1992. However, in 1998, a 
lupus  like  syndrome  developing  in  64  minocycline  users  was  reported.  Patients 
developed positive ANA and elevated ESR. All patients recovered rapidly after drug 
removal,  and antibody levels became normal.  In several cases, re-challenge was 
positive, indicating a causal relationship (161).  A case-control study, of 27,688 acne 
patients aged 15 to 29 years, recorded on the General Practitioners database in the 
United Kingdom was reported in 2001. Controls were matched to cases on age, sex, 
and practice.  The main outcome was the development  of  a lupus like syndrome 
defined as the occurrence of polyarthritis or polyarthralgia of unknown origin, with 
negative  rheumatoid  factor  or  latex  agglutination  test,  positive  or  unmeasured 
antinuclear factor and elevated or unmeasured erythrocyte sedimentation rate. The 
results  showed that  a single use of  minocycline was associated with an 8.5-fold 
increased risk of developing a lupus like syndrome compared with non-users and 
past  users  of  tetracyclines  combined.  The  risk  of  past  exposure  to  any  of  the 
tetracyclines  was  closely  similar  to  non-use.  Current  use  of  doxycycline, 
oxytetracycline, or tetracycline combined was associated with a 1.7-fold increase of 
risk. The risk increased with longer use (162).  In a Leeds study, in 2007, where 69% 
of a total of 252 patients with acne vulgaris were treated with minocycline antibiotic, it 
was shown that no statistical difference existed in the prevalence of ANA positivity 
between patients  exposed (13%) and not  exposed patients  (11%).  However,  the 
higher titres of  ANA (1/160 or more) were found more in the minocycline treated 
group (45%) compared to non-treated group (12%) (163). 
All the above studies confirmed the increased risk of drug induced LE with the use of 
minocycline for the treatment of acne vulgaris. To my knowledge, I could not find any 
study evaluating  the mincycline  induced  LE in  treatment  of  rosacea,  and  this  is 
probably because minocycline is not the favorite oral antibiotic in rosacea treatment 
as well  as doctors avoiding prescribing minocycline because of the reported side 
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effects, especially in patients who were tested positive for ANA to avoid the risk of 
developing the drug induced LE.
In the study reported in this thesis, there was no increase in the positivity of ANA 
among rosacea patients who were treated with courses of oral antibiotics. Only 15 
patients (11%) out of a total of 139 patients treated with oral antibiotics had a positive 
ANA compared to 7 patients (23%) out of 30 patients who were not treated with oral 
antibiotics. This was not a significant difference. Patients were treated with a variety 
of different tetracyline antibiotics including doxycycline, oxytetracycline, minocycline 
and  lymecycline.  We did  not  record  the  specific  type  of  oral  antibiotic  used  for 
treatment  of  our  rosacea  patients  to  check  the  specific  antibiotic  effect  on  the 
positivity  of  ANA  test,  however,  the  overall  results  indicated  that  there  is  no 
relationship between all antibiotics usage and a positive ANA result.   
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4. Conclusion
With respect to the questions originally posed in this piece of research, the following 
conclusions are drawn:
1. In the cohorts of patients studied, what was the frequency of ANA positivity? 
The  overall  frequency  of  ANA positivity  was  5%  for  those  patients  without  a 
connective tissue disease. This study confirmed strongly that there is no evidence of 
an increased incidence of a positive ANA blood test in a large group of patients with 
rosacea diagnosed clinically. There is also no evidence that any particular clinical 
sub-type of the disease is associated with a positive ANA.
2. Is there a sub-group of patients with rosacea that has systemic symptoms 
with or without immunological abnormalities? 
Similarly,  there  was no increase in  symptoms suggestive  of  CTD in  the disease 
overall, or any of its sub-types. Systemic symptoms occurred, but usually in patients 
with an underlying CTD.
3.  Is  there any relation between rosacea and its  sub-types  and connective 
tissue diseases, particularly lupus erythematosus?
The more interesting elements of the study came from comparing the two cohorts of 
patients derived from the two recruiting centres. These centres were quite different in 
their backgrounds. One, Doncaster, was a district general hospital, where patients 
were seen in a general clinic with no specific special interest. The second, in Leeds, 
was based in a teaching hospital, and most patients were recruited through more 
specialist clinics, where even the ‘general’ clinics had a tertiary referral element, and 
saw mainly complex medical dermatology. 
  124
Patients recruited in  the Doncaster  cohort  were more broadly  spread across the 
range  of  rosacea  sub-types,  had  low  levels  of  ANA positivity  compatible  with 
previously  published  research  and  low levels  of  associated  CTD.  In  Leeds,  the 
patients  were more likely to  have the PPR pattern of  disease,  had much higher 
frequencies of CTD, mainly lupus erythematosus, more regularly used steroids (oral, 
topical or inhaled), and had higher frequencies of systemic symptoms. There were 
also more with a positive ANA. Many of the patients with these features had a real 
CTD that was concomitant, as well as their rosacea. Diagnosis could sometimes be 
made clinically, but confirmation often required biopsy to separate cutaneous lupus, 
particularly the rosaceous pattern (98) from true rosacea. This diagnosis was usually 
clear cut on histological grounds.
The unanswered question in this study is whether rosacea occurs more frequently in 
certain CTD, and if  so, whether this is due to treatment with steroid, or for some 
other reason. The data here are suggestive of the involvement of steroid treatment, 
because of  its  frequent  occurrence and the papulo-pustular  bias  of  the  rosacea. 
Whilst  confusion  of  the  malar  rash  of  lupus  with  the  ETR  sub-type  of  rosacea 
remains a further issue, in this study, this did not appear to be a major diagnostic 
problem for the dermatologists involved, although may well be more difficult for non-
dermatologists.
.      
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5. Strength of the Study
1. To my knowledge, this is the biggest study in terms of number of patients (169 
patients) investigating the association of different subtypes of rosacea with positivity 
of the ANA blood test, connective tissue related symptoms and CTD.
2. Numbers were high enough to allow appropriate comparisons to be made with 
statistical strength.
3. Recruitment from two very different centres allowed for interesting comparisons to 
be  made,  particularly  since  one  had  a  strong  bias  towards  complex  medical 
dermatology and CTD.
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6. Limitations of the Study
1. Recruited patients had all had a blood test for ANA performed. This implied that 
there was at least some possibility in the clinician’s mind that an alternative diagnosis 
might  be  possible.  Mild  or  frankly  pustular  clinical  patterns  might  be  under-
represented since it is these categories of patients in whom an alternative diagnosis 
is less likely to have been considered. Certain sub-groups e.g. ocular rosacea might 
also  be  under-represented  since  cutaneous  disease  was  a  necessary  inclusion 
criterion and is not always present in those with eye disease.
2.  All rosacea patients with ANA blood test were recruited retrospectively as there 
was no budget for this study to investigate ANA or DIF study prospectively in newly 
diagnosed rosacea patients. Because of this reason the ethical approval was given 
on basis not to investigate rosacea patients for the purpose of the study.
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7. Weakness of the Study
1.  Histology and DIF was not performed on all  patients, being requested only as 
clinical need required. It is theoretically possible that some cases of either lupus or 
rosacea were consequently  misdiagnosed.  However,  our  study was retrospective 
and  observational,  and  rosacea  in  most  instances  is  diagnosed  clinically.  Any 
occurrence of misdiagnosis is likely to have been very limited, particularly since all 
patients  had been tested for  ANA.  The study also was not  ethically approved to 
investigate any patients further by performing including blood tests or histology on 
skin tissue prospectively. 
2. We did not record the titre of the ANA in our positive ANA patients. The laboratory 
cut off  for reporting positivity was  ≥ 1:80, a lower level than has been previously 
accepted as being clinically important (1:160) in some investigations. However, with 
modern automated techniques in most laboratories, and certainly in the two involved 
in performing the ANA screening in this study, the 1:80 cut off is accepted as being 
positive for the screening nature of the test, and sufficient to prompt further clinical 
assessment  and  investigation.  Collecting  data  on  titres  would  have  been  an 
interesting addition to the study but is unlikely to have unduly influenced the results.
3.  We did  not  record  Anti-DNA,  ENA or  any  of  the  inflammatory  blood  markers 
including C Reactive Protein (CRP) or ESR to correlate these markers with positivity 
of the ANA. None of the patients with rosacea alone in the Leeds cohort had any 
antibodies other than the ANA, whilst those with associated CTD had an array of 
antibodies compatible with their underlying diagnosis. These were not specifically 
recorded, since they were related to the underlying CTD. Collection on data relating 
to  additional  antibodies  would  have  been  very  important  had  there  been  a 
relationship  of  ANA to  rosacea  and  its  sub-types,  but  this  relationship  was  not 
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identified in this study.
4. We did not record the specific type of oral antibiotic used for treatment of our 
rosacea patients and then correlate this antibiotic with positivity of ANA. The reason 
was that not all patients had full record of their antibiotics prescribed by their general 
practitioners  documented  in  their  referral  letters  or  hospital  notes.  However,  the 
overall results indicated no relationship between antibiotic usage and a positive ANA 
result.   
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8. Recommendations
1. Further studies are still needed to investigate particularly the frequency of rosacea 
in a connective disease population. A community based study, identifying patients 
from a primary care setting with a diagnosis of rosacea, would be valuable to assess 
the frequency of ANA positivity in this unselected group. There would be a need for 
the confirmation of the diagnosis, either by an experienced dermatologist, or through 
skin biopsy, but this would allow the most accurate data to be acquired. 
2. A  further  prospective  controlled  hospital  based  study  investigating  rosacea 
patients with ANA to establish the frequency of anti-DNA and ENA antibodies in this 
group  would  be  helpful.  A study  looking  at  the  frequency  of  positive  DIF  in  an 
adequately powered investigation of rosacea patients compared to a healthy control 
group is recommended, although this would need to be large enough to allow for the 
relatively high frequency of non-specific DIF positivity in light exposed normal facial 
skin, as well as the frequency of around 5% ANA positivity in healthy individuals. 
3. More studies needed to check the role of the cathelicidin LL-37 in pathogenesis of 
rosacea and potentially  in  cutaneous lupus as well.  This  is  particularly important 
since it may provide a target for therapeutic intervention in these diseases.
4. The role of the DF in the pathogenesis of rosacea is another area of study and the 
eradication of DF by topical and oral ivermectin to help to control rosacea symptoms 
especially in the PPR is worth further research.
5. The impact of steroid usage, whether oral or topical is more important, and the 
balance of rosacea sub-types would also be important areas of further study.
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6. The  possibility  of  a  role  for  genetic  predisposition  in  rosacea  as  a  whole, 
particularly  in  the  light  of  a  positive  family  history  of  rosacea,  should  be  further 
investigated. A simple HLA study or more complex investigations of the genetics of 
vascular factors, pro-inflammatory cytokines and the innate immune system would 
be valuable. 
   
  131
Chapter Five - References
  132
References
1. Frank  C.  Powell  (2009).  Rosacea  Diagnosis  and  Management.  Informa 
Healthcare, USA. Pages: 11, 33, 37, 57, 82, 101, 106.
2. Wilkin  J,  Dahl  M,  Detmar  M,  Drake  L,  Feinstein  A,  Odom  R,  Powell  F. 
standard classification of  rosacea:  report  of  the National Rosacae Society expert 
committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002 
Apr;46(4):584-7.
3. Chosidow O, Cribier B. Epidemiology of rosacea: update data. Ann Dermatol 
Venereol. 2011 Nov; 138(Suppl 3):179-83.
4.  Drolet B, Paller AS. Childhood rosacea. Pediatr Dermatol.  1992 Mar;9(1): 
22-6.
5. Rosen T, Stone MS. Acne rosacea in blaks. J Am Acad Dermatol. 1987 Jul; 
17(1):70-3.
6. Neves  H.  Incidence  of  skin  diseases  1952-1965.  trans  St  John's  Hosp 
Dermatol Soc. 1966;52(2):255-71. 
7. Berg M, Lieden S. An epidemiological study of rosacea. Acta Derm Venereol. 
1989;69(5):419-23.
8. McAleer  MA,  Fitzpatrick.  P,  Powell  FC.  Prevalence  and  pathogenesis  of 
rosacea. Br J Dermatol. 2008;159(Suppl 1):26.
9. Abram K, Slim H, Oona M. Prevalence of rosacea in an Estonian working 
population  using a standard classification.  Acta  Derm Venereol.  2010 May;90(3): 
269-73.
10. Khaled A, hammami H, Zeglaoui F, Tounsi J, Zermani R, Kamoun MR, Fazaa 
B. Rosacea: 244 tunisian cases. Tunis Med. 2010 Aug;88(8):597-601.
11. Spoendlin J, Voegel JJ, Jick SS, Meier CR. A study on the epidemiology of 
rosacea in the UK. Br J Dermatol. 2012 Sep;167(3):598-605.
12. National Rosacea society Survey (1996). New evidence shows rosacea may 
  133
be linked to heredity. Available at: www. rosacea.org (Accessed: 1996).
13. National  Rosacae  Society  Survey (2008).  Survey suggests  heredity  plays 
part in development of rosacea.  Available at: www. rosacea.org (Accessed: 2008).
14. Dorschner RA, Petonjamasp VK, Tamakuwala S, Ohtake T, Rudisill J, Nizet 
V, Agerberth B, Gudmundsson GH, Gallo RL. Cutaneous injury induces the release 
of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest 
Dermatol. 2001 Jul;117(1):91-7.
15. Yamasaki  K,  Schauber  J,  Coda  A,  Lin  H,  Dorschner  RA,  Schechter  NM, 
Bonnart C, Descargues P, Hovnanian A, Gallo RL. Kallikrein-mediated proteolysis 
regulates  the  antimicrobial  effects  of  cathelicidins  in  skin.  FASEB  J.  2006 
Oct;20(12):2068-80.
16. Murakami  M,  Lopez-Garcia  B,  Braff  M,  Dorschner  RA,  Gallo  RL. 
Postsecretory  processing  generates  multiple  cathelicidins  for  enhanced  topical 
antimicrobial defense. J Immunol. 2004 Mar;172 (5):3070-77. 
17. Yamasaki  K,  Di  Nardo  A,  Bardan  A,  Murakami  M,  Ohtake  T,  Coda  A, 
Dorschner RA, Bonnart  C, Descargues P,  Hovnanian A,  Morhenn VB, Gallo RL.. 
Increased serine protease activity and cathelicidin  promotes skin inflammation in 
rosacea. Nat Med. 2007 Aug;13(8):975-80. 
18. De Y, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim 
JJ, Chertov O. LL-37, the neutrophil granule and epithelial cell derived cathelicidin , 
utilizes formyl peptide receptor-like 1 (FPRL1) as receptor to chemoattract human 
peripheral  blood  neutrophils,  monocytes  and  T  cells.  J  Exp  Med.  2000 
Oct;192(7):1069-74.
19. Koczulla R, von Degenfeld G, Kupatt C. et al. An angiogenenic role for the 
human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003 Jun;111(11):665-72.
20. Gollo RL, Ono M, Povsic T, Page C, Eriksson E, Klagsbrun M. Syndecans, 
cell surface heparin sulphate proteoglycans  are induced by proline rich antimicrobial 
peptidefrom wounds. Proc Natl Acad SCi USA .1994 Nov;91(23):11035-9.
  134
21. Morizane S, Yamasaki K, Kabigting FD, Gallo RL. Kallikrein expression and 
cathelicidin  processing  are  independently  controlled  in  keratinocytes  by  calcium, 
vitamin D(3), and retinoic acid. J Invest Dermatol. 2010 May;130(5):1297-306. 
22. Peric M, Lehmann B, Vashina G, Dombrowski Y, Koglin S, Meurer M, et al. 
UV-B-triggered induction of vitamin D3 metabolism differentially affects antimicrobial 
peptide expression in keratinocytes. J Allergy Clin Immunol. 2010 Mar;125(3):746-9. 
23. Park K, Elias PM, Oda Y, Mackenzie D, Mauro T, Holleran WM, Uchida Y. 
Regulation  of  cathelicidin  antimicrobial  peptide  expression  by  an  endoplasmic 
reticulum  (ER)  stress  signaling,  vitamin  D  receptor-independent  pathway.  J  Biol 
Chem. 2011 Sep;286(39):34121-30.
24. Reinholz  M,  Ruzicka  T,  Schauber  J.  Cathelicidin  LL-37:  n  antimicrobial 
peptide  with  a  role  in  inflammatory  skin  disease.  Ann  Dermatol.  2012  May: 
24(2):126-35.
25. Tan  SG,  Cunliffe  WJ.  Rosacea  and  migraine.  Br  Med  J.  1976  Jan  3;I 
(6000): 21.
26. Guarrera M, Parodi A, Cipriani C, Divano C, Rebora A. Flushing in rosacea: a 
possible mechanism. Arch Dermatol Res. 1982;272(3-4): 311-6.
27. Gomaa  AH,  Yaar  M,  Eyada  MM,  Bhawan  J.  Lymphangiogenesis  and 
angiogenesis in non phymatous rosacea. J Cutan Pathol. 2007 Oct;34(10):748-53.
28. Yamasaki K, Gallo RL. Rosacea as  a disease of cathelicidine and skin innate 
immunity. J Investig Dermatol Symp Proc. 2011 Dec;15(1):12-15. 
29. Sibenge S, Gawkrodger DJ. Rosacea: a study of clinical patterns, blood flow, 
and role of Demodex Folliculorum. J Am Acad Dermatol. 1992 Apr; 26(4): 590-3.
30. Pelle  MT,  Crawford  GH,  James  WD.  Rosacea:  II.  Therapy.  J  Am  Acad 
Dermatol. 2004 Oct;51(4):499-512.
31. Rosina P, Zamperetti M, Giovannini A, et al. Videocapillaroscopic alterations 
in erythematotelangiectatic rosacea. J AM Acad Dermatol. 2006 Jan;54(1):100-104.
32. James Q,  Del  Rosso,  Advances in  understanding and managing rosacea: 
  135
part 2. J Clin Aesthet. 2012 Mar; 5(3): 26-36.
33. Aylesworth  R,  Vance  JC.  Demodex  folliculorum  and  Demode  brevis  in 
cutaneous biopsies. J Am Acad Dermatol. 1982 Nov;7(5):583-9.
34. Forton F, Seys B. Density of Demodexfolliclorum in rosacea: a case control 
study using standardized skin surface biopsy. Br J Dermatol. 1993 Jun;128(6):650-9.
35. Moravvej H, Dehghan-Mangabadi M, Abbasian MR. Association of rosacea 
with demodicosis. Arch Iran Med. 2007 Apr;10(2):199-203.
36. Casas  C,  Paul  C,  Lathfa  M,  Livideanu  B,  Lejeune  O.  Quantification  of 
Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune 
activation. Exp Dermatol. 2012 Dec;21(12):906-10.
37. Erbagci Z, Ozgoztasi O. The significance of Demodex folliculorum density in 
rosacea. Int J Dermatol. 1998 Jun;37(6):421-5.
38. Bonnar E, Eustace P, Powell FC. The Demodex mite population in rosacea. J 
Am Acad Dermatol. 1993 Mar;28(3):443-8.
39. Nutting  WM,  Andrews  JRH,  Desch  CE.  Studies  in  symbiosis:  hair  follicle 
mites of mammals and man. J Biol Educ. 1979;13:315-321.
40. Rebora A, Drago F, Picciotto A. Helicobacter pylori in patients with rosacea. 
Am J Gastroenterol. 1994 Sep;89(9):1603-4.
41. Szlachcic A. The link between Helicobacter pylori infection and rosacea.
J Eur Acad Dermatol Venereol. 2002 Jul;16(4): 328-33.
42. Boixeda de Miquel D, Vazquez Romero M, Vazquez Sequeiros E. Effect of 
Hilicobacter  pylori  eradication  therapy in  rosacea patients.  Rev Esp Enferm Dig. 
2006 Jul:98(7):501-9.
43. El-Khalawany M, Mahmoud A,  Mosbeh AS, ABD Asalam F,  Ghomniam N. 
Role of Helicobacter pylori in common rosacea subtypes: a genotypic comparative 
study of Egyptian patients. J Dermatol. 2012 Dec;39(12):989-95.
44. Dakovic  Z,  Vesic  S,  Vukovic  J,  Milenkovic  S,  Jankovic-terzic  K.  Ocular 
rosacea and treatment of symptomatic helicobacter pylori infection: a case series. 
  136
Acta Dermatovenerol  Alp Panonica  Adriat. 2007 Jun;16(2):83-6
45. Szlachic  A,  Aliwowski  Z,  Karczewska  E  et  al.  Helicobacter  pylori  and  its 
eradication in rosacea. J Physiol Pharmacol. 1999 Dec;50(5):777-86.
46. Bamford  J,  Tilden  R,  blankush  J,  Gangeness  D.  Effect  of  treatment  of 
Helicobactor pylori infection on rosacea.  Arch Dermatol. 1999 Jun;135(6):659-63.
47. Herr  H,  You CH. Relationship between Helicobacter pylori  and rosacea:  it 
may be a myth. J Korean Med Sci. 200 Oct;15(5):551-4
48. Miyachi  Y,  Yoshioka  A,  Imamura  S,  Niwa  Y.  Effect  of  antibiotics  on  the 
generation of reactive oxygen species. J Invest Dermatol. 1986 Apr,86(4):449-53.
49. Akamatsu  H,  Komura  J,  Asada  Y,  Miyachi  Y,  Niwa  Y.  Inhibitory  effect  of 
azelaic  acid  on neutrophil  functions:  a  possible  cause for  its  efficacy  in  treating 
pathogentically unrelated disease.  Arch Dermatol Res. 1991;283(3):162-6.
50. Akamatsu H, Oguchi M, Nishijima S, Asada Y, Takahashi M, Ushijima T. The 
inhibition  of  free  radical  generation  by  human  neutrophil  through  the  synergistic 
effects of  metronidazole with palmitoleic acid: a possible mechanism of  action of 
metronidazole in rosacea and acne. Arch Dermatol Res. 1990;282(7):449-54. 
51. Yoshioka A, Miyachi Y, Imamura S, Niwa Y. Anti-oxidant effects of retinoids on 
inflammatory skin disease. Arch Dermatol Res. 1986;278(3):177-83.
52. Young  CN,  Koepke  JI,  Terlecky  LJ,  Borkin  MS,  Boyd  SL,  Terlecky  SR. 
Reactive oxygen species in tumor necrosis factor-alpha activated primary human 
keratinocytes:  implications  for  psoriasis  and  inflamatory  skin  disease.  J  Invest 
Dermatol. 2008 Nov;128(11):2606-14. 
53. Kawaguchi Y, Tanak H, Okada T, Konishi H, Takahashi M, Ito M, Asai J. The 
effects of ultraviolet A and reactive oxygen species on the mRNA expression of 72-
KDa type IV collagenase and its tissue inhibitor in cultured human dermal fibroblasts. 
Arch Dermatol Res. 1996;288(1):39-44.
54. Oztas MO, Balk M, Ogus E, Bozkurt M, Ogus IH, Ozer N. The role of free 
oxygen radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol. 2003 Mar; 
  137
28(2):188-92.
55. Bas K, Cimen MY, Kokturk A Aslan G, Ikizoglu G, Demirseren DD, Kanik A, 
Atik U. Plasma reactive oxygen species activity and antioxidant  potential  level in 
rosacea patients: correlation with seropositivty to Hlicobacter pylori. Int J Dermatol. 
2004 Jul;43(7):494-7.
56. Powell  FC.  Clinical  practice.  Rosacea.  N  Engl  J  Med.  2005  Feb;352(8): 
793-803
57. Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 
2009 Aug,55(2):77-81.
58. Bielenberg DR, Bucana CD, Sanchez R, Donawho CK, Kripke ML, fiddler IJ. 
Molecular regulation of UVB induced cutaneous angiogenesis. J Invest Dermatol. 
1998 Nov;111(5):864-72.
59. National  Rosacea  Society  (2009),  Rosacea  triggers  survey.  Available  at: 
www.rosacea.org (Accessed: 2009).
60. Leyden  JJ,  Thew M,  Kligman  AM.  Steroid  rosacea.  Arch  Dermatol.  1974 
Oct;110(4):619-22.
61. Weston WL, Morelli JG, Steroid rosacea in prepubertal children . Arch Padiatr 
Adolesc Med. 200 Jan;154(1):62-4.
62. Egan  CA,  Rallis  TM,  Meadows  KP,  Krueger  GG.  Rosacea  induced  by 
beclomethasone dipropionate spray. Int Dermatol. 1999 Feb;38(2):133-4.
63. Jean  L.  Bolognia,  Joseph  L.  Jorizzo,  Julie  V.  Schaffer.  Text  Book 
Dermatology; third edition, 568. 
64. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat 
Rev cancer. 2006 Oct;6(10):803-12.
65. Gerber  PA,  Kukova  G,  Buhren  BA.,  Homey  B.  Density  of  Demodex 
folliculorum  in  patients  receiving  epidermal  growth  factor  receptor  inhibitors. 
Dermatology. 2011;222(2):144-7.
66. Lewis VJ, Holme SA, Wright A, Anstey AV. Rosacea fulminans in pregnancy. 
  138
Br J Dermatol. 2004 Oct;151(4)917-9.
67. Ciss M, Maruani A, Bre C, Domart P, Joville-Bera AP, Machet L. Rosacea 
fulminans in the early course of  a pregnancy by in  vitro fertilization with embryo 
transfer. Ann Dermatol Venereol. 2008 Oct;135(10):675-8.
68. Ozcan S, An HJ, Vieira AC, Park GW, Kim JH. Characterization on novel O-
Glycans isolated from tear and saliva of ocular rosacea patients. J Proteome Res. 
2013 Mar;12(3):1090-100.
69. Marks R, Harcourt-Webster JN. Histopathology of rosacea. Arch Dermatol. 
1969 Dec;100(6):683-91.
70. Lavker RM, Kligman AM. Chronic heliodermatitis: a morphologic evaluation of 
chronic actinic dermal damage with emphasis on the role of  mast  cells.  J Invest 
Dermatol. 1988 Mar;90(3):325-30. 
71. Marks  R,   Jone  EW.  Disseminated  rosacea.  Br  J  Dermatol.  1969 
Jan;81(1):16-28.
72. Gubisch W. Otophyma: a rare disease. HNO. 1983 Feb;31(2):56-8.
73. Starr  PA,  Macdonald A.  Oculocutaneous aspects of  rosacea.  Proc R Soc 
Med. 1969 Jan;62(1):9-11.
74. Keshtcar-Jafari A, Akhyani M, Ehsani AH, Ghiasi M, Lajevardi V, Baradran O, 
Toosi S. Correlation of the severity of cutaneous rosacea with ocular rosacea. Indian 
J Dermatol Venereol Leprol. 2009 Jul-Aug;75(4):405-6.  
75. Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs 
in acne rosacea: comparing patients from ophthalmology and dermatology clinics. 
Cornea. 2003 Apr;22(3):230-3. 
76. Akpek  EK,  Merchant  A,  Pinar  V,  Foster  CS.  Ocular  rosacea:  patient 
characteristics and follow-up. Ophthalmology. 1997 Nov;104(11):1863-7.
77. Ravage  ZB,  Beck  AP,  Macsai  MS,  Ching  SS.  Ocular  rosacea  can  mimic 
trachoma: a case of cicatrizing conjunctivitis. Cornea. 2004 Aug;23(6):630-1. 
78. Faraj  HG,  Hoan.g-Xuan  T.  Chronic  cicatrizing  conjunctivitis.  Curr  Opin 
  139
Ophthalmol. 2001 Aug;12(4):250-7. 
79. National Rosacea Society Survey (2004). New survey shows rosacea tends 
to evolve beyond one  subtype. Available at: www.rosacea.org (Accessed: 2004).
80. Tan  J,  Blume-Peyavi  U,  Ortonne  JP,  Wihelm  K.  An  observational  cross 
sectional survey of rosacea: clinical associations and progression between subtypes. 
Br J Dermatol. 2013 Sep;169(3)555-62.
81. Sánchez JL, Berlingeri-Ramos AC, Dueño DV. Granulomatous rosacea. Am J 
Dermatopathol. 2008 Feb;30(1):6-9.
82. Helm KF, Menz J, Gibson LE, Dicken CH. A clinical and histopathologic study 
of granulomatous rosacea. J Am Acad Dermatol. 1991Dec;25(6):1038-43.  
83. Kennedy Carney C, Cantrell  W, Elewski BE. Rosacea: a review of current 
topical,  systemic and light-based therapies.  G Ital  Dermatol Venereol.  2009 Dec; 
144(6): 673-88.
84. Massa MC, Su WP. Pyoderma faciale: a clinical study of twenty nine patients. 
J AM Acad Dermatol. 1982 Jan;6(1):84-91.
85. Plewig G, Jasen T, Kligman AM. Pyoderma faciale. A review and report of 20 
additional cases: is it rosacea? Arch Dermatol. 1992 Dec;128(12):1611-7.
86. Ljubojeviae  S,  Basta-Juzbasiae  A,  Lipozeneiae  J.  Steroid  dermatitis 
resembling rosacea: aetiopathogenesis and treatment. J Eur Acad Dermatol Venerol. 
2002 Mar;16(2):121-6.  
87. Litt JZ. Steroid-induced rosacea. Am Fam Physician. 1993 Jul;48(1):67-71.  
88. Sneddon I. Iatrogenic dermatitis. Br Med J. 1969 Oct;4(5674):49-50.  
89. Rapaport MJ, Rapaport VH. Serum nitric oxide levels in "Red" patients: 
Separating corticosteroid addicted patients from those with chronic eczema. Arch 
Dermatol. 2004 Aug;140(8):1013-4. 
90. Ruo V,  Hochberg MC. The epidemiology of systemic lupus erythematosus. 
In:  Wallac  DJ,  Hahn  BH  (eds).  Duboi's  Lupus  Erythematosus,  6th 
edn.Philadelphia:Lippincott, Williams & Wilkins, 2002:65-83.
  140
91. Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus 
erythematosus. Br J Dermatol. 1996 Sep;135(3):355-62. 
92. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of 
lupus erythematosus. J Am Acad Dermatol. 1981 Apr;4(4):471-5.
93. Walling  HW,  Sontheimer  RD.  Cutaneous  lupus  erythematosus:  issues  in 
diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365-81. 
94. Obermoser  G,  Sontheimer  RD,  Zelger  B.  Overview of  common,  rare  and 
atypical  manifestations  of  cutaneous  lupus  erythematosus  and  histopathological 
correlates. Lupus. 2010 Aug;19(9):1050-70.
95. Lin JH, Dutz JP, Sontheimer RD, Werth VP. Pathophysiology of cutaneous 
lupus erythematosus. Clin Rev Allergy Immunol. 2007;33:85–106.
96. Bangert JL, Freeman RG, Sontheimer RD, Gilliam JN. Subacute cutaneous 
lupus erythematosus and discoid lupus erythematosus. Comparitive histopathologic 
findings. Arch Dermatol. 1984;120:332-7.
97. Burnham TK, Neblett TR, Fine G. The application of the fluorsence antibody 
technique to the investigation of lupus erythematosus and various dermatoses . J 
Invest Dermatol. 1963 Dec;41:451-6.
98. Chorzelski  TP,  Jablonska  S,  Blaszczyk  M,  Fabjanska  L.  Annular  atrophic 
plaques  of  the  face.  A  variety  of  atrophic  descoid  lupus  erythematosus.  Arch 
Dermatol. 1976 Aug;112(8):1143-5.
99. Lande  R,  Ganguly  D,  Facchinetti  V,  Frasca  L,  Conrad  C,  Gregorio  J. 
Neutrophils  activate  plasmacytoid  dendritic  cells  by  releasing  self-DNA peptide 
complexes  in  systemic  lupus  erythematosus.  Sci  Transl  Med.  2011Mar 
9;3(73):73ra19.
100. Sun CL, Zhang FZ, Li P, Bi LQ. LL-37 expression in the skin in systematic 
lupus erythematosus. Lupus. 2011 Aug;20(9):904-11.
101. Kreuter A, Jaouhar M, Skrygan M, Tigges C, Stuker M, Altmeyer P, Glaser R, 
Gambichler  T.  Expression  on  antimicrobial  peptides  in  different  subtypes  of 
  141
cutaneous lupus erythematosus. J Am Acad Dermatol. 2011 Jul;65(1):125-33.  
102. McClellan KJ, Noble S. Topical metronidazole. A review of its use in rosacea. 
Am J Clin Dermatol.2000 May;1(3):191-9.
103. Dahl  MV,  Jarratt  M,  Kaplan  D,  Tuley  MR,  Baker  MD.  Once  daily  topical 
metronidazole  cream  formulations  in  the  treatment  of  papules  and  pustules  of 
rosacea. J Am Acad Dermatol 2001 Nov;45(5):723-30.
104. Gupta AK, Gover MD. Azeliac acid 15% gel in treatment of acne rosacea. Int 
J Dermatol. 2007 May;46(5):533-8.
105. Thiboutot DM, Fleischer AB, Del Rosso JQ, Graupe K. Azelaic acid gel once 
daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008 June; 7 
(6): 541-6.
106. Sauder DN, Miller R, Gratton D, Danby W, Griffiths C, Philips SB, et al. The 
treatment  of  rosacea:  the safety  and efficacy of  sodium sulfacetamide 10% and 
sulfur 5% lotion (Novacet) is demonstrated in a double blind study. J Dermatol Treat 
1997;8:79-85.
107. Mills OH, Kligman AM. Letter: Topically applied erythromycin in rosacea. Arch 
Dermatol 1976 Apr;112(4):553-4.
108. Wilkin JK, DeWitt S. Treatment of rosacea: topical clindamtcine versus oral 
tetracycline. Int Dermatol 1993 Jan;32(1):65-7.
109. Goldman  D.  Tacrolimus  ointment  for  the  treatment  of  steroid  induced 
rosacea: a preliminary report. J Am Acad Dermatol. 2001 Jun;44(6):995-8.
110. Smilack JD. The tetracyclines. Mayo Clin Proc. 1999 Jul;74(7):727-9. 
111. Sapadin AN, Fleischmajer R. Tetracyclines: Nonantibiotic properties and their 
clinical implications. J Am Acad Dermatol. 2006 Feb;54(2):258-65. 
112. McKeage  K,  Deeks  ED.  Doxycycline  40mg  capsules  (30  mg  immediate 
release / 10mg delayed release beads): anti inflammatory dose in rosacea. Am J 
Clin Dermatol. 2010;11(3):217-22.
113. Del  Rosso JQ,  Webster  GF,  Jackson M,  et  al.  Two randomized phase III 
  142
clinical  trials  evaluating  anti-inflammatory  dose  doxycycline  (40-mg  doxycycline, 
USP  capsules)  administered  once  daily  for  treatment  of  rosacea.  J  Am  Acad 
Dermatol. 2007 May;56(5):791-802. 
114. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory 
dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs 
Dermatol. 2008 Jun;7(6):573-6. 
115. Fowler  JF.  Combined effect  of  anti-inflammatory dose doxycycline  (40-mg 
doxycycline,  USP  monohydrate  controlled-release  capsules)  and  metronidazole 
topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007 Jun;6(6):641-5. 
116. De Rosso JQ. Effectiveness and safety of doxycyclines 40mg once daily as 
add on therapy to existing topical regimens for treatment of papulopustular rosacea: 
results from community based trail. Cutis 2010 Nov;86(5 Suppl):16-25.
117. Webster GF. An open-label community based 12 weeks assessment of the 
effectiveness  and  safety  of  monotherapy  with  doxycycline  40mg.  Cutis  2010 
Nov;86(5 Suppl):7-15.
118. Baldwin  HE.  A community  based  study of  the  effectivness of  doxycycline 
40mg on quality of life and satisfaction witj treatment in participants with rosacea. 
Cutis 2010 Nov,86 (5 Supple):26-36.
119. Baldwin  HE.  Systemic  therapy  for  rosacea.  Skin  therapy  Lett.  2007 
Mar;12(2):1-5.
120. Torresani C, Pavesi A, manara GC. Clarithromycin versus doxycycline in the 
treatment of rosacea. Int J Dermatol 1997 Dec;36(12):942-6.
121. Bakar  O, Demircay Z,  Gurbuz O.  Therapeutic  potential  of  azithromycin in 
rosacea. Int J Dermatol. 2004 Feb;43(2):151-4.
122. Pye RJ,  Burton JL.  Treatment of  rosacea by metronidazole.  Lancet.  1976 
Jun;5(7971):1211-2.
123. Saihan  EM,  Burton  JL.  A  double  blind  trail  of  metronidazole  versus 
oxytetracycline therapy for rosacea. Br J dermatol 1980 Apr;102(4):443-5.
  143
124. Erdogan  FG,  Yurtsever  P,  Aksoy  D,  Eskioglu  F.  Efficacy  of  low  dose 
isotretinoin  in  patients  with  treatment  resistant  rosacea.  Arch  Dermatol.  1998 
Jul;134(7)884-5
125. Hoting E,  Paul  E,  Plewig  G.  Treatment  of  rosacea with  isotretinoin.  Int  J 
Dermatol. 1986 Dec;25(10):660-3. 
126. Sadick NS. A structural approach to the non-ablative rejuvenation. Cosmetic 
Dermatol 2002;15:39-43.
127. Lowe NJ, Behr KL, Fitzpatrick R, Goldman M, Ruiz-Esparza J. Flash lamp 
pumped dye laser for rosacea associated telangiectasia and erythema. J Dermatol 
Surg Oncol 1991 Jun;17(6):522-5.
128. Silver BE, Livshots YL, Preliminary experience with KTP/532 nm laser in the 
treatment of facial telangiectasia. Cosmetic Dermatol 1996;9:61-4.
129. Shim TN,  Abdullah A.  The effect of pulsed dye laser on dermatology life 
quality index in erythematotelangiectatic rosacea patients. J Clin Asesthet Dermatol. 
2013 April;6(4):30-2.
130. Angermeier MC. Treatment of facial vascular lesions with intense pulsed light. 
J Cutan Laser Ther. 1999 Apr;1(2):95-100. 
131.  Weiss RA, Weiss MA, Beasley KL. Rejuvenation of photoaged skin: 5 years 
results with intense pulsed light of the face, neck and chest. Dermatol Surg 2002 
Dec,28(12):1115-9.
132. Rodder  O,  Plewig  G.  Rhinophyma and rosacea:  combined treatment  with 
isotretinoin and dermabrassion. Martin Dunitz 1988:335-38.
133. Roenigk R. CO2 Laser vaporization for teatment of rhinopyma. Mayo Clinic 
Pro. 1987 Aug;62(8):676-80.
134. Bourrat E, Rybojad M, Deplus S, Morel P. Rosacea with ocular involvment in 
a child. Ann Dermatol Venereol 1966;123(10)664-5.
135. Allen KJ, Davis CL, Billings SD, Mousdicas N. Recalcitrant papulopustular 
rosacea in an immunocompetent patient responding to combination therapy with oral 
  144
ivermectin and topical permethrin. Cutis 2007,80:149-51.
136. Aquilina  C,  Viraben R,  Sire  S.  Ivermectin-responsive  Demodex infestation 
during human immunodeficiency virus infection: a case report and literature review. 
Dermatology 2002;205:394-7.
137. Clyti  E,  Nacher  M,  Sainte-Marie  D,  Pradinaud  R,  Coppie  P.  Ivermectin 
treatment of three cases of demodecidosis during human immunodeficiency virus 
infection. Int J Dermatol 2006; 45:1066-8.
138. Stein L,  Kircik  L,  Fowler  J,  Draelos Z,  Fleischer A.  Efficacy and safety of 
ivermectin  1%  cream  in  treatment  of  papulopustular  rsacea:  results  of  two 
randomized, double-blind, vehicle controlled pivotal studies. J Drugs Dermatol. 2014 
Mar;13(3):316-23.
139. Brown M, Hernandez-Martin A, Clement A, Colmenero I, Torrelo A. Severe 
demodex folliculorum associated occulocutaneous rosacea in  a girle  successfully 
treated with ivermectin. JAMA Dermatol. 2014 Jan;150(1):61-63.
140. Hooper B, Wittingham S, Matjews JD, Mackay IR, Curnow DH, Autoimmunity 
in a rural community. Clin Exp Immunol 1972;12:79-87.
141. Tan EM, Feltkamp TEW, Smolen JS, et al. Range of antinuclear antibodies in 
healthy individuals. Arthritis Rheum. 1997;40:1601-11.
142. Shu  S,  Nisengard  RJ,  Hale  WL,  Beutner  EH.  Incidence  and  titers  of 
antinuclear, antismooth muscle, and other autoantibodies in blood donors. J Lab Clin 
Med 1975;86:259-65.
143. Anderson P. correlation of smooth muscle and nuclear antibodies in normal 
subjects. Clin Exp  Immunol 1977;27:74-7.
144. Hayashi  N,  Koshiba  M,  Nishimura  K,  Sugiyama.  Prevalence  of  disease 
specific antinuclear antibodies in general populatio: estimates from annual physical 
examinations  of  residents  of  a  small  town  over  a  5  year  period.  Mod 
Rheumatol.2008;18(2):153-60.
145. Fernandez S, Lobo A, Oliveira Z, Fukumori L, Périgo A, Rivitti E. Prevalence 
  145
of antinuclear autoantibodies in the serum of normal blood donors.  Rev Hosp Clin 
Fac Med Sao Paulo. 2003;58:315–319. 
146. National  Rosacea  Society  Survey  2011,  Experimental  studies  in  the 
pathogenesis of rosacea. Available at: www.rosacea.org (Accessed: 2011).
147. Pope  JE.  Raynaud's  Phenomenon  (Primary).  Clinical  Evidence.  2011 
Mar;14:1119.
148. Shahla Eltayeb, J bart Staal, Janneke Kennes, Petra HG Lamberts and Rob 
A de Bie.  Prevalence of  complaints  of  arm, neck and shoulder  among computer 
office  workers  and  psychometric  evaluation  of  a  risk  factor  questionnaire.  BMC 
Musculoskelet Disord. 2007 July 14;8:68. 
149. Salo OP. SLE-like deposition of immunoglobulines in the skin in rosacea. A 
clinical and immunoflurescent study. Ann Clin Res. 1970 Mar; 2(1):28-31.
150. Fabre VC, Lear S, Reichlin M, Hodge SJ, Callen JP. Twenty percent of biopsy 
specimens  from sun-exposed  skin  of  normal  young  adults  demonstrate  positive 
immunofluorescence. Arch Dermatol. 1991 Jul; 127(7):1006-11. 
151. Nunzi E, Rebora A, Hamerlinck F, Cormane RH. Immunopathological studies 
on rosacea. B J Dermatol. 1980 Nov; 103(5):543-51.
152. Manna  V,  Marks  R,  Holt  P.  Involvement  of  immune  mechanisms  in  the 
pathogenesis of rosacea. B J Dermatol. 1982 Aug; 107(2):203-8.   
153. Black AA, McCauliffe DP, Sontheimer RD. Prevalence of Acne Rosacae in a 
rheumatic skin diseases subspeciality clinic. Lupus. 1992 Aug, 1(4):229-37. 
154. Woźniacka A, Salamon M, McCauliffe D, Sysa-Jędrzejowska A. Antinuclear 
antibodies in rosacea patients. Postepy Dermatol Alergol. 2013 Feb;30(1):1-5. 
155. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline-induced 
autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996 
Jan 20;312(7024):169-72.  
156. Shapiro  LE,  Knowles  SR,  Shear  NH. Comparative  safety  of  tetracycline, 
minocycline, and doxycycline. Arch Dermatol. 1997 Oct;133(10):1124-30.
  146
157. Walling  HW,  Sontheimer  RD.  Cutaneous  lupus  erythematosus:  issues  in 
diagnosis and treatment. Am J Clin Dermatol. 2009; 10(6):365-81.
158. Callen JP.  Drug-induced subacute cutaneous lupus erythematosus. Lupus. 
2010  Aug; 19(9):1107-11. 
159. Schlienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus. A systemic 
review. Dermatology. 2000; 200(3):223-31.
160. Yung RL,  Richardson BC. Drug-induced lupus. Rheum Dis  Clin  North Am. 
1994 Feb ;20(1)61-86.
161. Knowles  SR,  Shapiro L,  Shear  NH. Serious  adverse  reactions  induced by 
minocycline. Arch Dermatol. 1996  Aug; 132(8):934-9.
162. Sturkenboom MC, Meier CR, Jick H, Stricker BH. Minocycline and lupus like 
syndrome in acne patients. Arch Intem Med. 1999 Mar 8; 159(5);493-7.
163. Marzo-Ortega H, Baxter K, Strauss RM, Drysdale S, Griffiths B, Misbah SA, 
Emery  P.  Is  minocycline  therapy  in  acne  vulgaris  associated  with  antineutrophil 
cytoplasmic antibody positivity? Across sectional study. Br J Dermatol. 2007 May; 
156(5):1005-9.
  147
Chapter Six – Appendix
1. Leeds (Central) Research Ethics Committee 
2. Doncaster Hospital Ethical Approval
3. Leeds Teaching Hospital R&D Approval
4. Tables
5. Figures
 
  148
1. Leeds (Central) Research Ethics Committee
                                                                                               
Room 23, Floor CD
                                                                                                      
Block 40 King Edward Home
                                                                                                    
Leeds General Infirmary
                                                                                                     
LS1 3EX
                                                                                                
Telephone: 0113 3923772 
                                                                                                      
Facsimile: 0113 3922863
                                                                                                     
21 April 2009
Dr. Mustafa Marai
Associate Specialist, Dermatology
Dermatology Department,
Doncaster Royal Infirmary & Bassetlaw Hospitals NHS Foundation Trust
Armthorpe Road
DN2 5LT
Dear Dr. Marai
Full title of study: A  clinical  and  Pathological  Investigation  of 
Rosacea
REC reference number: 09/H1313/3
Thank you for your letter of 15 April 2009, responding to the Committee’s request for 
further  information on the above research and submitting revised documentation. 
The further information has been considered on behalf of the Committee by the Vice-
Chair. 
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Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for 
the above research on the basis  described in  the application form,  protocol  and 
supporting documentation as revised, subject to the conditions specified below.
Ethical review of research sites
The Committee has designated this study as exempt from site-specific assessment 
(SSA).  The  favourable  opinion  for  the  study  applies  to  all  sites  involved  in  the 
research. There is no requirement for other Local Research Ethics Committees to be 
informed or SSA to be carried out at each site. 
Conditions of the favourable opinion
The favourable opinion is subject to the following conditions being met prior to the 
start of the study.
Management permission or approval must be obtained from each host organisation 
prior to the start of the study at the site concerned.
Management permission at NHS sites (“R&D approval”) should be obtained from the 
relevant  care  organisation(s)  in  accordance  with  NHS  research  governance 
arrangements.   Guidance  on  applying  for  NHS  permission  is  available  in  the 
Integrated Research Application System or at http://www.rdforum.nhs.uk.
The participant information sheets and consent forms need to be given validation 
numbers  (3).  This  will  also  need  to  correspond  to  the  text  in  the  consent  form 
referring to the participant information sheet. 
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Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document   Version Date   
Letter of Invitation - LTHT 2 04 March 2009 
Letter of Invitation - Doncaster 2 04 March 2009 
Response to Request for Further Information  02 March 2009 
Interview Schedules/Topic Guides 1 04 March 2009 
CV of supervisor  30 December 2008 
GP/Consultant Information Sheets  07 January 2009 
Compensation Arrangements  02 October 2008 
Statistician Comments    
Letter from Sponsor  16 December 2008 
Protocol  07 January 2009 
Investigator CV  31 December 2008 
Application  31 December 2008 
Response to Request for Further Information  15 April 2009 
Participant  Consent  Form:  Leeds  Teaching 
Hospitals 
3 15 April 2009 
Participant  Consent  Form:  Doncaster  and 
Bassetlaw Hospitals 
3 15 April 2009 
Participant  Information  Sheet:  Leeds  Teaching 
Hospitals 
3 15 April 2009 
Participant  Information  Sheet:  Doncaster  and 
Bassetlaw Hospitals 
3 15 April 2009 
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for 
Research  Ethics  Committees  (July  2001)  and  complies  fully  with  the  Standard 
Operating Procedures for Research Ethics Committees in the UK.
After ethical review
Now that  you  have  completed  the  application  process  please  visit  the  National 
Research Ethics  Website.  After  Review You are  invited  to  give  your  view of  the 
service that you have received from the National Research Ethics Service and the 
application  procedure.  If  you  wish  to  make  your  views  known  please  use  the 
feedback form available on the website. The attached document “After ethical review 
guidance  for  researchers”  gives  detailed  guidance  on  reporting  requirements  for 
studies with a favourable opinion, including:
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- Notifying substantial amendments
- Progress and safety reports
- Notifying the end of the study
The NRES website also provides guidance on these topics, which is updated in the 
light of changes in reporting requirements or procedures.
We would  also  like  to  inform you  that  we  consult  regularly  with  stakeholders  to 
improve our  service.  If  you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk.
09/H1313/3 Please quote this number on all correspondence
With the Committee’s best wishes for the success of this project
Yours sincerely
Dr Margaret L Faull       Chair
Email: rachelt.bell@leedsth.nhs.uk
Enclosures: “After ethical review – guidance for researchers” 
Copy to: Rachel de Souza
R&D office for Leeds Teaching Hospitals Trust
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2. Department of Clinical Audit, Research & Effectiveness
Doncaster & Bassetlaow Hospitals NHS Foundation Trust
Tel: 01302 366666 Extension 3820
Fax: 01302 553187
Email: katie.smith@dbh.nhs.uk
18 June 2009
CONFIDENTIAL
Dr. Mustafa Marai
Doncaster Royal Infirmary Hospital
Dermatology Department
Armthorpe Road
Doncaster, DN2 5LT
Dear Dr Marai
Re: A clinical - pathological investigation of rosacea with particular regard to 
systemic diseases
I am pleased to inform you that the above project has now been given authorisation 
to commence within Doncaster & Bassetlaw Hospitals NHS Foundation Trust.  For 
your information, the project reference is 207/2008/STU.  I would be grateful if you 
could quote this number in any further correspondence with this department.
Documentation
Your  authorisation  has  been  granted  based  on  submission  of  the  following 
documentation:
1. Research Protocol 8171/19699/1/523
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2. IRAS/REC form (Signed by Mrs Rachel DeSouza, 1 May 2009)
3. SSI form (Signed by Dr Mustafe Marai 10 May 2009)
4. Sponsorship statement (University of Leeds, 29 April 2009)
5. Letter stating ‘favourable ethical opinion’ from Leeds (Central) Research 
Ethics Committee (21 April 2009)
6. Indemnity  statement  (AIG  Europe  (UK),  letter  from  Marsh,  2  October 
2008)
7. Study data proforma (22 April 2009)
8. Invitation to participation in Rosacea Study (22 April 2009)
9. GP information letter (22 April 2009)
10. Consent form (22 April 2009)
11. Rosacea Study Participation Information Sheet (22 April 2008)
12. Patient Information sheet and questionnaire (all documents) with version 
and date
13. MHRA approval with date
14. Clinical Trial Agreement with version and date
Please note that approval is limited to the dates stated on the research application 
form and that you are obliged to notify the R&D Department of any adverse events 
that arise during the course of the project.  You are also obliged to inform us if your 
project  deviates in any way from the original proposal /  documentation you have 
submitted.  This may result  in the suspension of your project until  changes have 
been agreed with the Trust.
Permissions
This  letter  authorises  you  in  principle  to  undertake  research  within  the  Trust. 
However, it is your responsibility to ensure that individuals appropriate to your work 
have no objections to your studies.  This department accepts no liability for non co-
operation of staff or patients.
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Contracts
It  is  your  responsibility to ensure you have sufficient  indemnity to undertake this 
project  and  that  letters  of  authority  /  honorary  contracts  are  in  place  where 
necessary.
Auditing
I would strongly urge you to maintain an accurate and up to date site file for your 
documentation, as the Trust randomly audits projects to assess compliance with the 
relevant frameworks and legislation.  If your study is chosen, you will be notified in 
writing  not  less  than  two  weeks  prior  to  the  required  submission  date  of 
documentation.
May I  take this  opportunity to  wish you well  with your  project.   If  you have any 
questions or I can be of any further assistance to you, please do not hesitate to 
contact me.
Yours sincerely
Emma Hannaford
Research Governance Co-ordinator
CC Local Investigator
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3. Leeds Teaching Hospital R&D Approval
Dr Mark Goodfield
Consultant Dermatologist
Dermatology Department
Leeds General Infirmary
31/07/2009
Dear Dr Mark Goodfield
Re: LTHT R&D Approval of: A clinical and Epidemiological Investigation of     
Rosacea with particular regard of systemic symptoms
LTHT R&D Number: EX09/8870
LREC: 09/H1313/3
I confirm that this study has R&D approval and the study may proceed at The Leeds 
Teaching Hospitals NHS Trust  (LTHT). This organisational level approval is given 
based on the information provided in the documents listed below.
In undertaking this research you must comply with the requirements of the Research 
Governance Framework for Health and Social Care which is mandatory for all NHS 
employees. This document maybe accessed on the R&D website; 
http://www.leedsth.nhs.uk/sites/research_and_development/ 
R&D approval is given on the understanding that you comply with the requirements 
of the Framework as listed in the attached sheet “Conditions of Approval”.  If  you 
have any queries about  this approval please do not  hesitate to contact  the R&D 
Department on telephone 0113 392 2878.
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Indemnity Arrangements:
The  Leeds  Teaching  Hospitals  NHS  Trust  participates  in  the  NHS  risk  pooling 
scheme administered by the NHS Litigation Authority 'Clinical Negligence Scheme 
for NHS Trusts' for; (i) medical professional and/or medical malpractice liability; and 
(ii) general liability. 
NHS Indemnity for negligent harm is extended to researchers with an employment 
contract (substantive or honorary) with the Trust.  The Trust only accepts liability for 
research activity that has been managerially approved by the R&D Department.
The  Trust  therefore  accepts  liability  for  the  above  research  project  and  extends 
indemnity  for  negligent  harm  to  cover  you  as  principal  investigator  and  the 
researchers  listed  on  the  Site  Specific  Information  form.   Should  there  be  any 
changes to the research team please ensure that you inform the R&D Department 
and that s/he obtains an employment contract with the Trust if required.
Yours sincerely
Dr D R Norfol
Associate Director of R&D
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